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Abstract
Bipolar disorder is a common and serious mental illness. The occurrence o f mania is 
central to the diagnosis, but affected individuals typically also suffer episodes of 
depression.
The results o f family, twin and adoption studies argue convincingly for genetic 
susceptibility to bipolar disorder. Linkage studies conducted at the Molecular Psychiatry 
Laboratory, UCL have previously implicated the regions 12q24, 21q22, lq42 and 11 p 14- 
15 as harbouring susceptibly loci for bipolar disorder.
In this thesis I report fine mapping o f the 12q24, 21q22 and lq42 regions by linkage 
disequilibrium methods, employing a case-control design. For the llp l4 -1 5  region 
association with the candidate gene BDNF was tested. I also present attempts to replicate 
findings o f association at the genes DAOA and COMT, located in regions implicated by 
meta-analysis o f the linkage data. I have attempted to put these investigations in context, 
necessitating consideration o f the conceptual developmental of bipolar disorder, the 
classical techniques for assessing the genetic contribution to aetiology, and mapping 
strategies.
Fine mapping o f the UCL linkage regions implicated two novel susceptibility loci and 
provided support for two previously identified loci. Association of multiple markers 
within a 180 kb region o f 12q24.3 was found, implicating Slynar and LOC387895. 
Association was also found with two markers in the more centromeric gene P2RX7, 
previously implicated in a Canadian sample. Multiple associated markers were found on 
21q22.3. Two candidate genes - C21orf29 and TRPM2 - were identified from this region. 
Initial efforts to fine map the lq42 region suggested the involvement o f the previously 
implicated DISCI gene. However association was only found with a single marker. 
Although haplotypic association was found with BDNF, the complex structure of the 
microsatellite marker hindered interpretation of the results. Partial replication o f the 
association with DAOA was achieved but the involvement o f COMT was not supported.
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Chapter 1: What is Bipolar Disorder?
In this opening chapter I will introduce bipolar disorder. I will stray from convention 
slightly in not taking a strictly chronological approach to the recognition and 
classification o f this disease. Firstly, I will attempt to describe bipolar disorder as it is 
currently conceptualised. I will then go on to outline the clinical aspects of the disorder, 
discuss its place in the global burden o f ill health and critically consider the efficacy of 
contemporary treatments. Finally, I will outline the historical development o f bipolar 
disorder as a diagnostic entity.
1.1 Modern conceptualisation
Bipolar disorder, or manic depression as it is still sometimes referred to, is a disorder of 
mood. Despite the implications o f both these terms, modem definitions demand the 
ocurrence o f mania or hypomania but not necessarily depression.
Mania is a syndrome, the core feature o f which is a sustained, abnormally elevated or 
irritable mood. However, changes can be observed across many domains: cognitive, 
behavioural, physiological and perceptual. Listed below are some o f these changes, with 
accompanying sketches o f typical clinical presentations. This is intended to give a flavour 
of how a patient suffering from a manic episode might appear:
Increased activity
The patient appears restless and their activity becomes unrestrained and urgent. In this 
state the patient is at risk o f physical exhaustion. The patient may, for example, report 
starting a number o f courses or setting up multiple businesses. Initially they may claim 
increased productivity but as the episode becomes more severe tasks are not finished and 
activity becomes chaotic.
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Flight o f  ideas and pressure o f  speech
The patient’s speech can be very rapid with increased volume. Accompanying this the 
patient may rapidly flit from one subject to another. In contrast to the formal thought 
disorder o f schizophrenia one can appreciate the connection between the thoughts even if 
their rapidity makes them very difficult to follow.
Increased self-esteem and lack o f  judgment
Generally, patients will experience an increase in confidence and impaired judgment. 
This often affects social interactions, with the patient becoming over-familiar or 
indiscreet. The patient may engage in reckless activities, such as driving at high speed. 
Often there will be a period o f profligacy with money.
Somatic symptoms
Somatic symptoms are commonly referred to in the context o f depressive disorder. In an 
analogous but reverse way there are often somatic perturbations in the manic syndrome. 
One of the earliest clinical signs of mania is decreased need for sleep. It is also common 
to experience increased libido and appetite.
Clearly many o f the symptoms described above are interrelated. However, the 
relationship between them at an aetiological level remains unknown. Although necessary 
for a diagnosis o f bipolar disorder, it is not established that the mood change is causative 
of, say, the phenomenon o f flight o f ideas. Interestingly, patients may be able to exert 
some control over symptoms for short periods by effort o f will, such as in the context of a 
clinical interview.
Psychotic symptoms, i.e. symptoms in which there is a loss o f contact with reality, may 
also be present during an episode o f mania. Essentially these are hallucinations or 
delusions - fixed beliefs held in contrariness to the evidence. They are usually, although 
not exclusively, mood congruent, i.e. in keeping with the prevailing mood state o f elation. 
A typical example would be the grandiose delusion of divine birth.
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It is now recognised that the psychotic symptoms previously associated with 
schizophrenia, Schneider’s first-rank symptoms, also occur in approximately 20% of 
manic patients (Gonzalez-Pinto et a l  2003). These symptoms include certain types o f 
auditory hallucinations, somatic hallucinations, delusions of control, thought broadcasting 
and delusional perception. In the case of mania, however, these are transitory 
phenomenon occurring at the peak o f a manic episode.
Insight, often spoken o f in psychiatry, refers to the degree to which the patient realises 
that they are unwell. In patients with mania insight into their problem is invariably 
impaired, and may be completely absent in the more severe stages. This has obvious 
implications for the treatment and management o f such patients.
Whilst I have described above the typical presentation o f a manic episode, some 
variations can be seen. Mania can, for example, present as manic stupor. This is when 
patients present in a mute and immobile state but subsequently report that they 
experienced racing thoughts. However, this condition is now rarely seen, probably due to 
better surveillance and modem treatments.
I have described above the presentation of mania from the clinician’s viewpoint. Below I 
have inserted a more personal description of mania. Here, one o f the bipolar individuals 
contributing to my study describes the manic behaviour o f his girlfriend and fellow 
sufferer in a book he wrote about his experience of the illness:
When [her] mania was at its peak, she became so uninhibited and carefree 
that at such times she put herself at very considerable risk... Anything could 
happen... She was walking down the middle of the road, drinking a can of 
Coke. There were cars racing past her in both directions.
I have not referenced this book in order to maintain the participant’s anonymity.
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Depending on the classification system used a diagnosis o f bipolar disorder can be 
ascribed following a single episode o f mania. However, the usual presentation o f bipolar 
disorder is one o f recurrent episodes of mania and depression. Indeed, it has been found 
that 90% of patients experiencing mania will also experience depression (Goodwin and 
Jamison 1990).
In Western culture, depression is a more familiar concept than mania. I will not, therefore, 
enter into a detailed explanation here. However, it is important to draw a distinction 
between transitory feelings o f depression, universally experienced in relation to adverse 
events, and an episode o f depression. The core feature o f a depressive disorder is 
persistent low mood. This is typically evident as anhedonia (lack o f enjoyment), low 
energy, slowness and a negative mindset accompanied by the somatic symptoms of 
disturbed sleep, poor appetite with weight loss, loss o f libido and diurnal variation o f 
mood. As is apparent, many o f the symptoms are the opposite o f those found in mania.
There is considerable variation in the clinical presentation o f depression, affected both by 
cultural and demographic factors. In China, for example, presentation with somatic 
complaints is more common than in the West (Gelder et a l  2001). It would seem that 
there are no major differences in the symptom profiles o f unipolar and bipolar depression 
(Mansell et al. 2005). However, there is a suggestion that psychomotor retardation and 
the symptoms o f atypical depression, namely hyperphagia, hypersomnia and laden 
paralysis, are particularly associated with bipolar depression.
Here the same volunteer describes his own experience of a depressive episode:
I know I’m unable to live life in the same apparent matter of fact way that I 
see most people doing. My whole existence terrifies me. I try to retreat from 
it even to the point o f wishing to end it all.
Diagnosis of bipolar disorder remains purely clinical, as reliable biochemical or genetic 
markers have yet to be established. The presentation of mania can be very dramatic, with 
little diagnostic difficulty. However, there can be initial difficulty differentiating bipolar
13
disorder from schizophrenia when psychotic features are prominent. Diagnostic 
uncertainty can lead to sub-optimal treatment due to the differing treatments for the two 
disorders.
The two main psychiatric classification systems currently in use are International 
Statistical Classification o f Diseases, 10th edition, ICD-10, (WHO 1993) and Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition, DSM-IV(APA 1994). These set 
out operational criteria by which to diagnose bipolar disorder. The criteria are similar, but 
in DSM-IV the occurrence o f one manic episode is sufficient for a diagnosis of bipolar 
disorder while another mood disturbance is required for ICD -10. However, if the manic 
or hypomanic episode is precipitated by treatment it is not counted in DSM-IV. Important 
exclusion criteria include mood disturbance attributable to psychoactive substance use or 
any organic mental disorder.
DSM-IV also makes the distinction between bipolar I and II, which will be returned to in 
discussing the historical development of the diagnosis o f bipolar disorder in section 1.5. 
Personal distress and social dysfunction are important criteria in differentiating bipolar I 
from bipolar II.
In addition, variants o f bipolar disorder are recognised: rapid cycling and mixed affective 
states. Rapid cycling is defined as at least four distinct episodes of mood disturbance in 
one year, separated by periods of remission. Rapid cycling has some interesting features. 
It is associated with hypothyroidism, can be triggered by antidepressant drugs and is 
relatively unresponsive to lithium treatment. Mixed affective states occur when 
symptoms o f depression and mania co-exist temporally, or follow one another in very 
quick succession. These states also have some specific correlations with drug response.
1.2 Clinical aspects
I will not describe in detail the clinical aspects o f bipolar disorder. Instead, I will give a 
sketch of the natural history o f the disorder. Whilst I present generally accepted figures, it
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should be stated that there is considerable variability in estimates o f epidemiological 
facets of the disorder.
A lifetime risk o f 0.3-1.5% for bipolar disorder was found in an epidemiological study 
covering 10 countries from different global regions (Weissman et al. 1996). The same 
study showed that men and women were affected equally. There are a number o f 
controversies over gender differences in bipolar disorder, but it does seem that rapid 
cycling occurs more commonly in women (Gelder et a l  2001).
The mean age o f onset o f bipolar disorder is approximately 21 years. This is some years 
earlier than unipolar depression. The average length o f a manic episode is about 6 months. 
Multiple episodes are the norm (Gelder et al. 2001). The length o f the interval between 
successive episodes decreases and frequency increases (Angst and Sellaro 2000). There is 
high comorbidity o f bipolar disorder with anxiety disorders and substance use disorder 
(Krishnan 2005).
A number o f prognostic factors have been identified in relation to bipolar disorder, many 
o f which are common to a range of psychiatric conditions. Previous episodes and early 
onset are the main risk factors. The risk of future episodes is also increased with poor 
social support, poor physical health, comorbidity, substance misuse, personality disorder 
and high trait neuroticism. Bipolar II has a relatively good prognosis, while the prognosis 
for rapid cycling is poor (Gelder et al. 2001).
1.3 Is bipolar disorder important?
I will consider the importance o f bipolar disorder from two viewpoints: global and 
personal. To take the former, it is evident from lifetime risk rates of around 1% that 
bipolar disorder affects a considerable number of people worldwide. The Global Burden 
of Disease Study used Disability Adjusted Life Years (DALYs) to measure disease 
burden for many conditions (Murray and Lopez 1997). DALYs are a composite measure 
o f the sum of life years lost to premature death and years lived with disability adjusted for
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severity. Out o f the 107 disorders considered, bipolar disorder ranked 22nd. According to 
this study, bipolar disorder accounted for the loss o f 1.43><107 DALYs in 1990. It has 
been estimated that the total cost o f bipolar disorder in the UK is two billion pounds 
sterling per year (Das Gupta and Guest 2002).
The personal cost o f bipolar disorder can be considered from the perspectives o f both 
mortality and morbidity. Simply put, if  you have a diagnosis of bipolar disorder you are 
more likely to die. Harris and Barraclough (Harris and Barraclough 1997) demonstrated a 
Standardised Mortality Ratio (SMR) o f 15.0 for suicide with bipolar disorder. More 
recently, Osby (Osby et a l  2001) found an all causes SMR o f 2.5 for males and 2.7 for 
females. A much greater risk o f suicide was found in females with an SMR of 22.4 
compared with 15.0 in males. There has been significant variability in estimates o f rates 
o f completed suicide in people with bipolar disorder, ranging between 4% and 19% 
(Dalton et al. 2003).
In terms o f morbidity, it is evident from the above clinical characteristics that bipolar 
disorder generally affects people early in life, involves prolonged periods o f illness and is 
likely to recur and worsen. Although virtually all patients recover from acute episodes, 
only around 20% have prolonged periods of occupational and social stability (Gelder et al. 
2001). This is reflected in a number o f measures o f reduced social functioning. Bipolar 
sufferers have higher rates o f unemployment, increased use o f health services and 
increased marital dysfunction (Sajatovic 2005).
Furthermore, evidence seems to be accumulating of a link between bipolar disorder and 
cognitive dysfunction (Robinson and Ferrier 2006). However, the link between bipolar 
disorder and creativity has long been discussed and has recently received some support 
from empirical evidence (Santosa et a l  2006).
Patients suffering manic episodes often spend protracted periods in hospital. Compulsory 
admission under the mental health act is frequently required. Analysis o f patients in 
Psychiatric Intensive Care Units has revealed that bipolar cases constitute a large
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proportion o f such admissions, e.g. (Brown and Bass 2004). Use o f the Mental Health 
Act and treatment in more restrictive environments can be particularly distressing to both 
the patient and carer.
As alluded to above, the impact o f bipolar disorder is not necessarily restricted to patients 
but can also affect friends and family.
1.4 Is bipolar disorder treatable?
In this section, I will briefly comment on the treatments currently available for bipolar 
disorder. There are important differences in the treatment o f the manic and depressive 
phases of the illness, although some pharmacological agents can be thought o f as 
treatment o f bipolar disorder per se. I will consider first the treatment o f mania, then that 
o f depression and finally maintenance therapy.
Whilst patients experiencing a manic episode may not feel that they need treatment, they 
often present a risk to themselves, e.g. through risk-taking behaviour. Furthermore, they 
may pose a risk to others or find themselves at risk from others. Prior to the development 
o f modem pharmacological agents ‘manic exhaustion’ was a commonly stated cause of 
death. However, it has been questioned whether this existed as a clinical entity or whether 
it arose because o f physical causes of the mania (Derby 1933). Due to the high level of 
risk involved, vigorous treatment o f mania is required.
Currently, treatment o f mania - in terms of trying to alter the aberrant mental state - is 
essentially pharmacological. The social intervention o f hospital admission could also be 
viewed as treatment. Since its discovery by Cade in 1947, lithium has been considered 
the first line treatment of bipolar disorder. Indeed, a meta-analysis by Poolsup (Poolsup et 
al. 2000) suggests that lithium is still the agent of choice. In the case o f lithium, the 
number needed to treat (NNT) was calculated as five and would thus generally be 
considered an effective treatment. By way o f comparison with treatments in other 
branches o f medicine, triple therapy for H. Pylori has a roughly equivalent NNT
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(McQuay and Moore 1997). Similar response rates were found for the other mood 
stabilisers sodium valporate and carbamazepine. Carbamazepine may have an advantage 
in rapid cycling disorder, while valporate may act more swiftly. More recently, 
lamotrigine and gabapentin have come into clinical use.
Antipsychotics are also widely used in the clinical treatment o f mania. The typical 
antipsychotics haloperidol and chlorpromazine have been demonstrated to be effective in 
the treatment o f mania by randomised control trials. A recent meta-analysis o f atypical 
antipsychotics - including aripiprazole, olanzapine, quetiapine, resperidone and 
ziprasidone - concluded that they were all superior to a placebo, but only small 
differences in efficacy were observed between them (Perlis et al. 2006). Benzodiazepines 
are widely used as an adjunct treatment for behavioural disturbance, although they carry 
the risk o f disinhibition. ECT is probably as, if  not more, effective a treatment for mania 
than the pharmacological agents outlined above, yet this procedure is rarely used now in 
clinical practice.
Treatment of depression as part of bipolar disorder does not differ substantially from that 
o f unipolar depression. Whilst there is an ever-expanding pharmacopeia for the treatment 
o f depression, psychological interventions have also been shown to be effective. Overall, 
antidepressants are effective treatments for moderate and severe depression with an NNT 
o f 3-4 (Gelder et al. 2001). There are now three main classes o f anti-depressants: tricyclic 
antidepressants (TCA), monoamine oxidase inhibitors (MAOI), and serotonin specific 
reuptake inhibitors (SSRI), plus other miscellaneous antidepressants. Efficacy is similar 
between antidepressants, although there are notable differences in the side effect profiles. 
SSRIs are generally used as first line agents because o f their higher tolerability and safety 
in overdose. Whilst it is important to treat depression in bipolar disorder, as it causes 
much suffering and brings with it the risk o f suicide, particular care has to be taken due to 
the danger o f antidepressant induced mania.
For those who do not respond to single agent antidepressants there are a number of 
effective augmentation strategies available. For instance, a NNT of 3.7 is obtained with
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lithium augmentation in non-responders to antidepressants. ECT may be more effective 
in severely depressed patients than antidepressants. However, as mentioned above, the 
clinical use of ECT remains limited. There has been considerable evaluation of 
psychological treatments in depression, and for mild to moderate forms o f the disorder 
CBT is as effective as antidepressants. Interpersonal therapy is also effective (Gelder et al. 
2001).
Evidence suggests that some pharmacological agents modify the natural history o f BP. 
Many patients are therefore on long-term maintenance medication. It would appear that 
the mood stabilising drugs - valporate, carbamezipine and lithium - are broadly similar in 
their prophylactic effect. Most experience has been gained with lithium, with about 50% 
of patients responding positively. It appears equally effective in the prevention of mania 
and depression. Importantly, lithium prophylaxis seems to lead to a decrease in mortality 
from suicide. Currently, the prophylactic effects of lamotrigine, gabapentin, olanzpine 
and rispedone are being studied. The role for psychological interventions in maintenance 
appears limited. There is, however, evidence that relapse rates are reduced by education, 
particularly when this is geared to recognising the warning signs o f relapse, thus enabling 
prompt treatment.
The agents used, particularly in the treatment and maintenance o f acute mania, are not 
well liked by patients. For example lithium, the most commonly used prophylactic agent 
for bipolar disorder in the UK, is associated with serious side effects. Increased rates of 
hypothyroidism have been found, particularly in women (Freeman and Freeman 2006). 
Polyuria secondary to lithium-induced anti-diuretic hormone insensitivity is seen in a 
significant proportion o f people. As lithium has a narrow therapeutic index, there is the 
danger of lithium toxicity, a condition that is potentially fatal. Risk o f lithium toxicity is 
much increased by a state of dehydration, induced, for example, by diarrhoea and 
vomiting. Monitoring o f these problems has improved, for example through the setting up 
of lithium clinics, although there remains the need for repeated blood tests. In addition, 
there are a number o f minor side effects, which, nonetheless, can have a significant
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impact on quality of life. Patients often describe weight gain, tremor and dulling of 
mental faculties.
Thus it can be seen that useful, although not brilliant, treatments are available. Whilst 
some of the response rates are reasonable, care should be taken in their interpretation, as 
response is rarely defined as a return to the pre-morbid state. Better service provision and 
standardisation o f best treatment practices may improve the outcome in bipolar disorder. 
This has been the guiding principle behind the development o f the National Institute for 
Clinical Excellence guidelines for bipolar disorder, published in July 2006. However, 
even with the perfect implementation o f current treatment methods there is still a pressing 
need for the development o f better treatments.
1.5 Historical perspective
I wish to consider the historical emergence of depression and mania, both as distinct 
clinical entities and as a unitary condition. In so doing, I hope to shed light on how the 
relationship between mania and depression has been perceived historically. Constructing 
a history o f disease is necessarily complex. My aim in this section is therefore modest: to 
outline a working chronology and highlight salient figures in the history of the diagnosis 
and classification of bipolar disorder.
Clinical descriptions, recognisable as depression and mania to the contemporary 
psychiatrist, date back to Antiquity. The first systematic clinical descriptions of 
melancholia and mania were by Hippocrates (460-337 BC) (Angst and Mameros 2001). 
However, it was Aretaeus o f Cappadocia (150-200 AD) who perceived a relationship 
between melancholia and mania, recognising that the two states could occur in the same 
individual. Indeed, Angst maintains that Aretaeus’ recognition o f a connection between 
mania and melancholia “can justifiably be considered the first conception o f bipolarity”, 
whilst Porter (Berrios and Porter 1995) more reservedly remarks that Aretaeus may have 
had “an inkling o f manic-depressive disorders”.
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Aetiological theories for both melancholia and mania were developed within the 
theoretical framework o f humoralism, established by physicians in the Classical period 
and remaining the dominant tradition in Europe throughout the Middle Ages. 
Simplistically stated, excess blood and yellow bile could lead to mania and excess black 
bile to melancholy. The treatments of blood letting and diet to balance the humors were 
thus prescribed in accordance with the model, for instance by Robert Burton in his 
Anatomy o f Melancholy (1621).
Although various writers continued to note the association o f melancholia and mania 
during the 17th and 18th Centuries, it was not until the 19th Century that significant 
headway was made in the classification o f these disorders. Indeed, Berrios argues that 
the modem concepts o f depression and mania arose at this time, developing out of the 
previous broader concepts o f melancholia and mania (Berrios and Porter 1995). 
Melancholia, previously thought to be a disease o f the intellect, was redefined as a 
primary disorder o f emotion. The term depression, taken from cardiovascular medicine, 
gradually infiltrated medical discourse during the second half o f the 19th Century. Mania 
was similarly refigured as a disorder of emotion and behaviour. It was against this 
background o f conceptual clarification that a new combined concept could emerge.
It was within the tradition o f French psychiatry, which had become predominant in 
Europe through the promotion of careful observation of psychopathology, that the 
concept o f mania and melancholy as a dual disorder took systematic form. Such careful 
observation over a prolonged period of time led the pre-eminent French psychiatrist 
Falret to identify a condition he termed “folie circulaire” in 1851. He described a single 
condition constituting a continuous cycle of melancholy and mania with periods of 
wellness in between. It was possible that Falret was influenced by the views of German 
psychiatrist Griesinger, who in 1845 had used the image o f a circle to describe the 
relation of mania and melancholy (Angst and Mameros 2001).
In 1854, the same year that Falret published his theory in full, Jules Baillarger presented 
his own unitary concept o f mania and melancholia, which he referred to as “folie a
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double forme”. Baillarger’s views differed from those o f Falret, as he recognised that the 
symptoms alternated, but accorded no importance to the intervening periods o f wellness. 
In contrast, these intervals were central to Falret’s concept o f a circular disorder (Angst 
and Mameros 2001).
These developments found a receptive audience, both within France and throughout 
Europe. The German psychiatrist Karl Kahlbaum, himself significant in the development 
o f the concept o f a single disorder, used both the terms o f Falret and Baillarger in his 
book of 1863 The Grouping and Classification o f  Mental disorders (Angst and Mameros 
2001). In France, other descriptions o f bipolar disorder were proposed, for example “a 
double phase” (Billod, 1856) and “folie alteme” (Delaye and Legrand du Salle). It was 
not until 1883 that some conceptual clarity was afforded by the prize-winning 
monographs o f Ritti and Mordret (Berrios and Porter 1995).
The next significant stage in classification was due to Kraepelin. He coined the term 
“manic depressive insanity” in 1899. This concept unified the affective disorders, 
including both the circular and depressive types. A broader category was thus created. 
More importantly, Kraepelin also differentiated manic depressive insanity, as a form of 
psychosis, from dementia praecox (Berrios and Porter 1995). This Kraepelinian 
dichotomy has had a fundamental influence on the search for genes, a topic that will be 
revisited at various points in the thesis.
Kraepelin’s unified view o f the affective disorders faced considerable opposition, 
particularly in Germany. Karl Kleist (1953) challenged Kraepelin’s concept o f manic- 
depressive disorders, believing that people who suffered from both manic and depressive 
episodes were suffering from a different illness to those that experienced only one type of 
affective state. Kleist’s views were in all likelihood influenced by those of his senior 
colleague Carl Wernicke, who was likewise of the opinion that single or recurrent 
episodes of either depression or mania should be differentiated from the disorder 
involving both o f these states. It is to Kleist that we owe current nomenclature o f 
“einpolig” (unipolar) and “zweipolig” (bipolar) disorder. Kleist’s ideas underwent further 
refinement by another o f his colleagues, Karl Leonhard (Angst and Mameros 2001).
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As was mentioned at the start o f this chapter, bipolar disorder has become something o f a 
misnomer according to ICD-10 and DSM-IV definitions, as it is mania that is the defining 
feature o f the syndrome. Monomania is classified as bipolar disorder and unipolar 
disorder now refers to depression. These changes are largely based on the work o f Angst, 
Perris and Winkour in the 1960’s, who brought a genetic epidemiological approach to the 
classification table. The studies o f Angst (1959-1963) and Perris (1963-1966) showed 
that unipolar mania was strongly related in genetic terms to “bipolar disorder” and thus 
should be more properly included in that category (Angst and Mameros 2001).
In DSM-IV bipolar disorder is split into Bipolar I and II, with Bipolar II being defined as 
a milder form of Bipolar I. In Bipolar II, people experience hypomania rather than mania. 
In essence, people with hypomania have fewer and less severe symptoms than those with 
mania, but the division does seem rather arbitrary. Although Hippocrates used the term, 
hypomania only really came to be recognised as a different form of mania through the 
work of Mendel (1881) and has gained in usage over recent years due to the descriptions 
o f Bipolar II. The nosology of Bipolar II is due to Dunner (1976) (Angst and Mameros 
2001).
Accompanying this division of bipolar disorder by severity, investigation has taken place 
into the relationship between bipolar disorder and schizoaffective disorders. It was 
Kahlbaum who first described schizoaffective disorders as a separate group (1863). 
Subsequently Kraepelin was exercised by the problem o f cases which fell between his 
categories of manic depressive insanity and dementia praecox (1920). Schizoaffective 
psychosis was a term coined by Kasanin in 1933. Research since the 1960s has indicated 
a strong relationship between schizoaffective disorders and affective disorders. Cadoret 
(1974) separated schizoaffective disorders into schizoaffective bipolar and 
schizoaffective unipolar. Based on data that relatives of bipolar probands are at elevated 
risk of schizoaffective bipolar disorder, Mameros (1999) has argued that schizoaffective 
bipolar disorder should be included in the bipolar group (Angst and Mameros 2001).
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Hence in our studies patients with schizoaffective bipolar disorder have been included in 
the case group.
The development of the concept o f bipolar disorder appears to have followed a course of 
contraction and expansion. This process has involved the gradual refinement of 
categories - most notably during the 19th Century when the traditional, broader concepts 
o f mania and melancholia were remodelled and the concept o f a circular disease took 
hold. The concept expanded again with the inclusive approach o f Kraeplin, and narrowed 
in opposition to this. In more recent years, there has been increasing interest in 
subdividing this complex phenotype.
The above description o f the development of the working concept o f bipolar disorder 
should not, however, be seen as the sole historical narrative. There has been a parallel 
movement to consider bipolar disorder as on a continuum from affective disorder to 
schizophrenia (Berrios and Porter 1995). I will return to this idea of ‘unitary psychosis’ 
later.
1.6 Summary
The observation that states o f depression and mania could occur in the same individual 
appears to be long-standing, arguably stretching back to the Classical period. However, 
almost two thousand years later there is still no unanimous agreement on how these 
patterns of mood disturbance relate to assumed underlying pathological entities. Leaving 
aside for a moment the complex classification problems that stem from this uncertainty, 
bipolar disorder, as currently defined, is a severe psychiatric disorder, which affects 
approximately 1 in 100 people.
Although there are a number o f effective treatments, the global burden o f disease remains 
great. Although the bipolar pharmacopeia has enlarged, no major treatment 
breakthroughs have been made for 50 years. The development of new treatment and
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prevention strategies is crucially impeded by our relative lack o f understanding o f the 
basic biology underpinning this disorder.
It is beyond the scope o f this thesis to comprehensively review all the biological findings 
in bipolar disorder -  hormonal, neuro-anatomical, neuro-imaging, pharmacological etc. 
However, I think that it is justified to say that despite much research spanning many 
disciplines the biological perturbations in bipolar disorder are poorly understood.
In general, the elucidation o f the underlying genetic pathology has greatly enhanced our 
understanding o f human disease, if  not its treatment. For example, identification of the 
loci for Duchene Muscular Dystrophy has led to the characterisation of the dystrophin 
protein and given a molecular explanation for the progressive muscular wasting that is 
seen clinically. Hence, it would seem a worthy endeavor to try and understand the genetic 
pathology o f bipolar disorder.
Such genetic understanding may allow the classification system to be rationalized, 
placing it on a more robust aetiological footing. Likewise, it should inform investigations 
in other disciplines and help clarify the back catalogue o f biological findings. In turn, it is 
hoped that this knowledge will greatly facilitate the rational design o f novel treatments 
and the tailoring o f treatments according to predicted response. Furthermore, the potential 
exists for genetic advances to have a major impact on the developments of strategies to 
prevent, diagnose and monitor bipolar disorder.
The idea that bipolar disorder has a genetic aetiology is not a recent one. Falret (1854) 
observed that “circular insanity” seemed to run in families (Maj et al. 2002). I hope to 
demonstrate in the next section that there are compelling epidemiological arguments for 
searching for genes o f aetiological importance.
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Chapter 2: Is Bipolar Disorder Genetic?
Before launching into a discussion of the evidence for the genetic aetiology o f bipolar 
disorder, which will be referred to henceforth as BP, I will pause to consider the main 
methodological problem in examining the role of genes in BP. This is the problem of the 
definition o f ‘caseness’ -  in other words, the difficulties involved in accurately 
identifying and defining a category o f cases.
2.1 The problem of phenotype definition
The definition o f caseness is crucial to all forms o f genetic investigation. Ideally, the 
definition would include all cases o f a particular genetic aetiology whilst excluding any 
individuals who had a different genetic aetiology but shared the phenotype. This situation 
is approached in some simple Mendelian conditions, such as Huntington’s Disease. 
However, even in simple Mendelian disorders genetically homogenous categories often 
cannot be defined a priori based on clinical phenotypes alone.
As was seen in Chapter 1, there has been a great struggle to precisely define BP. Genetic 
epidemiology has informed modem definitions o f BP and supports their general validity 
for genetic studies. However the precise relationship o f the BP diagnostic grouping to 
putative underlying genetic aetiologies is not yet known. Any deviation from a perfect 
correlation between genetic aetiology and clinical phenotype will have implications for 
genetic studies. An over-inclusive category would make it harder to find the aetiology of 
a particular case whilst an under-inclusive category would mean that not all cases would 
be identified, which would also hamper gene discovery. This issue is relevant to 
segregation analysis, twin and adoption studies (discussed below) as well as the mapping 
strategies discussed in subsequent chapters.
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Even if conceptually imperfect, the definition o f BP must be consistently applied if 
meaningful conclusions are to be drawn from genetic studies. From around the 1940’s 
onwards it was increasingly recognised that there was considerable diagnostic variability 
between clinicians. For example, Beck (Beck et al. 1962) found only 54% agreement on 
specific diagnoses between psychiatrists independently examining a series o f 153 patients. 
This provided the impetus for the development o f operational criteria to improve inter­
rater reliability o f diagnoses.
Initially the St. Louis group developed criteria for 15 psychiatric disorders, called the 
Feighner Criteria (Feighner et al. 1972). With the application to research studies in mind, 
Spitzer (Spitzer et al. 1978) published the Research Diagnostic Criteria (RDC) which 
extended and modified the Feighner Criteria, and claimed a high reliability. Very shortly 
after, Endicott (Endicott and Spitzer 1978) published a semi-structured interview based 
on the RDC: the Schedule o f Affective Disorders and Schizophrenia - Lifetime Version 
(SADS-L). The use o f a structured or semi-structured interview further increased 
reliability (Helzer et al. 1977), aiding the objective and comprehensive acquisition o f 
clinical data and facilitating the consistent application o f this data to the diagnostic 
criteria. I should just mention that DSMIII (Diagnostic Statistical Manual o f Diseases, 
1980), which marked a major change in psychiatric classification systems, can be seen as 
the child o f the RDC, but broadening its perspective to clinical as well as research 
applications.
The subsequent history o f the development of other diagnostic instruments such as the: 
Diagnostic Interview Schedule (DIS), Mini Neuropsychiatric Interview (MINI), 
Structured Clinical Interview for DSM-IIIR (SCID), Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN) and Diagnostic Interview for Genetic Studies (DIGS) is 
rather involved. However, in essence they have evolved to reflect the changes in 
operational definitions embodied in subsequent versions o f DSM (DSM-IIIR and DSM- 
IV) and ICD-10. Broadly speaking, diagnostic concordance between the SADS-L and 
other interviews has been found to be good (Hesselbrock et al. 1982; Farmer et al. 1993).
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While it is not clear to me that there is an appreciable difference in the validity o f the 
various interviews in their application to genetic studies, it has been shown that the 
definition of caseness can have a major impact on the outcome o f genetic studies in 
psychiatry (McGuffin et al. 1991). An attempt has been made to circumvent the problem 
of ‘top down’ diagnostic systems by developing an operational criteria checklist for 
psychotic illness (OPCRIT) in the context o f collaborative genetic studies, which could 
be applied to a number o f diagnostic systems (McGuffin et al. 1991).
2.2 Evidence for genetic aetiology to bipolar disorder
Despite more than 150 years having elapsed since it was observed that BP runs in 
families, a genetic contribution to the aetiology has yet to be unequivocally proven.
To understand the seemingly slow progress in unravelling the genetics o f BP, general 
consideration o f how it is known that a disease is genetic has to be made. That a disease 
phenotype follows a Mendelian pattern of inheritance through families, i.e. autosomomal 
dominant, co-dominant, recessive or X-linked, is strong evidence that the disease has a 
genetic basis. Mendelian inheritance, such as the vertical transmission affecting both 
males and females seen in autosomal dominant disorders, may be inferred by inspection 
o f the pedigree alone, e.g. Huntington’s Chorea.
However, in less clear-cut cases formal analysis o f the segregation ratios within families 
can be performed to test whether a Mendelian pattern o f inheritance is operating. In 
families where BP recurs, the segregation ratios do not perfectly conform to Mendelian 
patterns. This has provoked investigations to test the degree o f genetic contribution to the 
aetiology. Classically, three approaches have been employed for this purpose: family, 
twin, and adoption studies. In this section I will outline the theoretical construct behind 
each of these approaches and then briefly review the findings in BP. I will also mention 
in passing some o f the major criticisms o f these methods.
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2.2.1 Family studies
Family studies are studies of the risk o f disease(s) in relatives o f the affected subject. Of 
primary interest will be the disease under scrutiny, but it is also usual to look for changes 
in the risk o f other diseases in relatives. Applying this to BP, it is typical that once the 
index case o f BP is identified relatives are screened for psychiatric illness and morbid 
risk thus determined. The risk estimate can then be compared with the population risk of 
the disease or the risk derived from relatives of control probands to obtain a relative risk 
value. This approach can be thought o f as formally testing whether a disease is familial. 
However, one cannot infer with certainty whether this familiarity is due to genetic factors 
or to the shared environment within the family. However, family studies may give an 
indication o f the genetic relationship between different diseases.
Early family studies made no differentiation between BP and depression and did not 
routinely assess psychiatric comorbidity (Althoff et al. 2005). Therefore little can be 
inferred about familial risk o f BP from these studies. A meta-analysis o f eight family 
studies where such a differentiation was made yielded an odds ratio of 7 for BP in first- 
degree relatives o f BP probands (Craddock and Jones 1999). No heterogeneity was found 
between studies.
Alzheimer’s Disease represents an example, within the realm o f psychiatric genetics, o f a 
disorder where the early onset form is more familial than the late onset form. The familial 
early onset forms have proved more amenable to linkage analysis and the genetic 
aetiologies are now well characterised. Therefore, one might expect more of an increase 
in morbidity risk in first-degree relatives o f probands with early age o f onset BP. 
Empirical data has supported this assertion, whether the data is analysed by stratifying the 
sample according to age o f onset or specifically recruiting early onset cases: (Rice et al. 
1987); (Strober et al. 1988); (Pauls et al. 1992); (Neuman et al. 1997); (Grigoroiu- 
Serbanescu et al. 2001); (Somanath et al. 2002). However, this analysis is complicated by 
the rather arbitrary delineation o f early and late onset cases and the birth cohort effects 
found in some studies, e.g. (Rice et al. 1987).
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Investigators have questioned whether BPI and BPII represent genetically distinct entities. 
Heun (Heun and Maier 1993) found the risk o f BPI to be similarly elevated in relatives of 
BPI probands and BPII probands. However, the risk of BPII was much greater in 
relatives o f BPII probands than BPI probands. This finding argues for at least some 
commonality in susceptibility to BPI and BPII.
It has been found that the first-degree relatives of BP probands are at increased risk of 
developing unipolar disorder, henceforth referred to as UP, (McGuffin and Katz 1989). 
This has lead to the assertion that BP and a proportion o f UP may share a genetic 
aetiology. The converse has not been convincingly demonstrated; relatives o f UP 
probands do not have increased rates o f BP. However it may be harder to detect this 
effect, as UP depression is much more common and only a small proportion may have a 
putative UP/BP liability.
The risk o f schizophrenia has not been found to be altered by relatedness to a BP proband, 
but the risk of schizoaffective disorder (BP type) has consistently been found to be 
elevated (Craddock and Jones 1999). It was found that the risk in relatives was equivalent 
if  the proband had a diagnosis of BP or schizoaffective disorder (BP type) (Rice et al. 
1987). Hence, as mentioned in chapter 1, schizoaffective disorder (BP type) has been 
considered to share a genetic aetiology with BP and has been included in many linkage 
and association studies. Relatives of schizoaffective probands were found to have a 
higher risk o f major affective disorder than relatives of BP probands (Gershon et al. 
1982). This perhaps suggests that there is a higher genetic loading in schizoaffective 
disorder.
There has also been interest in the effect of gender (of proband or relative) and nature of 
relationship (i.e. sibling, parent or offspring) on risk o f BP. No clear sex-related effect on 
risk has been shown. With regard to the effect of nature o f the relationship on risk, no 
consensus has been reached. Either, studies have only presented pooled risks, or the
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findings have been contradictory. Furthermore, reliable data is only available for risk in 
first-degree relatives (Craddock and Jones 1999).
The application o f family studies in BP is not without its problems. Some o f these relate 
to the nature o f BP, e.g. the already mentioned phenotypic definition and possible birth 
cohort effects and variable age of onset. Other problems relate to the conduct of the 
studies, e.g. lack o f direct interviews (Faraone et al. 1990). Nonetheless, studies from 
independent groups and different geographical regions have shown a convincing 
familiarity in BP. Family studies have not, however, really clarified the genetic 
relationship between BPI, BPII, schizoaffective disorder and UP depression.
Family data can also be used for formal testing of the mode o f inheritance by segregation 
analysis, to the consideration o f which we now turn.
2.2.2 Segregation analysis
In a general sense, segregation analysis refers to the statistical testing o f the observed 
distribution o f disease within a family identified as containing a BP proband, compared to 
that predicted by a hypothetical genetic model. As mentioned above, the occurrence of 
BP in families does not neatly follow Mendelian ratios. The most obvious explanation 
that the observed ratios do not conform to predicted segregation ratios is that the BP trait 
does not follow Mendelian inheritance. However, there are other possible reasons for 
deviations from Mendelian ratios, including: misspecification o f the method of 
ascertainment, differential survival, phenocopies, and incomplete penetrance (Sham
1998).
Allowance must be made for the effect of ascertainment. In practical terms this means 
that a defined systematic method o f ascertainment must be employed before a valid 
segregation analysis can be carried out on family samples. Differential survival refers to 
gametes that contain certain haplotypes that have less chance o f surviving. This is a 
theoretical possibility but there is little evidence o f this effect being important in BP.
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Phenocopies are environment-caused mimics o f the trait under investigation. They 
probably do have relevance to BP. For instance, it is known that a number o f medical 
conditions can give rise to symptoms that resemble those o f BP. It is widely thought that 
incomplete penetrance, i.e. the phenomenon of individuals with the disease genotype not 
manifesting the disease, is an important explanation for the deviations from the 
Mendelian ratios. To deal with these issues more complex models o f inheritance, 
incorporating the parameters of phenocopy rate and incomplete penetrance, have been 
developed.
Polygenic theory is an alternative explanation for non-Mendelian inheritance. For 
discontinuous traits, it is also necessary to hypothesise a threshold or multiple thresholds; 
if  an individual has enough liability they will cross the threshold and develop the trait. 
This is the theoretical stance underpinning the Multifactorial Polygenic Model, MFP 
(Falconer 1965) where the variance is conceptualized as arising from the additive effect 
o f many genes and environmental determinants.
Hence, it can be seen that there has been a great effort to mathematically model 
inheritance. However, consistent support has not been found for a specific mode of 
genetic transmission in BP (Faraone et al. 1990), with some authors supporting a MFP 
model, e.g. (Smeraldi et al. 1977), and others supporting a single major locus model 
(SML), e.g. (Rice et al. 1987). However, many authors have rejected a SML model, e.g. 
(Bucher et al. 1981; Goldin et al. 1983). The SML model has also been criticised on 
mathematical grounds based on the rapid decline in recurrence risk from monozygotic 
(MZ) twins to first-degree relatives to the general population (Craddock et al. 1995; 
Craddock et al. 1997). Interestingly, an age of onset effect on model fitting has been 
found. Early onset BP was found to be compatible with a single major gene with a 
polygenic component, while late onset BP favoured a multifactorial model (Grigoroiu- 
Serbanescu et al. 2001).
There seems to be some evidence that the problem of phenotypic definition could be 
causing inconsistencies in the fitting o f mathematical models to the data. For instance,
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transmission o f BPI was found to be consistent with autosomal dominant inheritance in a 
subset o f closely related Old Order Amish families (Pauls et al. 1995). However, it also 
transpired that this finding could be rejected when atypical BP, major depressive disorder 
and hypomania were included in the analysis of these families. A similar conclusion was 
reached by Spence (Spence et al. 1995). However, the inconsistencies may alternatively 
be due to the operation of more complex modes of inheritance, which are not accurately 
accounted for by the mathematical models that have been applied to the segregation 
analysis.
Thus overall the inheritance o f BP is considered complex. Jones and Craddock (Craddock 
and Jones 1999) have reviewed some of the mechanisms invoked for explaining complex 
inheritance: genetic heterogeneity, interaction, dynamic mutations, imprinting, and 
mitochondrial inheritance.
Genetic heterogeneity means that the disease has a variety o f genetic etiologies. This 
includes both locus and allelic heterogeneity. Locus heterogeneity refers to a situation 
where there are a number o f loci that act independently to give rise to disease. Thus a 
particular locus may have a major effect, but only in a proportion o f cases (Hodgkinson et 
al. 1987). As will be discussed in the next section, genomewide significant LOD scores 
have been found at various loci which, it could be argued, is evidence for locus 
heterogeneity. Allelic heterogeneity refers to the situation where more than one allele at a 
given locus is relevant to disease manifestation. For example, greater evidence for 
linkage on l i p  in the Old Order Amish data was found with a three-allele model 
(Sandkuyl and Ott 1989).
Craddock (Craddock et al. 1995) proposed that multiplicative models are plausible for the 
inheritance o f BP. However, it is difficult to test these interaction models without having 
identified aetiological mutations.
Dynamic mutations refer to the expansion o f certain trinucleotide repeats, which lead to 
various forms o f human disease. Examples of such diseases include Fragile X and Spinal
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Muscular Atrophy. Dynamic mutations give rise to unusual patterns o f inheritance. For 
example, they can lead to the phenomenon of anticipation, where age o f onset decreases 
whilst severity increases in successive generations. The molecular explanation for this is 
that repeat numbers correlate with severity and increase down through the generations. 
Some evidence has been found for anticipation in unilinear BP families (Mclnnis et al.
1993).
The term ‘epigenetic’ is used to refer to varying concepts, but here the following 
definition will be used: heritable information that is encoded by modifications of the 
genome and chromatin components that affects gene expression. A number of epigenetic 
mechanisms may have relevance to the inheritance o f BP. However, it is genomic 
imprinting which has been specifically studied.
Imprinting refers to the effect o f parental origin on the expression o f an allele in the 
offspring. In relation to human disease the most often quoted example is that of Prader- 
Willi/ Angelman syndrome. The aetiology of Prader-Willi/Angelman syndrome can be 
traced to genes located in the 15ql 1-13 region. Prader-Willi syndrome results from lack 
of, or inactivation o f genes that are usually expressed on the paternally inherited 
chromosome. Conversely, Angelman syndrome occurs from a lack of, or inactivation of 
genes which are usually expressed on the maternally derived chromosome. A possible 
parent o f origin effect was found in BP, with a higher rate o f illness in offspring of 
affected fathers than mothers (Komberg et al. 2000). This suggests that the father may 
transmit a more penetrant form o f the disorder.
Mitochondrial inheritance denotes the inheritance o f the mitochondrial genome. 
Mitochondrial DNA is only inherited from the mother. Therefore a typical pattern of 
maternal transmission is seen, with no father to offspring transmission. This is seen in 
conditions such as Progressive External Ophthalmoplegia. It was found that there was a 
higher risk of BP in offspring o f affected mothers than affected fathers, and lack of 
paternal transmission of illness in a number of large pedigrees (McMahon et a l  1995).
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However, if  mitochondrial inheritance and/or imprinting are operating one would still 
have to postulate locus heterogeneity to account for the fact that males and females are 
equally likely to be affected at a population level.
2.2.3 Twin studies
Both twin studies and adoption studies are used to differentiate genetic and shared 
environmental contributions to the variance of a trait. In this section I will briefly outline 
the theory behind twin studies and mention some o f the major criticisms. I will then go on 
to summarise the findings from twin studies in BP.
Theory o f  twin studies
Within the umbrella o f twin studies there are a number o f different approaches: classical 
twin method, co-twin control method, and the method of monozygotic twins reared apart. 
Consideration o f these approaches first requires a brief word on the genetic features of 
twins that make them so useful in genetic studies.
Monozygotic (MZ) twins share 100% of their DNA while dizygotic (DZ) twins share, on 
average, 50%. It can readily be appreciated that this has implications for the sharing of a 
genetic trait between a given twin pair. Twins that share a trait are said to be concordant. 
Assuming that twins, whether they be MZ or DZ, are exposed to a common environment 
- the ‘equal environment assumption’, then one can infer a genetic effect if MZ are more 
concordant than DZ twins. For example, if one considers a fully penetrant autosomal 
dominant trait all MZ twins will be concordant while, on average, 50% of DZ twins will 
be concordant.
In the classical method the ratio o f MZ concordance to DZ concordance is estimated. The 
ratio is reported as either ‘proband-wise’ or ‘pair-wise’. The proband-wise ratio is defined 
as the proportion of affected twin partners of probands. In other words, it is the 
probability that an affected proband’s twin will have the disease. The pair-wise method
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expresses concordance as the proportion o f all twin pairs that are concordant. Generally, 
proband-wise concordance is quoted, as this is directly comparable with the relative risk 
derived from family studies. Heritability (H2) estimates can be derived from concordance 
ratios.
However, care must be taken in interpretation o f heritability estimates as they have a 
circumscribed meaning. Heritability is usually defined as the proportion o f the total 
phenotypic variance that is associated with the genetic variance in a specific sample with 
a specific genetic composition and environmental context (Vitzthum 2003).
In co-twin control studies, MZ twins discordant for the disease are recruited. They are 
predicated on the disease not being solely genetic and are used to identify environmental 
factors relevant to development o f the phenotype using the healthy twin as the control.
Criticisms o f  twin studies
There are various criticisms of the classical twin studies method, both theoretical and 
practical, to which we now turn.
It has been suggested that MZ twins have a more similar environment than DZ twins, 
which could also lead to greater concordance. In particular, MZ twins are more likely to 
share a common intrauterine environment, although approximately 19% will have 
separate placentas (http://www.twins.org.au/). There are a number of precedents for 
intrauterine environments modifying disease risk in later life. For instance intrauterine 
growth retardation (IUGR) predisposes to hypertension in later life (Baum et al. 2003).
However, although competition can occur between different placentas, competition 
effects are more significant between twins that share a blood supply, i.e. share a chorion. 
Twins that share a chorion are always MZ. This can result in selective IUGR. In 
monochorionic twins, twin-to-twin transfusion syndrome can occur where there is 
unequal exchange o f blood. In this case both twins will be affected, but asymmetrically.
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Therefore it is not necessarily true that the interuterine environment is more alike for MZ 
twins than DZ twins.
It has been asserted that MZ twins are treated more similarly, e.g. dressed the same way, 
thus inflating trait concordance. Rarely twins are separated early in life and raised apart. 
Comparison o f MZ twins raised together and MZ twins raised apart can avoid this 
problem.
A further criticism is the potential for bias to be introduced by the method o f sample 
ascertainment. However, the MZ:DZ ratio o f the sample can be used to test for these 
biases. This ratio is approximately 1:1 in the population, although it may vary slightly 
from year to year. Therefore the MZ:DZ ratio for a sample o f same sex pairs should 
mirror the population ratio of 1:1. If opposite sex DZ pairs are included the ratio becomes 
1:2 according to Weinberg’s rule (Hawkes 1997).
By examining these ratios evidence was found for volunteer bias in same sex twin 
samples obtained through volunteer recruitment (Lykken et al. 1987). Samples were 
found to be % MZ twins and % female twins -  ‘the 2A rule’. It is generally thought that 
there is not only an excess of MZ twins but an excess o f concordant monozygotic twins.
Many scenarios are imaginable where ascertainment may be biased towards monozygotic 
concordant twins. For example, concordant twin pairs for BP may be inherently more 
likely to respond to adverts for twins with BP, since they are, as a pair, more interested in 
the disease. Over-recruitment o f concordant twins would lead to overestimation of 
heritability. Strict population based ascertainment can, at least in theory, overcome such 
biases. This is feasible in a number o f countries, such as Denmark, which have national 
twin registries. Indeed the Danish twin registry has been exploited to perform a twin 
study in BP e.g. (Bertelsen et al. 1977). Denmark also has a register o f psychiatric 
admissions allowing cross-referencing. Not all twins with BP will be thus identified but 
they should provide an unbiased sample, assuming that concordance does not affect rate 
o f hospitalisation.
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Determination o f zygosity in same sex twins is, o f course, crucial to twin studies. 
Determination o f zygosity is non-trivial. The most common error is that MZ twins are 
misdiagnosed as DZ due to lack o f similarity in appearance. This might inflate the 
concordance rate in the DZ group. DNA fingerprinting is the most accurate method of 
determining zygosity, with an error rate of less than 1%. However, analysis of a 
combination of biomarkers - e.g. blood group, secretor status, haptogobulin types and 
dermatoglyphics - is also highly discriminative. The inspection o f fetal membranes or of 
chorion is not a reliable method. Neither placenta nor chorion number always correlate 
with zygosity. MZ twins are often dichorionic and the chorion may be fused in DZ twins 
giving the appearance of monochorioncity.
Twin studies and bipolar disorder
We turn now to the results o f twin studies in relation to BP. Again, early studies did not 
distinguish between UP and BP and thus concordance rates for BP cannot be calculated. 
Studies that have applied the modem concept of BP have found consistently higher 
concordance for MZ twins than DZ twins. Jones and Craddock (Craddock and Jones
1999) estimated MZ concordance for narrowly defined BP as 50% from pooled data of 
six available studies at the time. However, they commented that this is likely to be an 
underestimate due to the methodology of three of the studies included.
More recent studies have given very high heritability estimates for BP. Thirty MZ and 37 
DZ from the Maudsley twin register were studied and a heritability estimate of 0.85 was 
obtained using a narrow definition o f affectation (McGuffin et al. 2003). Meanwhile, a 
population based twin study o f 26 twin pairs obtained a heritability estimate of 0.93 
(Kieseppa et al. 2004). Non-shared rather than family environment was implicated in 
explaining the remaining variance by these more recent studies.
Phenotypic definition has caused consternation in twin studies just as it has in segregation 
analysis. Since family studies have demonstrated an increased risk of UP in relatives of 
BP probands, some authors have performed analyses where UP co-twins are classified as
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affected. As would be expected, broadening the definition o f affection in the co-twins 
results in higher concordance rates for both MZ and DZ pairs, e.g. (Kieseppa et al. 2004).
Although discordant MZ twins have been studied in BP they have not quite been used 
according to the usual co-twin control method to identify environmental risk or protective 
factors. Investigators have generally measured various biological features in the affected 
and unaffected twin and normal controls. For example, affected twins were found to be 
significantly impaired on some measures o f visuo-spatial functioning and verbal memory 
compared with the unaffected twin (Gourovitch et al. 1999). Furthermore, the right 
hippocampus was identified as smaller and less asymmetric in the affected co-twin 
compared to the unaffected co-twin (Noga et al. 2001). However, both these studies 
found significant differences between the unaffected co-twin and normal controls. This 
raises the spectre that while the BP phenotype is not expressed in the unaffected co-twin 
the genotype is being expressed sub-clinically - in these cases in terms o f brain 
morphology and neuropsychological function. These ‘hidden’ effects are referred to as 
endophenotypes.
Discordant MZ twins have also been used to identify risk factors at a molecular level by 
investigating gene expression differences. However, rather counter-intuitively, these 
differences have been used to try and identify aetiological genes (Kakiuchi et al. 2003). I 
will return to both these issues later.
To my knowledge there are no studies o f twins reared apart for BP.
2.2.4 Adoption studies
Adoption studies are a powerful technique to distinguish genetic from environmental 
influences on a given trait. They are based on the assumption that only genetic factors are 
transmitted from the biological parents to the child and that the child does not share an 
environment with its biological parents. Hence, elevated rates of the trait in the biological
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parents or offspring compared with the appropriate control provide direct evidence o f a 
genetic aetiology.
In essence, there are two approaches to adoption studies. In the first, BP adoptees are 
identified and matched with control adoptees without BP. The rates o f BP in biological 
parents and adopted parents are then compared. In the second approach, adopted-away 
offspring of BP probands are identified and matched with adopted-away offspring o f non- 
BP probands. The rates o f BP in the two groups o f offspring are thus compared.
However, adoption studies have also been criticised. One criticism is that the 
environment into which the child is adopted is not infrequently chosen to be similar to 
that of the biological parents. However, even if  this effect were operating a higher rate of 
BP in the biological versus adoptive parents would still argue for a genetic aetiology. 
Another criticism, that familial aggregation can arise through the shared family 
environment prior to adoption, would seem more pertinent. As was mentioned in the twin 
studies section, intrauterine environment has been shown to have long-term consequences 
on health. Furthermore, early childhood experiences are implicated in aberrant 
psychological development by many theorists.
To my knowledge only two adoption studies have been carried out in BP, both o f the 
affected adoptees type. A higher risk o f BP was found in the biological parents o f BP 
adoptees than in their adoptive parents (Mendlewicz and Rainer 1977). A subsequent 
study supported this finding, although only ten BP probands were included (Wender et al. 
1986).
2.3 Summary
Returning to the question posed in the title of this chapter, is BP genetic? The tests of 
‘geneticness’ are not unequivocal because o f intrinsic methodological problems. 
Furthermore, there are specific difficulties applying these methodologies to BP, which
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expose the findings to further criticism. However, taken in their totality I believe there is 
robust evidence for genetic factors being o f prime importance in the aetiology of BP.
However, it is not yet clear what modes of inheritance are operating in BP. This may be 
related to the problem of phenotypic definition or due to the lack of sufficiently 
sophisticated models o f complex inheritance. It was this sentiment which led Faraone 
(Faraone et al. 1990) to suggest that “genetic modelling studies have reached the limit if 
their utility” in relation to major affective disorder. Instead, he promoted a shift o f focus 
to genetic linkage studies as a means o f bypassing these problems and attempting to map 
genes influencing BP.
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Chapter 3: Mapping Bipolar Disorder I - Chromosomal Aberrations
and Linkage Analysis
In this chapter I will first introduce the range of methods which can be used to map genes 
in humans. I will then discuss the study of chromosomal aberrations and linkage analysis 
in more detail. I will give a theoretical outline o f these techniques, highlight 
methodological problems encountered when applying them to BP and review the findings 
for BP.
3.1 Methods of gene mapping
Gene mapping o f human traits represents a far greater challenge than gene mapping in 
organisms amenable to experimental manipulation, such as the fruit fly Drosophila. 
Nonetheless, mapping efforts for Mendelian traits/diseases have been hugely successful, 
with approximately two thousand genes mapped (Antonarakis and Beckmann 2006). 
Some success can also now be claimed for the mapping o f susceptibilty loci in complex 
diseases.
The main techniques o f gene mapping in human disease are: the study of cytogenetic 
abnormalities, linkage analysis, and linkage disequilibrium mapping. The first two of 
these techniques will be considered in this chapter. It is common for a combination of 
these techniques to be employed in the mapping of a particular gene, for example in the 
case of Cystic Fibrosis (Gelehrter and Collins 1990).
Generally, approximate localisation o f traits has been achieved through linakge analysis 
or study o f chromosomal abnormalities. Linkage disequilibrium fine mapping and 
sequencing can then be employed for gene identification. A candidate gene approach, 
where pathophysiological knowledge regarding the trait o f interest is utilised, has often 
been applied to the fine mapping stage. However in many diseases, such as BP, the
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underlying biology is not well elucidated. Increasing a systematic approach to linkage 
disequilibrium mapping is being adopted, facilitated by recent technological advances.
3.2 Chromosomal aberrations
Chromosomal aberrations have played an important role in the mapping of disease genes. 
Although there are a variety o f chromosomal aberrations, two have a particular place in 
gene mapping. These are translocations and deletions.
Rarely, a disease co-segregates with a translocation. Mapping may then be relatively 
straightforward if one o f the breakpoints directly disrupts a gene or nearby control region. 
However, it has been proposed that a breakpoint may not necessarily have a direct effect 
on gene function, but could cause disease by separating genes on the same chromosome 
which act in unison (Klar 2002). If such mechanisms were in operation, mapping efforts 
would clearly be more difficult.
The identification o f chromosomal deletions has, arguably, had an even greater impact on 
mapping human disease. Even a small chromosomal deletion can affect a number of 
genes. A consequence o f this is that an individual can present with a number of different 
genetic conditions. Cytogenetic studies of such individuals can prove invaluable, as 
identification o f the deletion directly localises a disease gene to an approximate 
chromosomal position.
Both of these types of cytogenetic abnormalities were important in the mapping o f the 
gene for Duchenne Muscular Dystrophy (DMD). DMD is an X-linked recessive disorder 
and therefore is very rare in females. Cytogenetic investigation o f rare instances of 
females with DMD revealed an X-autosome translocation. The autosomes involved 
varied, but the X chromosome breakpoint always mapped to Xp21. Xp21 was also 
implicated by a study o f a boy presenting with DMD and three other X-linked conditions. 
Cytogenetic analysis demonstrated an Xp21 deletion. From there, cloning of the DMD 
gene was possible (Gelehrter and Collins 1990).
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From the discussion above it can be seen that there is the potential for a serendipitous 
chromosomal aberration to unequivocally localise a disease gene to a defined 
chromosomal region. Thus, the problems of applying linkage and association mapping to 
a complex disorder could be circumvented. However, there are disadvantages to this 
reliance upon chance. Informative cases are likely to be rare and even more rarely 
detected. In some countries, such as Denmark, national psychiatric admission registers 
and cytogenetic abnormality databases have been set up. Cross-referencing of these can 
facilitate the identification o f potentially informative individuals. However, cytogenetic 
analysis is not generally considered routine in psychiatric practice. Aetiological genes 
identified by chromosomal aberrations may only represent atypical forms o f the disease 
and not implicate the genes that are important in the wider population of people with BP.
A number of loci in BP have been implicated by cytogenetic studies. A review o f the 
literature reporting chromosomal aberrations in BP identified four genomic regions o f 
potential interest: llq21-25; 15ql 1-13; chromosome 21, and Xq28 (Craddock and Owen
1994). A more general review of chromosomal abnormalities in mental illness found 
evidence in the literature implicating lq32, lq42, llq 2 3 , 15 q l2-13, 16q22, 18pl 1, 
18q21 -22, chromosome 21, 22ql 1-13 and X specifically in BP (MacIntyre et al. 2003). 
Considerable interest has been aroused by the lq42 locus. Analysis of a large Scottish 
kindred showed a reciprocal 1; 11 translocation to co-segregate with schizophrenia and 
severe affective disorder (St Clair et al. 1990). Breakpoint analysis identified disruption 
o f two genes, which have been termed DISCI and DISC2 (Millar et al. 2000b). I will 
return to this region and DISCI in chapter 5.
Since MacIntyre et aVs review, a number of reports of chromosomal abnormalities in BP 
have been published. Duplication o f 15 q l4 due to a maternal reciprocal translation was 
identified in a patient with dismorphic features suffering from BP with psychotic features 
(Reif et al. 2004). Positron emission tomography scanning revealed bilateral 
hypometabolism in many brain regions. This is not typically observed in BP, suggesting 
that applicability o f the finding to BP in general may be limited. Sixty-nine patients with
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learning difficulties and co-existing severe psychiatric disorder were screened for 
subtelomeric deletions (Pickard et al. 2004). One patient with comorbid schizoaffective 
disorder was found to have a 4q35.2 deletion - compatible with the linkage results from a 
large multiply affected Australian pedigree (Badenhop et al. 2003).
Three case reports of BP in patients with sex chromosome abnormalities have been 
published. One described a patient with a deletion o f the long arm of chromosome Y 
(Olajossy et al. 2005), while another cited a patient with 48, XXYY syndrome (Lolak et 
al. 2005). Most recently a patient with a ring Y chromsome was reported (Mouaffak et al. 
2007). This patient also had gender identity disorder.
In addition abnormalities mapping to 1 lq  and 8q have been described. Bohm et al (Bohm 
et al. 2006) reported a young woman with Jacobsen syndrome. The deletion, of 
approximately 8 Mb, was mapped to llq24 .2  o f the paternal chromosome. Magnetic 
resonance imaging results showed hyperintensities in the frontotemporal regions. Finally, 
a seven-year-old boy with duplication of 8q22.1-q24.1 was diagnosed with BP and 
speech delay (Macayran et al. 2006).
3.3 Linkage
In this section I will firstly define linkage analysis. I will then highlight some of the 
methodological developments in linkage analysis that have occurred in response to the 
challenge of applying the technique to disorders with complex inheritance. Finally, I will 
address some o f the specific issues o f using linkage in BP and review the findings in this 
context.
3.3.1 Basic concept
Since the mapping o f the first autosomal gene (Donahue et al. 1968), linkage analysis has 
played, and continues to play, a central role in human gene mapping efforts. While gene
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aberrations can be highly informative serendipitously, linkage analysis, in its current form, 
allows systematic screening o f the whole genome to position trait loci.
Mendel’s law of assortment states that different inherited traits are inherited 
independently o f one other. A post-Watson and Crick interpretation of this law would be 
that the segregation o f any one allelic pair is independent of other allelic pairs during 
meiosis. However, linkage analysis is predicated on the fact that the physical proximity of 
two loci results in non-random assortment of alleles at these loci during gametogenesis. 
While it is apparent why loci on different chromosomes will randomly assort during 
meiosis, recombination o f homologous chromosomes will also cause random assortment 
o f loci widely separated on the same chromosome. As the distance between loci reduces, 
the recombination fraction - the proportion of meiotic events resulting in recombination 
between the two loci - will decrease. Hence, alleles at two closely sited loci will tend to 
be inherited together, i.e. they will be linked.
This phenomenon can be exploited in the mapping of disease-causing genes, as it means 
that within families a genetic disease will have a tendency to co-segregate with particular 
alleles at loci close to the aetiological gene. These patterns o f co-segregation can be 
identified by statistical testing of datasets which include genotypes and affection status 
from known pedigrees. Either parametric or nonparametric linkage analysis can be 
performed. The parametric technique of LOD score analysis has been pre-eminent in the 
history o f linkage studies.
3.3.2 Parametric and non-parametric analysis
LOD score analysis was initially developed by Morton (Morton 1955) but now has many 
derivatives. In essence LOD score analysis tests for linkage between two loci, the disease 
and the marker loci. This is achieved by postulating differing distances - or more strictly 
speaking, recombination fractions - between them and testing for compatibility with the 
observed pattern o f segregation o f disease and marker within the pedigree(s). An odds 
ratio is calculated. The numerator is the probability o f the pattern of segregation occuring
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given that they are linked at a certain recombination fraction (<0.5). The denominator is 
the probability o f the pattern occuring given that the loci are unlinked (recombination 
fraction =0.5). This calculation is repeated for linkage with different recombination 
fractions.
The LOD is the log of the odds ratio. The LOD is a measure o f the degree of certainty 
with which the null hypothesis that the loci are unlinked can be accepted or rejected.
Since traits rarely accord to perfect Mendelian inheritance, LOD score analysis has 
undergone many revisions in an attempt to improve its ability to model traits whose 
inheritance shows such deviation. Morton (Morton 1956) realised that locus 
heterogeneity could reduce the power of the LOD score method to detect linkage and 
developed a test for linkage heterogeneity, the K-test. Other tests o f heterogeneity have 
subsequently been developed, including the Admixture or A test (Smith 1963) and the B 
test (Risch 1988).
It can be readily appreciated that the phenomenon of incomplete penetrance could have a 
great effect on likelihood calculations. Hence, a penetrance function was introduced in an 
attempt to account for this (Ott 1974). However, misspecification of parameters can have 
important effects on the LOD scores (Clerget-Darpoux et a l  1986). Consequently, many 
authorities have advocated the use o f model-free analysis for complex disorders.
Model-free analysis is based on testing for deviations from the expected ratios o f allele 
sharing between affected relatives. Model-free analysis can be performed on affected sib- 
pairs or more extended pedigrees. I will pause for a moment to describe the theory behind 
affected sib-pair analysis, as I believe it illustrates the concepts behind the study o f allele 
sharing. Sib-pair analysis requires the genotypes of two affected siblings and their parents. 
For any given locus the probabilities that the siblings share 0, 1 or 2 alleles identical by 
descent are 0.25, 0.5 and 0.25 respectively. Evidence that these probabilities do not hold 
implies that the marker allele is linked to the disease locus.
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The Affected Pedigree Member Method (Weeks and Lange 1988; Weeks and Lange 1992) 
and the Nonparametric Linkage Score (NPL) method, as implemented in the program 
GENEHUNTER, can be used to look for excess allele sharing in extended pedigrees.
Linkage analysis has traditionally considered loci individually in relation to the disease. 
However, complex inheritance may arise through gene interaction. Attempts have been 
made to perform two-locus linkage analysis. To my knowledge, the first report o f a two- 
locus linkage analysis was applied to Multiple Sclerosis families and provided evidence 
for two unlinked loci (Tienari et al. 1994). More recently, a systemic two-dimensional 
genome scan of essential hypertension was performed and was able to identify novel 
epistatic loci (Bell et al. 2006). In BP, two-locus admixture linkage analysis was 
employed, with some indication that it increased the power to detect linkage when loci on 
chromosome 21q and 1 lp  were both taken into account (Smyth et al. 1997).
3.3.3 Markers
While the development o f statistical techniques has facilitated linkage analysis, the utility 
o f the approach has massively expanded as a wider array o f markers has become 
available. In the first application of linkage analysis it was possible to assign the Duffy 
blood group locus to chromosome 1 only by the observation o f an anomalous uncoiled 
region on chromosome 1 which co-segregated with the Duffy blood group antigen in 
three families (Donahue et al. 1968). Early linkage studies relied on biological markers to 
which linkage of the disease could be tested, e.g. the HLA antigens (Dupont et al. 1977).
Linkage analysis was revolutionised by the proposal o f using anonymous polymorphic 
DNA markers across the genome, rather than a very limited set o f biological markers 
(Botstein et al. 1980). The Restriction Fragment Length Polymorphisms (RFLPs) 
proposed by Botstein were superceded by the use of microsatellite markers (Olson et al. 
1989). Microsatellite markers are polymorphic repeat sequences. They offer a number o f 
advantages: they are easier to type than RFLPs, requiring only a one stage PCR; they are
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more polymorphic, and they provide more dense coverage o f the genome. Whole genome 
scans employing sets o f approximately 300-400 microsatellites have now become routine.
The ability to test markers across the whole genome, while undoubtedly advantageous, 
brings with it the important issue o f interpretation of results. Most notably, the problem 
of determining the level o f statistical significance of linkage in the face of such multiple 
testing (Lander and Schork 1994). Criteria for significance of genomewide linkage results 
have been set out (Lander and Kruglyak 1995).
Linkage analysis is able to localise a gene only to a broad region, approximately 20-30 
cM (Botstein and Risch 2003). It usually represents the first stage in gene mapping, 
requiring other techniques for finer mapping - in particular, linkage disequilibrium 
approaches. However, linkage has proved very important in the mapping of genes 
causing Mendelian disorders. One o f many notable examples o f linkage findings leading 
to cloning o f an aetiological gene being the mapping of the Cystic Fibrosis gene 
(Wainwright et al. 1985). The path from linkage to cloning has been much less direct in 
diseases demonstrating complex inheritance. However, there are successful precedents in 
complex disorders, such as the implication of HF1 gene in age related Macular 
Degeneration (Hageman et al. 2005).
3.3.4 Linkage findings in bipolar disorder
One of the earliest linkages in genetics was the report o f X-linkage to BP using colour 
blindness as a marker (Reich et al. 1969). The first linkage study of BP to employ DNA 
markers was carried in an Old Order Amish pedigree and showed linkage to chromosome 
l ip  (Egeland et al. 1987). However, lateral extension o f the family resulted in 
disappearance of the evidence for linkage (Kelsoe et al. 1989). Since Egeland’s original 
paper there has been well over a dozen linkage studies in BP. Generally results from 
these have shown poor consistency. This inconsistency could be interpreted as evidence 
of extensive locus heterogeneity in BP. It is beyond the scope o f this thesis, and probably 
o f dubious benefit, to exhaustively review each linkage paper. Consequently, I will defer
49
detailed discussion o f the evidence for linkage in particular regions of interest until 
subsequent chapters.
In the rest o f this chapter I will briefly discuss the results o f the three meta-analyses of 
linkage studies and the results which have been published subsequent to this. Before 
reviewing the results I will consider some of the particular problems o f performing 
linkage analysis in BP. I think this helps to place the discussion o f the results in a better 
critical context. I will emphasise how these difficulties might explain the inconsistent 
pattern of linkage results which are seen.
Methodological considerations
Challenges are encountered at all stages of linkage analysis in BP. There are problems 
designing appropriately powered studies, determining the ‘caseness’ of individuals, and 
applying appropriate statistical analysis - both in terms of specifying the genetic model to 
use and the interpretation of results. These issues are interrelated and cannot be dealt with 
strictly separately.
Many factors will affect the power o f linkage analysis to detect disease-causing genes. 
Power calculations are rendered very difficult, as the mode o f inheritance is not known. 
In general, linkage analysis has greater power to detect genes o f major effect than genes 
o f smaller effect (Risch and Merikangas 1996). Segregation analysis has provided some 
evidence for major effects, but it is not possible to accurately determine the size o f these 
effects in the presence o f genetic heterogeneity. While linkage analysis is robust to allelic 
heterogeneity, locus heterogeneity will reduce power.
As a common disease, it has been postulated that there are relatively high frequency 
disease alleles. If this is the case, the problem of bilineality in pedigrees is increased, 
which must be excluded in the pedigree ascertainment methodology for successful 
linkage analysis. However, retrospectively the apparent genetic heterogeneity o f BP 
shown by linkage makes multiple rare variants more likely to explain the commonness of 
the disease.
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Lack of knowledge about the mode of inheritance has caused much debate as to whether 
to apply parametric or nonparametric methods o f linkage analysis to BP. It has been 
argued that in the presence of locus heterogeneity, parametric analysis o f large multiply 
affected families is more powerful than nonparametric methods, in particular sib-pair 
analysis. Assuming that individuals within the multiply affected pedigree share a genetic 
cause, it can readily be seen that the likelihood of detecting the susceptibility locus will 
be maximised if  the whole family is considered rather than, say, an affected sib-pair 
subset o f it. However, the statistical approach used has power implications and therefore 
influence on the original design o f studies. Underpowered studies increase the probability 
o f type II (false negative) error.
Linkage is an attractive technique for the mapping of BP genes, as it does not require any 
prior knowledge o f biology o f the disease. However, linkage does have some pre­
requisites, the most significant o f these being a secure phenotype. While this problem is 
not unique to BP, is has already been seen that defining affection status is non-trivial. The 
response to this problem has been to analyse linkage results under different affection 
models. These have generally involved a division into broad and narrow phenotypes, e.g. 
a narrow phenotype classifying only those with BPI as affected and a broad phenotype 
including those with depressive disorder. Misclassification o f the phenotype could result 
in inconsistent findings by increasing the likelihood o f both type I (false positive) and 
type II error. The multiple testing which results from the use o f different affection models 
would, if left uncorrected, lead to an increase in type I error.
The difficulty with phenotype definition may, at least in part, be due to genetic 
heterogeneity. As has already been seen with segregation analysis, some authors have 
attempted to reduce any heterogeneity by using affection criteria likely to select for cases 
o f major gene effect, such as age o f onset. Applying this strategy to linkage studies has 
had striking success in mapping breast cancer genes where the BRCA1 was mapped after 
age o f onset was used to enrich pedigrees (Hall et al. 1990). From early in the history of
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BP linkage studies, researchers have attempted to incorporate age o f onset as a covariable, 
e.g (Morton and Kidd 1980), but this approach has not been universally adopted.
Other attempts to improve the phenotype definition, and thus potentially reduce 
heterogeneity, have centred on the identification o f endophenotypes. Endophenotypes can 
be thought of as cryptic phenotypes o f BP. Endophenotypes used have included lithium 
responsiveness, e.g. (Turecki et al. 2001), and white matter hyperintensities, e.g. (Aheam 
et al. 2002). However, there are as yet no clear successes for this strategy in BP, although 
it would seem to have considerable potential.
Misspecification o f the parameters for LOD score analysis is a major problem, as the 
mode of inheritance is not known in BP. Misspecification of the disease allele frequency, 
penetrance and dominance can all lead to errors in estimates o f the recombination fraction 
(Clerget-Darpoux et a l  1986). Misspecification may also have an effect on the power to 
detect linkage. Phenotype definition is also intimately related to misspecification, as 
narrow models may underestimate penetrance while broad models overestimate it. 
Clerget-Darpoux considered that there may be significant errors, particularly when 
dominant and recessive models were confused. While this is less likely to happen, the 
effect o f applying any o f these models to a complex mode of inheritance is not known.
One response to the problem o f misspecification of the model parameters is to analyse 
under a number o f different models with different parameter specification, and this has 
widely been the modus operandi in BP linkage scans. However, this compounds the 
problem of multiple testing which is inherent in genomewide linkage scans. While 
methods have been developed to correct for type I error resulting from such LOD 
maximisation techniques, e.g. (Weeks et al. 1990), such effects may not be discussed in 
some studies.
It has been determined that a LOD score of 3.3 is needed to declare significant linkage in 
a genomewide linkage scan given the use of multiple markers (Lander and Kruglyak
1995). However, this assumes that only one model o f inheritance is tested. Furthermore,
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multiple scans have now been performed in BP, perhaps as a consequence o f a number of 
underpowered studies producing negative results. As more scans are performed, the 
probability that one will, by chance alone, give a significant LOD in the absence o f true 
linkage increases. Rather than attempt to formally correct for this source o f multiple 
testing, researchers have generally considered the best evidence for a formally significant 
LOD being a true positive result is independent replication of that linkage result. 
However, this in itself has caused some statistical controversy.
While failure to replicate under formal Lander and Krugylak criteria may cast doubt on 
the original findings, in the presence of locus heterogeneity much larger sample sizes 
may be required to replicate an original positive finding. Hence, underpowered studies 
may falsely report non-replication. It has therefore been argued that the threshold for 
significance should be lowered in regions where previous evidence for linkage has been 
obtained (Suarez et al. 1994). Overall, while there is clear potential for false negatives if 
too stringent significance levels are set, it seems likely that at least some of the linkage 
results reported as significant are false positives.
3.3.5 Review of meta-analyses of bipolar linkage studies
Badner and Gershon (Badner and Gershon 2002a) performed the first meta-analysis of 
BP genome scans. The technique o f Multiple Scan Probability (MSP) was applied to 
combine reported p-values for individual linkage studies with a correction for the size of 
region containing the minimum p-value (Badner and Gershon 2002b). Badner and 
Gershon claimed that this method was a more robust means o f studying heterogeneity 
than pooling of data. They only used whole genome scans, considering linkage reports for 
particular regions more susceptible to publication bias.
In total 11 genome scans were included. Only chromosome regions with a reported p- 
value of <0.01 were included in the analysis. They found strongest evidence for a BP 
locus on chromosomes 13q (/?<6X10'6) and 22q (/K lx lO ’5). These probabilities were 
considered significant on the basis o f simulations. In this report Badner and Gershon also
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performed a meta-analysis o f schizophrenia linkage scans. Interestingly, significant 
evidence for linkage to both the 13q and 22q regions was found for schizophrenia as well.
Segurado et al (Segurado et al. 2003) performed the second meta-analysis o f BP genome 
scans. A rank-based technique referred to as Genome Scan Meta-Analysis (GSMA) was 
applied (Wise et al. 1999). In this analysis the genome was divided into 120 ‘bins’, 
representing, on average, 29.1 cM. For each study, every bin was given a rank according 
to the linkage score (or p-value) within that bin. The average rank across the studies was 
then calculated for each bin. A weighted analysis was also performed where the within 
study ranks were weighted according to the study size. Two p-values were calculated for 
each average rank value. Simulations were performed to determine p-value at which 
significant evidence for a bin containing a BP locus could be declared.
An attempt was made to identify all genome scans in BP, whether published or 
unpublished. However, scans o f less than 20 affected cases were excluded, as they were 
not thought to increase the power to detect linkage under this methodology. In total, 18 
genome scans were included. Data was obtained for every marker in the scan rather than 
just using published data. The research groups were asked to indicate a primary linkage 
statistic and this was used for ranking, otherwise the most significant statistic was used. 
Segurado et al stated that there was reasonable homogeneity between studies in terms of 
diagnostic instruments, genome coverage and statistical analysis used, although 
homogeneity was not formally tested. Analysis under three affection models was carried 
out: very narrow, narrow and broad. No bin achieved genomewide significance under any 
of the models. Nominally significant results were obtained on 14q, 9p, lOq, 18p-q and 8q.
Most recently, McQueen et al (McQueen et al. 2005) performed a meta-analysis using 
original genotype data. It was argued that this approach would increase the power to 
detect linkage and allow control over sources of heterogeneity. Original genotype data 
from 11 BP scans was included. This represented 5,176 individuals from 1,067 families. 
There were several important exclusion criteria: studies with large pedigrees; those 
derived from unique, e.g. founder, populations; those employing non-standard
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ascertainment schemes, and those lacking original data. Where possible, all markers were 
located on a common genetic map. The genotypes were pooled and error detection was 
performed by checking for Mendelian errors and unlikely genotypes. The affection 
models were defined as narrow (BPI only) and broad (BPII and BPI). Nonparametric 
multipoint analysis was performed. The threshold for genomewide significance was 
calculated and a Bonferroni correction made as two affection models were employed. 
Significant linkage was found on 6q for the narrow phenotype and 8q for the broad 
phenotype.
In principle, meta-analysis should provide greater power to detect linkage than individual 
studies and be more conservative. However, there is little consistency even in meta­
analysis, the exception perhaps being the 8q region, which was formally significant in the 
analysis by McQueen et al and nominally significant in the Segurado et al analysis.
A number of explanations have been put forward to explain the discrepancies. Firstly, it 
is worth noting that only four datasets were common to all these meta-analyses. If the 
discrepancy between the Badner and Gershon and Segurado et al findings is considered, 
either the first reports false positives, or the second false negatives, or both. One 
mechanism by which false positives can arise is use o f data from the same families in 
more than one linkage study, a possibility that Badner and Gershon could not completely 
exclude. With Segurado et aVs study it should be bome in mind that the method is unable 
to exclude linkage, thus the interpretation should be that no significant evidence for 
linkage was found in the dataset used. Segurado et al excluded smaller studies, which 
may have provided some o f the evidence for the 13q and 22q loci. However, as 
commented by Levinson et al (Levinson et al. 2003), GMSA may be more powerful for 
detecting genes that have a small effect in most families, and therefore may not be 
appropriate where there is much locus heterogeneity of genes o f major effect.
McQueen et al may have succeeded to find linkage where Segurado et al failed because 
o f increased power o f using original genotypes. However, explanations for the 
inconsistency o f these results with those o f Badner and Gershon may be similar to those
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proposed for the inconsistency with Segurado et al. The exclusion criteria applied by 
McQueen et al may be of particular relevance here. In essence, they were applied on the 
basis that it was desirable to identify loci which are relevant in the majority o f BP cases 
rather than ‘personal loci’ present in a small proportion o f BP cases. However, as 
discussed with reference to the Segurado et al results, this may not be appropriate in the 
situation of extreme locus heterogeneity. In other words, it may be that this approach is 
inherently biased towards the identification of loci with smaller effect. Indeed, the effect 
sizes estimated for the significant 6q and 8q loci were both small (1.34 and 1.26 
respectively).
Further genomewide linkage studies o f BP have been published subsequent to McQueen 
et a l 's meta-analysis and are summarised in Table 3.3.1 below. Generally these studies 
have not supported the regions implicated by the meta-analyses. However, this needs to 
be formally tested by further meta-analysis incorporating the new data. The significant 
linkage reported in the 6q24-25 region (Schumacher et al. 2005b; Cheng et al. 2006) is 
not really compatible with McQueen et aVs findings. However, it is feasible that the 
linkage signal detected in kindred cr201 from Costa Rica (Service et a l  2006) originates 
from the same locus. With regard to chrossome 8q, the linkage found in the large 
pedigree from Eastern Cuba (Marcheco-Teruel et al. 2006) is too centromeric to accord 
with that reported in the meta-analysis.
Two trends seem to have emerged from recent linkage studies. Increasingly, attempts 
have been made to condition the linkage analysis on putative subtypes o f BP. Other 
investigators have sought to identify ‘common susceptibility’ loci by using affection 
models which span traditional diagnostic boundaries. These approaches have yielded 
evidence for two ‘psychotic’ BP loci. 16pl2-13 is supported by subanalysis of a large US 
study (Cheng et al. 2006) and linkage analysis of BP affective puerperal psychosis 
pedigrees (Jones et al. 2007). Analyisis o f psychotic pedigrees from the National Institute 
o f Mental Health (NIMH) samples yielded a linkage significant peak at the GABRA1 
gene on 5q34 (Kemer et al. 2007). Significant linakge was found very close to this gene
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in a combined analysis o f pedigrees from Columbia and Costa Rica (Herzberg et al. 
2006). O f note, significant linkage to schizophrenia has been found in this region.
Table 3.1: Summary of recent linkage findings in BP
Study Description of study
Significant or ‘best’ results
Region or 
marker
Linkage
statistic
(Hamshere et 
al. 2005)
24 ‘schizoaffective’ pedigrees identified by at least 
one member with SA, BP type. SA, BPI and SA, 
BP type coded as affected. 35 affected sib-pairs 
analysed.
lq42 LOD-3.54
(Schumacher 
e t al. 2005b)
52 BP families of Romany, Spanish and Bulgarian 
descent used in first stage. 56 German families 
included in subsequent fine mapping stage.
4q31 NPL=5.49
6q24 NPL=r4.87
lp35-36 NPL=3.97
(Service e t al. 
2006)
Single kindred (cr201) from the central valley of 
Costa Rica. 168 persons, 25 BPI. SNP genotyping 
performed. Two-point parametric analysis only 
due to computational constraints.
6ql4 LOD=2.78
(Cheng e t al. 
2006)
US sample of 1,060 individuals from 154 
multiplex families. Analysis by psychosis, suicide 
attempts, and comorbid panic disorder subtypes 
also performed.
10q25,10pl2,
16q24,
16p 13,16p 12 
(standard 
models) Significant according to 
own 
simulations
16p 12
(psychosis)
6q25 (suicide 
attempts)
7q21 (panic 
disorder)
(Kemer e t al. 
2007)
Re-analysed data from the NIMH samples. 
‘Psychotic’ BP pedigrees identified by at least two 
members with ‘psychotic’ BP or SA. Family 
members coded as affected according to the 
psychosis section of the DIGS, all others were 
coded as unknown. NPL analysis performed
5q34(GABRA
1) /?<0.00001
(Etain e t al. 
2006)
87 sib-pairs ascertained by an early onset BPI 
proband, (onset below 21 years of age). Siblings 
diagnosed as affected if reached criteria for: BPI, 
BPII or SA regardless of age of onset. Siblings 
experiencing episodes of major depression before 
the age of 21 also classified as affected. NPL 
analysis performed.
3pl4 p = 0.0002
(Faraone e t al. 
2006)
Re-analysed NIMH Genetics Initiative BP wave 1 
sample, using ordered subset analysis with 
minimal age of onset of mania in each family as 
the subset identifying covariate. Subset of 58 
families with onset of mania <20 identified.
9q34 LOD-3.21
(Jones e t al. 
2007)
‘bipolar affective puerperal psychosis’ pedigrees 
identified by at least one member with manic or 
psychotic episode within six weeks of delivery.
16pl3 LOD=4.07
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BPI, BPII and SA, BP type coded as affected. 54 
sib-pairs analysed.
(Venken et al. 
2007)
10 multigenerational BP pedigrees from Belgium, 
including one large Ashenazi Jewish pedigree.
10q21.3- 
10q22.3 HLOD-3.28
(Zandi e t al. 
2007)
98 pedigrees. 428 subjects genotyped. Covariate 
analysis performed for age of onset, psychosis and 
comorbid anxiety disorder.
2q24 (standard 
models) p-0.0012
(Cassidy e t al. 
2007)
Irish sample. Most significant result obtained 
under a narrow (BPI) only affection model. D14S588 p=0.0006
(Goes et al. 
2007)
Reanalysis of NIMHGI collaborative cohort (708 
pedigrees). Mood-incongruent psychotic features 
incorporated as covariate.
Increased evidence for linkage 
13q21-33 and 2pll-ql4
(Herzberg e t  
al. 2006)
Six multiplex BP pedigrees from Antioquia, North 
West Columbia. Follow up in expanded set of 
Costa Rican and Columbian pedigrees.
5q31-33 /?<0.00004
(Vazza e t al. 
2007)
16 pedigrees from North East Italy identified by 
either SZ of BP or probands. D15S1014 p=0.00197
(Marcheco- 
Teruel e t al. 
2006)
Six generation BPI pedigree from Eastern Cuba. 
28 affected members. SNP genotyping using 
Affymetrix chip. Most significant results NPL 
analysis using branches of family.
14ql 1.2-12, 
5q21.3-22.3, 
5p 13.1- 
ql2.3, 
6p22.3, 
8ql 3.3- 
21.13, 
10q22.3- 
23.32
p <  0.005
SA, BP type= sch izoaffective  d isorder (BP type) 
N IM H =N ational Institute o f  M ental Health 
N IM H G I-N atio n a l Institute o f  M ental Health G enetics Iniative 
H L O D =H eterogeneity  LOD
3.3.6 Homozygosity mapping
Homozygosity mapping has proved a useful technique for the mapping o f some rare 
recessive disorders. Examples o f diseases in which homozygosity mapping has been 
crucial to mapping efforts include the MRAP2 form of Familial Glucorticoid Deficiency 
(Metherell et a l  2005) and Charcot-Marie tooth disease, type 4C (LeGuem et al. 1996).
Homozygosity mapping requires multiply affected pedigrees in which all disease alleles 
are derived from a common ancestor. The greater the degree o f inbreeding within 
pedigrees, the greater the likelihood of this occurring. The affected individual will 
therefore be homozygous for the disease allele(s). There will also be varying 
homozygosity for markers extending from the disease locus. Attempts are therefore made
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to identify all regions of homozygosity between the affected individuals on the basis that 
one region will harbour the disease-causing allele.
Only limited evidence for recessive inheritance operating in BP has been drawn from 
segregation analysis (Faraone et al. 1990). However this could be due to preferential o f 
‘dominant’ looking families. A few linkage studies have found maximum LOD scores 
under a recessive model, e.g. (Tomas et al. 2006). This may be due the existence of a 
recessive form of the disorder or be an artefact of testing multiple modes o f inheritance.
Ewald et al (Ewald et al. 2003) performed genomewide linkage of a single pedigree 
containing two individuals with BP who were offspring o f a first cousin marriage. 
Homozygosity mapping was also performed, employing three affection status models. 
Evidence for a susceptibility loci at 2q31.3, 10, 12q24 and 21q22.3 was found by linkage 
analysis and haplotype sharing. Subsequently, homozygosity mapping in 22 
consanguineous families was performed using only one affected offspring from each 
family (Ewald et al. 2005). Approximately 1,500 Single Nucleotide Polymorphisms 
(SNPs) were typed in each of 24 individuals with BP using microarrays. A parametric 
multipoint LOD of 1.96 was found in the region of 17q24-q25.
3.4 Summary
A convincing aggregation o f chromosomal abnormalities in specific chromosomal 
regions in BP has not, as yet, clearly been seen. However, the chromosomal aberrations 
and linkage results are mutually supportive in some regions, e.g. Iq42. It could be argued 
that some of the cytogenetic findings have been somewhat neglected. Identification of 
chromosomal aberrations remains an attractive approach due to its directness and 
circumvention of many of the methodological problems o f linkage.
Aberrations that cause breakpoints are particularly desirable, as they may exactly identify 
the aetiological gene. The example of DISCI in schizophrenia sets a precedent for this in 
psychiatric genetics. The example of DISCI also demonstrates that linkage and
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chromosomal abnormalities, although considered separately above, can be used together 
in certain circumstances.
I believe that the study o f cytogentic abnormalities may still have a role to play in BP 
mapping efforts. The resolution of abnormality detection continues to improve and as an 
increasing number of individuals pass the peak age o f onset of BP the repository of 
chromosomal aberrations is bound to increase.
Despite the methodological problems, and in particular concerns over multiple testing, 
significant linkage has been found to a number of chromosome regions. This suggests 
considerable locus heterogeneity, although the sheer number o f loci raises concerns about 
false positives. Meta-analysis does not seem to have resolved this to date but is the 
logical response to the problem. It is questionable that a sufficiently powerful meta- 
analytical linkage technique, which can deal with extreme heterogeneity, has yet been 
developed.
While linkage studies continue to be performed, much o f the research effort has now 
turned to fine mapping. Fine mapping efforts have generally employed techniques based 
on the phenomenon o f linkage disequilibrium, which is the subject o f the next chapter.
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Chapter 4: Mapping Bipolar Disorder II - Linkage Disequilibrium
Mapping
In a similar manner to the last chapter, I will begin with a brief discussion o f the 
theoretical basis of linkage disequilibrium mapping - otherwise known as allelic 
association - and highlight some of the methodological problems related to this. I will 
then give a general review of the findings from association studies carried out in BP. 
Association studies have proliferated in the field and it is beyond the scope o f this thesis 
to deal with each one individually. Hence in this chapter I will consider only two loci as 
exemplars. These loci were chosen as meta-analysis o f association studies support their 
involvement in the aetiology o f BP. I will also refer to the recently published 
genomewide association studies (GWA). I will defer discussion o f association findings 
pertinent to the loci I have tested until chapter 5.
4.1 Basic concept
Whereas linkage analysis relies on the co-segregation of alleles with a disease within 
families, linkage disequilibrium mapping is based on co-segregation of alleles with a 
disease at the population level. This can occur due to the evolutionary phenomenon of 
linkage disequilibrium (LD). Simply stated, particular alleles at genetic loci that are 
physically very close to one another will tend to remain together during meiosis. Hence, 
their assortment will be non-random.
As the physical distance between two loci decreases, the probability that meiotic 
recombination will disrupt the relationship between the two alleles drops. It was 
estimated that useful LD is unlikely to extend beyond about 3 kb (Kruglyak 1999b). 
However, distances over which LD has been found to operate have been revised upwards 
as more empirical data has been gathered. For instance, it was shown that LD in a 
population o f northern European descent typically extends 60 kb from common alleles
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(Reich et al. 2001). However, LD has been shown to vary across chromosomal regions, 
e.g. (Nickerson et al. 1998).
Fine mapping of disease genes can be achieved by identification of LD between alleles at 
marker loci and a disease. LD is identified by testing for association between particular 
alleles at the marker locus and the disease (allelic association). If LD is present, an 
unequal distribution o f alleles at the marker locus should be seen when a group of 
individuals with the disease (cases) and a group without (controls) are compared. The 
associated allele or alleles thus identified could either be directly involved in disease 
susceptibility or, more likely, be in LD with an aetiological mutation.
To illustrate the processes from an evolutionary perspective let us assume that there is a 
single (unknown) aetiological mutation increasing susceptibility to BP. The mutation can 
be termed B. This mutation will have occurred on a certain haplotypic background. 
Consider a polymorphic ‘marker’ on this mutated chromosome in very close proximity to 
B. Let us assume that an allele referred to as M is present on this particular chromosome. 
Provided that the mutation does not adversely affect reproductive fitness and the 
population is in expansion, the number of people in the population with the disease will 
increase. If there are no recombination events between the two loci all individuals with 
BP in the population will also carry the M allele at the marker locus. Hence, if you can 
measure the number o f M alleles in a sample of people with the disease and compare it 
with a sample o f people without the disease one will find that M should be 
overrepresented in the case group.
Clearly the above example describes the simplest possible situation, but hopefully it 
illustrates the underlying concept. In realistic scenarios one could expect multiple 
susceptibility alleles and different founding mutations, resulting in private associations 
with neighbouring alleles. This has implications for both the optimal population to be 
studied and the sample sizes that might be needed to detect susceptibility when there is 
genetic heterogeneity in susceptibility to BP, as strongly indicated by the linkage results.
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It is important to note that the associated allele may be the common allele in the 
population which is in LD with the aetiological mutation. Hence, there may only be small 
differences in allele frequencies between the case and control groups.
4.2 LD measures
As a prerequisite to more in-depth consideration o f LD, a brief word on the measures of 
LD is necessary. There are several different measures of LD, each of which has 
advantages in certain situations.
Lewontin (Lewontin 1964) developed the first measure o f LD, denoted D. D is a simple 
measure of the difference between the observed frequency o f co-occurrence o f particular 
alleles at two loci and that which would be expected on the basis o f allele frequencies. 
Let us again consider the hypothetical loci B and M. We shall assume they are bi-allelic 
and denote the alleles Bi, B 2 and Mi, M2 . The expected frequency of the B1M 1 haplotype 
is the product o f their respective allele frequencies (pi=frequency Bi and ^i=frequency 
Mi). The observed frequency of the B 1M 1 haplotype can be denoted p u . Thus:
D=Pn-P \q \
If D  is greater than 0 then LD is said to exist. However, as the value o f D  is dependent on 
allele frequencies it is usual to quote the normalised measure D
D -D  / Dmax
A D  ’ o f 0 means there is no LD while 1 signifies complete LD. D  can also be normalised 
by division by the square root o f the product of all the allele frequencies. This value is 
denoted r.
r=D / square Too\{p\p2q\qi)
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4.3 Study design
I will expand my explanation of the theory and problems o f LD mapping by considering 
elements o f association study design. While I have tried to separate the elements by 
headings for clarity’s sake, it can be appreciated that many o f the issues are interrelated.
4.3.1 Power
There are a number o f factors which will affect the power o f a study to detect association 
between an allele and BP, including: LD between the marker and disease allele; genetic 
heterogeneity; sample size and effect size of disease allele.
A priori the extent of LD between the marker allele and a true susceptibility allele cannot 
be known. Since neither the totality o f allelic variation in the human genome nor the 
extent o f LD between them in all human populations is known, attempts at systematic LD 
mapping can only be approximate. However, the HapMap project is continually 
expanding knowledge of LD patterns, enabling increasingly comprehensive mapping 
efforts.
LD between a marker allele and a BP susceptibility allele will be influenced by numerous 
factors. The degree o f LD which exists will primarily be a function of the number of 
generations which have passed since the mutation occurred and the recombination rate. 
LD will decline with successive meiosis at any given recombination rate. However 
neither o f these values are known. Estimates of recombination are prone to error due to 
marked variance in recombination rates across the genome, with some recombination hot 
spots.
Models regarding the genesis o f BP susceptibility alleles are pertinent here. It has been 
hypothesised that susceptibility alleles for common diseases that are seen across the globe, 
of which BP is one, may have arisen before the ‘Out o f Africa’ expansion o f modem 
humans approximately 100,000 years ago (Kruglyak 1999a). One would now expect to
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observe only short range LD under such conditions, as LD has been eroded by the high 
number of generations since the mutational event. Thus, more markers would be required 
for mapping.
In addition to recombination, subsequent mutations of the marker allele, or indeed the 
susceptibility allele itself, will cause a breakdown in LD. The implication o f this for the 
choice of markers for LD mapping will be further discussed below.
Factors related to population history are the other main determinants of LD patterns and 
include genetic drift, population growth, admixture and population structure. However, 
the effect of these processes are not well characterised in human populations and their 
implication for LD mapping is not entirely clear.
Power to detect LD will be maximised when a single mutation arising on an uncommon 
haplotypic background accounts for all cases o f disease in subsequent generations of that 
population. Hence, when the cases are sampled from the population all susceptibility 
alleles will have arisen from a common ancestor. If susceptibility alleles have arisen on 
more than one haplotypic background the power to detect LD will be reduced. In contrast 
to linkage analysis, LD mapping is affected by allelic as well as locus heterogeneity. The 
linkage results suggest that there is considerable locus heterogeneity, while the extent of 
allelic heterogeneity is unknown.
It logically follows that for any given number of markers tested, the larger the effect size 
of a susceptibility allele at a population level the greater the power of LD mapping to 
detect that allele. However, it has been demonstrated that LD mapping has good power to 
detect genes of small effect (Risch and Merikangas 1996). There is controversy as to the 
likely effect size of BP susceptibility genes. It has been argued that the genes must be of 
modest effect size (Craddock et al. 1995). However, the linkage results are consistent 
with there being genes of large effect size which only operate in a small proportion of BP 
cases and hence have a small effect size on the BP population as a whole.
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4.3.2 Sample groups
As alluded to above, the basic requirement for LD mapping is a sample o f cases and a 
sample o f controls between which allele frequencies can be compared. Clearly one only 
wants to identify frequency differences which stem from LD between the marker and 
susceptibility allele, rather than from spurious causes. Hence, there has been much debate 
as to the optimal control group. There have been two basic approaches: population based 
case-control and family based studies.
The main methodological criticism with case-control studies is the potential confounding 
of results by population stratification. Allele frequencies for non-conserved bases may 
vary markedly between different ancestral populations. Hence, it can be seen how the 
unequal distribution o f individuals from different populations across the case and control 
groups could create allele frequency differences unrelated to disease association. There is 
also the danger that true associations could be masked by population allele frequency 
effects. For example, large interpopulation differences were found for the DRD2 Taq 1 
allele which had previously been associated with alcoholism (Goldman et al. 1993). No 
association was found between the Taq 1 allele and alcoholism in a case-control sample 
derived from a solely Cheyenne Indian population, although it has to be said the numbers 
were small. The problem of stratification can, however, be addressed at the recruitment 
stage by using ancestral screening for all volunteers. Furthermore, stratification can be 
tested for by determining the allele frequencies in the case-control groups at loci unlinked 
to BP (genomic control).
There has been some debate as to whether it is acceptable to use a control group derived 
from the general population or a ‘supernormal’ group which has been screened for BP 
and related illness. It has been asserted that the loss of power using unscreened controls is 
minimal (Owen et al. 1997). However, supernormal controls were used successfully in 
the LD mapping o f an asthma susceptibility gene, ADAM33 (Van Eerdewegh et al. 2002).
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These methodological pitfalls have to be set against a number o f distinct advantages of 
the case-controls paradigm. Sample size and cost considerations generally favour case- 
control designs over family based studies on the basis o f ease o f recruitment. Furthermore, 
it could be argued that the results o f case-control studies are more generalisable, or at 
least that different genetic susceptibilities may be identified because of inherent selection 
bias in the trio design (Brunn and Ewald 1999).
The alternative strategy involves the use of family based samples. It was recognised that 
the untransmitted haplotypes o f the parents of an affected proband could be used as the 
control (Falk and Rubinstein 1987). It has been noted that if  each case haplotype is 
effectively matched with a control haplotype derived from the same population the risk of 
false associations due to stratification are negated (Craddock et al. 2001). Falk and 
Rubenstein’s original haplotype relative risk method has undergone much modification 
and development. One important development was that of the transmission 
disequilibrium test (TDT) to take account of matched pair data (Spielman et al. 1993). 
Subsequent refinements o f the TDT have enabled it to deal with both multiallelic markers 
(Curtis and Sham 1995) and multiple markers (Wilson 1997). In addition, refinements 
have been made to utilise the various combinations of pedigree data that may be available.
Family based tests are not, however, immune to criticism on theoretical grounds. Firstly, 
the TDT is a test o f both linkage and association. Hence, there is the danger of 
confounding linkage with association. Secondly, TDT techniques are less efficient as not 
all alleles typed contribute to the analysis and some individuals will be uninformative. 
For instance, it was shown that trio TDT is only two thirds as efficient as case-control 
samples even if all the individuals are fully informative (Morton and Collins 1998).
The discussion above has focused on the control groups, but the characteristics o f the 
case group are o f course crucial to successful LD mapping. It can be understood that, for 
any given case sample size, power to detect a particular susceptibility locus will decrease 
as locus heterogeneity increases. Approaches to defining more homogenous samples have 
been mentioned with regard to linkage studies. However, the ‘Catch 22’ situation of the a
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priori uncertainty regarding phenotype/genotype correlation persists. Generally, 
association studies have used ICD-10, DSM-IV, or RDC definitions o f BP. However, 
some investigators have separated BPI and BPII for study on the basis that they may be 
genetically distinct, e.g. (Del Zompo et a l 2007).
4.3.3 Populations
There has been much debate as to the optimal population from which to draw samples for 
LD mapping. This debate has revolved around the age and extent of inbreeding which is 
desirable. It has been proposed that ‘young’ populations that have been genetically 
isolated, e.g. the Finns, should be used. Founding of a population can be thought of as 
taking a small sample o f the haplotypic variation of a much larger population -  the 
sample being the population founders. Thus, one could consider the founding o f a 
population as the resetting o f the LD clock. Generally, higher levels of LD have been 
demonstrated in younger populations (Peltonen et al. 2000). Furthermore, presuming that 
the disease-causing mutations in the population are not new, it follows that the disease 
alleles are derived from a small number o f founders. Thus, genetic heterogeneity should 
be reduced with a commensurate increase in power to detect the relevant alleles.
However, it is not universally accepted that genetic isolates are advantageous for LD 
mapping. Not all investigators have found increased LD in genetic isolates. For example, 
it was not found that LD was greatly increased in genetic isolates such as the Lapps and 
Basques (Lonjou et al. 1999). It has been argued that heterogeneity would only be 
reduced if  very severe bottlenecks had occurred under a common variant oligenic model. 
Furthermore, heterozygosity will be reduced in inbred populations, thus reducing the 
efficiency of TDT (Jorde 2000). In fact, it may be that lower LD is desirable to achieve 
higher resolution mapping.
Some investigators have advocated the use of admixture populations, e.g (Wright et al. 
1999). If there are different allele frequencies in the two populations, recombination 
events following mixture o f the populations will set up new LD relationships. LD will
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quickly break down between unlinked loci and this phenomenon can be exploited for 
admixture mapping. However, the need to use a population that is not continuing to 
undergo admixture limits its practical value.
Ultimately, the choice of population will depend on the aim of the study in terms of the 
mapping resolution required and resources available. In some situations a two stage 
mapping approach may be appropriate (Goldstein and Weale 2001). Initial mapping is 
performed in a younger population requiring a lower marker density. More precise 
localisation can then be achieved by mapping of associated regions in older populations.
I believe there is also an issue o f whether it is most appropriate to follow up linkage 
findings in an association sample derived from a broadly similar population. Given that 
the linkage results indicate heterogeneity in BP, and assuming that isolated populations 
do indeed increase the homogeneity o f BP, it is likely that individual susceptibility loci 
make differing contributions to the totality of disease across different populations. 
Therefore, attempting to fine map a region implicated in an isolated population might 
require a sample of higher power from an outbred population where this locus is 
contributing less to the disease burden.
4.3.4 Markers
There has been some debate as to whether to employ microsatellite or SNP markers for 
LD mapping. For both historical and theoretical reasons microsatellite markers have 
generally been preferred in linkage studies. Four of the key issues in marker selection for 
LD studies are: degree o f polymorphism, marker mutation rate, marker density, and ease 
of typing. Being more polymorphic, microsatellites have a theoretical advantage over 
SNPs in terms of power. It can be seen that with more potential marker alleles for a new 
aetiological mutation to associate with, the likelihood o f it occurring on a ‘rare’ 
haplotypic background is increased. This scenario will increase the power to detect LD 
(Jorde 2000). However, this advantage may be offset by the higher mutation rate o f some 
microsatellite loci which will cause a breakdown in LD (Weiss 1998).
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The Human Genome Mapping project has lead to the identification of thousands of 
microsatellite markers spanning the genome. However, SNPs account for a far greater 
proportion o f genetic variation, with an estimated ten million SNPs across the genome 
(http://www.hapmap.org/). Hence, a far higher marker density can be achieved with SNPs. 
It is the hope o f the HapMap project that the information collated will allow selection o f 
SNPs for both systematic and efficient mapping. As the LD relationships between SNPs 
are elucidated, it becomes possible to identify so called tagging SNPs -  SNPs that capture 
a pre-ordained amount o f the SNP diversity in that region. However, the extent of LD 
needed between the tagging SNPs and those SNPs being tagged in order to capture 
diversity relevant to the disease is unresolved.
Marker heterozygosity is a particular issue in SNP selection. Theoretically, a SNP with a 
heterozygosity o f 0.5 would maximise the power to detect LD with a susceptibility allele, 
assuming an equal likelihood o f the allele arising on the two backgrounds. This 
consideration has lead to SNPs with minor allele frequencies greater than 0.05 generally 
being used for LD mapping. However, it has been argued that SNPs of lower 
heterozygosity are more likely to be casual or in LD with a casual SNP (Collins et al. 
1999).
The emphasis on SNPs has fuelled the development o f multiple SNP typing methods. 
Breen (Breen 2002) has provided a useful review o f SNP technologies. Very high 
throughput methods have now been developed, culminating in SNP microarrays which 
allow testing of up to one million SNPs at a time.
4.3.5 Haplotype analysis
Simply stated, a haplotype is the combination of alleles at a particular set o f loci on a 
given chromosome. An aetiological mutation will have necessarily occurred on a 
particular haplotype. If  LD decay is indeed driven primarily by recombination, this 
ancestral haplotype will have progressively shortened with recombination events. It is
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this truncated ancestral haplotype which should be overrepresented in cases compared to 
controls. It has been argued that the identification o f such mutation-harbouring ancestral 
haplotypes is the primary goal o f LD mapping (Daly et al. 2001). It is intuitively clear 
that the single marker approach, that predominated until recently, will go only as far as to 
dichotomise the totality of haplotypes.
Daly et al (Daly et al. 2001) studied a 500 kb region o f 5q31 using 103 SNPs. Discrete 
haplotype blocks ranging from 10-100 kb in length, which contained only a few common 
haplotypes, were identified. Treating the haplotypes within each block as alleles, a 
stepwise decay in LD was observed as distance from a given block increased. It was 
assumed that these steps indicated historical sites of recombination. This pattern was 
more readily understandable than the pattern of single marker LD where considerable 
fluctuations in LD were observed. Such ‘noise’ in single marker analysis reflects the 
mutational history o f individual markers and has important implications for interpreting 
LD results, as true disease associations may be missed. Thus, Daly et al advocated the 
creation of a comprehensive haplotypic map to facilitate mapping approaches based on 
haplotypes within LD blocks.
These arguments provided much o f the motivation for the HapMap Project (2003). 
Determination o f the haplotypes present in various populations should enable haplotype- 
tagging SNPs to be identified. These should be able to capture a defined proportion o f the 
haplotype variation.
Despite the theoretical attractions o f haplotype analysis, there are both methodological 
obstacles and the potential for the introduction of errors. Unambiguous haplotype 
assignment necessitates the use o f a trio study design. Case-control samples can be used 
but haplotype frequencies have to be estimated using the EM algorithm. Haplotype 
analysis is very sensitive to genotyping error (Moskvina et al. 2006). This generally leads 
to type I error, with highly inflated significance values for haplotypes in the absence of 
any single marker associations. Various tests can be performed to try to identify 
genotyping error, including testing for Hardy Weinberg Equilibrium (HWE).
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4.3.6 Statistical considerations
I will not enter into a detailed account of the statistical tests which have been applied to 
association data, but merely point out some of the issues regarding sources o f error and 
interpretation o f association results.
The null hypothesis in association studies is that the locus (or loci) being studied does not 
have an effect on phenotype, and therefore the allele frequencies are expected to be the 
same in the case and control groups. Hence, one is in essence simply testing the 
significance o f the difference between observed and expected frequencies. This is 
generally achieved by use of the chi-squared test or a derivation thereof. The chi-squared 
test generates a p-value (nominal significance). This is the probability of obtaining the 
observed value o f the chi-squared statistic if the null hypothesis is correct, i.e. it is the 
probability o f obtaining a false positive result.
In the majority o f association studies more than one chi-squared test is performed. If one 
follows convention and declares a p-value below 0.05 significant, then if 100 independent 
tests are carried out one would expect five to render, by chance, significant p-values. 
Consequently, account must be taken of multiple testing to avoid the probability o f type I 
error increasing. The Bonferroni correction, a simple division o f the significance level for 
each test by the number o f tests performed, is often applied. However, it is generally 
considered conservative because the tests are not fully independent for markers in LD.
It is, of course, as important to avoid type II error as type I. Too stringent correction is 
one potential source o f this. Replication of positive findings in independent samples can 
circumvent this problem - by testing only the associated markers from the original sample 
the problem of multiple testing is minimised. The debate over the interpretation o f LOD 
scores in regions showing prior evidence for linkage has been recapitulated for 
association findings. The appropriate significance level to use given a priori evidence for 
association is unresolved. Theoretically, replication, or rather failure o f replication,
72
should detect type I error in the original sample. However, interpretation o f a negative 
result is complex in most realistic situations.
It is also possible to test for gene-gene interaction in association data using multivariate 
statistical techniques such as logistic regression. However, the study of such epistasis is 
hampered by lack o f confirmed aetiological mutations.
4.3.7 Systematic LD mapping versus candidate gene approach
At the end of chapter 3 I indicated that LD mapping naturally took over where linkage 
stopped. Linkage can be used for approximate localisation and then fine mapping 
achieved by LD. Indeed, this paradigm has been successfully applied to gene discovery in 
Mendelian disorders, e.g. Cystic Fibrosis (Kerem et a l 1989). However, the systematic 
LD mapping o f the multiple broad linkage regions implicated in BP has been prohibited 
by time and cost implications.
The alternative, but often complimentary, candidate gene approach has met with some 
success in the study o f complex diseases, e.g. the identification o f a susceptibility locus 
for Age Related Macular Degeneration (Hageman et a l  2005). However, as alluded to 
previously, the combination o f the high proportion of the total number of human genes 
expressed in the brain and our relative ignorance of the molecular pathology of BP makes 
it hard to refine candidate genes. The story in BP is essentially one of a hybrid approach 
where the focus has been on candidate genes, lying within a region implicated by linkage. 
This has a conceptual attraction from a Bayesian standpoint due to the a priori evidence 
that a region actually harbours a susceptibility gene.
Until very recently systematic association testing for even a single candidate gene has 
represented a major undertaking. It has been argued that functional polymorphisms 
should first be targeted when testing any given gene, as prior probability dictates this will 
be the most efficient strategy for identifying an association (Sobell et a l 1992). However, 
it is far from clear that the aetiology being searched for in BP is a change in protein
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sequence and laboratory based methods may be needed to determine the effect of a 
polymorphism on gene expression.
4.4 Association studies in bipolar disorder
The initial focus o f association studies in BP was on candidate genes from the 
monoamine systems, particularly 5HT and dopamine, noradrenaline. These systems were 
primarily implicated by the known actions of medications that have been found to be 
effective in the treatment o f BP. Genes coding for receptors o f these neurotransmitters as 
well as critical enzymes in their production and degradation were considered candidates. 
The emphasis in early studies was on polymorphisms o f known functional significance 
on gene expression or protein structure.
The association results in BP are analogous to the linkage results, in that the findings 
have not been strongly replicable. It has been proposed that the primary reason for this is 
that the effects of individual genes in BP are small and that few of the published studies 
have the power to detect these effects. However, it is equally plausible that the 
inconsistency may be primarily attributable to genetic heterogeneity. Susceptibility loci 
may have a major effect at an individual level but a small effect at a population level due 
to genetic heterogeneity. A similar argument as that used to explain inconsistent linkage 
can also be invoked here, i.e. that initial positive association requires greater numbers for 
replication. O f course, a combination of these two factors may be operating. Overall, 
however, the suggestion is that there are a lot of false negatives in the literature.
The burgeoning number o f association studies makes it impossible to talk about each 
individually. A search o f the GAD http://geneticassociationdb.nih.gov/cgi-bin/index.cgi 
(17.11.2006) for BP gave 272 entries. This will represent an underestimate of the total 
number of LD studies performed in BP as not all studies are submitted to the database. I 
will therefore restrict my consideration in this chapter to two functional candidate genes - 
the serotonin transporter gene (5-HTT) and monoamine oxidase A gene (MAOA) - in 
which meta-anlysis has supported association. For each gene I will discuss only the meta­
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analyses that has been performed. I will deal with these in some detail and hope that this 
will illustrate the critical appraisal necessary in interpretating association results. I will 
begin by consideration o f some general issues regarding meta-analysis of LD studies in 
BP.
4.4.1 Meta-analysis of association studies
As far as I am aware, there is no all-encompassing meta-analysis o f association results in 
BP. However, a number o f authors have reviewed the association findings, the most 
recent comprehensive review being that of Craddock et al (Craddock et al. 2001). Meta­
analysis has, though, been conducted for a number of individual loci.
As discussed for the linkage data, meta-analysis is the combining o f data derived from 
different studies. It has primarily been proposed as a solution to the problem of false 
negative results arising from underpowered individual studies’ inability to detect genes of 
small effect size. However, meta-analysis should also be helpful where there is genetic 
heterogeneity. The example of CAPN10 and type 2 diabetes has been cited as illustrative 
of the successful application o f meta-analysis to association studies which have yielded 
conflicting results (Munafo and Flint 2004). In essence, meta-analysis is achieved by 
determining the effect size that each study attributes to the genetic variant and weighting 
this according to the study size. The individual weighted effect sizes are then combined.
While the power gains o f analysing what is, in effect, a sample with a larger n are 
obvious, the method employed in the combination also has important implications for 
power (Munafo and Flint 2004). The fixed effects and random effects model can be 
employed. The assumption of the fixed effect model is that the variant has a single true 
effect size and that the variation in effect sizes is due to sampling. The random effects 
model allows for potential differences in true effect size between studies. It is not known 
which model is more appropriate in the context o f BP, but given the linkage 
heterogeneity it is highly likely that samples will differ with respect to the proportions of 
the various susceptibility loci present.
75
It is important to identify heterogeneity between studies included in the meta-analysis, as 
the fixed effects model assumes no heterogeneity and heterogeneity can decrease power 
with the random effects model. Heterogeneity has been found to be common between 
genetic association studies (Ioannidis et al. 2001). Both graphical methods and formal 
statistical tests o f between-sample heterogeneity have been developed. The graphical 
methods are based on plotting the effect sizes from the individual studies against standard 
error (SE) or some transformation thereof. Clustering or outliers can indicate 
heterogeneity. One statistical test, based on a chi-squared distribution, which is often used 
is the Q test. However, its power to detect heterogeneity is determined by the number of 
studies analysed. Hence, it is generally recommended that a combination of techniques be 
used. Sensitivity analysis - analysis with and without the studies identified as possible 
sources of heterogeneity - can then be performed to assess the effect on the summary 
effect size.
It has long been recognised that publication bias -  the increased likelihood of positive 
findings coming to publication -  may artificially inflate effect size estimates (Sterling 
1959). There are a number of approaches to detecting publication bias, including the 
funnel plot and calculation of the ‘fail safe n ’ (Munafo and Flint 2004).
Meta-analysis is not necessarily restricted to univariate analysis. Meta-regression has 
been applied to genetic association studies to test the effects of covariates such as 
ancestry, e.g. (Munafo et al. 2005). Although less susceptible to type I error than multiple 
subanalysis, such post hoc meta-regression does bring with it the danger of confounding.
4.4.2 Meta-analysis of 5-HTT association
Perhaps the most intensively studied of BP candidates is the 5-HTT gene. The 5-HTT 
gene is located on 17ql 1.2 and the receptor brings about re-uptake of 5HT into the pre- 
synaptic neuron. It is essentially a functional candidate, as the linkage evidence to this 
region of 17q is, at best, modest. The 5-HTT receptor has been thought of as a strong
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functional candidate for both BP and depression, primarily because it has been found that 
many antidepressants act to inhibit the re-uptake o f serotonin by 5-HTT. A NPL o f 1.59 
at the marker D17S841 was obtained in a sample of 82 affected sib-pairs, but other 
linkage studies have not been supportive (Murphy et al. 2000).
The most studied polymorphisms at 5-HTT are the intron 2 VNTR and the 5-HTTLPR. 
Both are thought to be functional polymorphisms. The intron 2 VNTR has 3 alleles: Stin 
2.9, Stin 2.10 and Stin 2.12. Stin 2.12 has been found to have strong enhancer properties 
in the mouse (MacKenzie and Quinn 1999). The 5-HTTLPR is a 44 bp insertion/deletion 
in the promoter region. Hence there are two allelic forms: the long (L) and short (s) 
alleles. The allelic form has been shown to have an effect on transcriptional activity, with 
lower transcription in the presence o f the s allele (Collier et al. 1996b).
There have been a total o f six meta-analyses of the association o f 5-HTT with BP. In 
chapter 3 I dealt with the meta-analyses of the linkage studies chronologically, because 
there was a certain methodological narrative that I thought was worth tracing. Here, the 
methodological approach has been broadly similar and successive meta-analyses 
generally represent a more up-to-date version of the previous analysis. Hence, it seems 
more logical to concentrate on the most recent, and therefore comprehensive, meta­
analyses and refer back to previous meta-analyses where appropriate.
The most recent meta-analysis is that o f Cho et al (Cho et al. 2005). A meta-analysis was 
performed on both o f the commonly studied polymorphisms, 5-HTTLPR and intron 2 
VNTR. Separate meta-analyses o f family based studies and population based case-control 
studies were conducted. Unlike previous studies, a pooled meta-analysis including both 
these datasets was then performed. This analysis gave a significantly elevated odds ratio 
(OR) for both polymorphisms.
Cho et al searched the literature for relevant articles up to September 2004. Studies o f the 
5HT associations in adults with BPI or BPII were included. ORs and SEs were calculated 
for the s allele of the 5-HTTLPR and Stin 2.12 for the intron 2 VNTR in each o f the 
studies. No significant heterogeneity was found for either polymorphism, therefore
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pooling under a fixed effects model was considered valid. Meta-analysis o f the 5- 
HTTLPR included 17 case-control studies and six family based studies. This gave a total 
o f 1,712 cases, 2,583 controls and 587 trios. A pooled OR of 1.12 (95% Cl 1.03-1.21) 
was obtained for the s allele. Meta-analysis of the intron 2 VNTR included 16 case- 
control studies and four family studies. This gave a total of 1,764 cases, 2,703 controls 
and 382 trios. A pooled OR of 1.12 (95% Cl 1.02-1.22) was also obtained.
The group also performed a meta-regression. It seems that this was primarily conducted 
to identify potential heterogeneity due to study type or ethnicity rather than exploring, say, 
phenotypic sub-groups that may account for the association. Neither ethnicity nor study 
type were found to contribute significantly to overall heterogeneity between studies. No 
evidence o f publication bias was found using Begg’s Funnel Plot, Normal Quantile Plot 
or Eggers Test. However a ‘double bum p’ in Normal Quantile Plot suggested the 
presence of two different populations.
The meta-analysis carried out by Lasky-Su et al (Lasky-Su et al. 2005) was published 
slightly before that o f Cho et al, but included more cases and controls for the 5-HTTLPR. 
Meta-analysis was performed only on case-control studies o f the two polymorphisms in 
both BP and UP, i.e. four separate meta-analyses.
Medline citations as o f June 2004 were identified. ORs were calculated and pooled under 
a random effects model. Meta-analysis o f the 5-HTTLPR included 15 studies comprising 
of 2,774 cases and 3,652 controls. Thus, it was larger than the Cho et al meta-analysis, 
although fewer studies were included. This can be explained by the slightly different 
composition o f studies included in the two meta-analyses.
However, a combined OR of 1.13 (95% Cl 1.05 -1.22) was found, which was entirely 
consistent with Cho et aVs findings. In contrast to Cho et al the OR did not significantly 
deviate from one for the intron 2 VNTR. Lasky-Su et aV s meta-analysis, however, 
comprised o f less individuals: 1,357 cases and 2,292 controls from 11 studies.
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There were some analytical differences from the Cho et al study. Allele length was 
modelled continuously in the logistic regression and a random effects model was applied. 
In addition, a Bonferroni correction was made for the testing of two polymorphisms. O f 
note, Lasky-Su et al found significant heterogeneity for the intron 2 VNTR, which could 
not be explained by ethnicity or diagnostic instrument. It is thus pertinent to mention that 
although Cho et al claimed no heterogeneity between the intron 2 VNTR studies the p- 
value was borderline (p=0.06).
Four other meta-analyses were performed prior to this: (Lotrich and Pollock 2004); 
(Anguelova et al. 2003); (Craddock et a l  2001); (Furlong et al. 1998b). Unfortunately, 
no clear pattern has emerged.
Lotrich and Pollock considered case-control and family studies in separate analyses. No 
significant association with either polymorphism was found. Studies using Asian 
populations here analysed separately, because of allele frequency differences between 
populations. For instance, the s allele and Stin2.12 allele are more prevalent in Asian 
populations. However, significant heterogeneity between studies was still found for both 
polymorphisms in both population groupings.
On the other hand another meta-analysis of case-control studies found significant 
associations for both the polymorphisms (Anguelova et al. 2003). A combined OR of 
1.14 (95% Cl 1.03-1.26) was obtained for the 5-HTTLPR polymorphism, where 1,382 
cases and 2,085 controls were considered. A combined OR of 1.18 (95% Cl 1.05-1.32) 
was obtained for the Stin2.12 allele. 1,368 cases and 2,252 controls were considered. 
Significant heterogeneity was not found in either analysis.
Craddock (Craddock et al. 2001) performed a meta-analysis of 11 case-control samples 
which gave a total o f 1,139 BP cases and 1,693 controls for the 5-HTTLPR 
polymorphism only. However, they failed to find evidence o f association.
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In addition to performing their own association study, Furlong et al (Furlong et al. 1998b) 
performed a meta-analysis of the 5-HTTLPR and intron 2 VNTR for both BP and UP. A 
significant association was found with the 5-HTTLPR, OR 1.21 (95% Cl 1.00-1.45), but 
none with the intron 2 VNTR.
Hence, it can be seen that in the case of these two 5-HTT polymorphisms, at least, meta­
analysis does not seem to entirely resolve the issue. Interpretation o f meta-analysis is, 
indeed, not as straightforward as one might have hoped. Unlike meta-analysis o f linkage 
studies, the meta-analytical techniques applied to association studies are well established. 
Yet there is still methodological variability between meta-analyses, which may explain 
the lack o f consistent results. There are many stages in the meta-analytical process where 
variability can occur.
There was some variation in the studies included. Although contemporaneous, three 
studies which where included in Lasky-Su et aVs analysis of 5-HTTLPR did not feature 
in Cho et aVs analysis. Furthermore, there is a possibility that some non-independent 
studies have been included. For example, the study of Mendes de Oliveria et al (Mendes 
de Oliveira et al. 1998) was excluded by Anguelova et al on the basis that it was not 
independent from Oliveria et al (Oliveira et al. 2000). However, both studies were 
included by Cho et al. Generally the random effects model has been employed, but not 
universally. Cho et al used the fixed effects model. It is not clear whether Anguelova et al, 
who also obtained positive findings for both polymorphisms, also used this.
It is of particular interest that the tests o f heterogeneity produced different results between 
meta-analyses. Again, it is difficult to know quite how to interpret this. While it would 
seem likely that the variation in allele frequencies, at least for the intron 2 VNTR, is 
culpable there is little empirical evidence for this. There is an indication that the studies 
o f Collier et al (Collier et al. 1996a); (Collier et al. 1996b) may be atypical. Sensitivity 
analysis by Anguelova et al demonstrated that these studies made a large contribution to 
the positive finding for the 5-HTTLPR and intron 2 VNTR respectively. While
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heterogeneity between studies does not necessarily impact on the result o f the meta­
analysis, it is concerning when the cause of the heterogeneity remains unknown.
It seems reasonable to conclude that the two polymorphisms do have a small effect on 
susceptibility to BP, with the 5-HTTLPR being the slightly more robust finding. Care has 
to be taken in interpreting small effect in this context; the effect is small at the population 
level but may be large at the individual level.
There is some modest evidence that the effect may be attributable to specific subgroups 
o f BP patients where these 5-HTT alleles confer a much higher OR. Coyle et al (Coyle et 
al. 2000) genotyped the VNTR in 97 women with BP or schizoaffective disorder who had 
experienced at least one episode o f mania or psychotic affective illness within 14 days of 
childbirth. The allele frequencies were compared to a control group of 72 women. The 
Stin2.12 allele was strongly associated, /?=0.001. It was found that the s allele was 
associated with antidepressant induced mania in a small patient only sample (Mundo et al. 
2001). The alternative explanation is that the polymorphisms do have a small effect in a 
greater proportion of the BP population. Development of BP would necessitate 
interaction with other genetic or environmental susceptibilities or a combination o f the 
two.
In the absence o f more refined phenotypes, meta-analysis will continue to be important in 
investigating loci of small effect size. The problem of detecting such effect sizes in 
individual studies is highlighted by Cho et aV s power analysis, which estimated that a 
sample size of 5,500 would be needed to give 80% power to detect at the 0.05 level.
4.4.3 Meta-analysis of MAOA association
The gene coding for MAOA is located on Xpl 1.3 (at ~43 Mb). MAOA is a key enzyme 
in the degradation o f the neurotransmitters adrenaline, noradrenaline, dopamine and 
serotonin. As has already been said, these neurotransmitters are widely thought to be 
relevant to the aetiology o f BP. Circumstantial evidence for the function candidacy of
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MAOA comes from different lines o f enquiry. Moclobemide, which is a highly specific 
inhibitor o f MAOA, is an effective antidepressant. A behavioural phenotype associated 
with a nonsense mutation of the MAOA that had some similarities to that o f mania was 
reported (Brunner et al. 1993). Subsequently, the behavioural phenotype o f MAOA 
knockout mouse was described (Cases et al. 1995). Elevated aggression (in males) was 
found to be a feature. Whether this is relevant to the BP phenotype is, however, debatable. 
Positionally, it is not a strong candidate.
MAOA was first implicated by association analysis (Lim et al. 1995). Three 
polymorphisms have been commonly studied: an intron 2 CA repeat (MAO-CA) with 12 
alelles; an intron 1 GT repeat, and an exonic /«w4HI RFLP site. This RFLP site 
corresponds to a synonymous G/T substitution at position 941. However, variation at this 
site has been shown to effect enzyme activity -  with the G allele corresponding to high 
activity (Hotamisligil and Breakefield 1991).
Three meta-analyses have been performed. The most recent is that of Preisig et al (Preisig 
et al. 2000), which included their own case-control study of 272 cases (BPI or BPII) and 
122 controls from France and Switzerland. They performed the meta-analysis on a total 
o f five studies for the three markers described above. The analysis was restricted to case- 
control studies employing Caucasian subjects. Consequently, the family based study of 
Nothen et al (Nothen et al. 1995) and a Japanese study (Kawada et al. 1995a) were 
excluded. Although not explicitly stated, it would seem that these totalled 535 cases and 
386 controls. No significant heterogeneity between studies was found. The MAO-CA 
analysis, using CLUMP, demonstrated a significant difference in the distribution of 
alleles between the cases and controls (pO.OOOl). The a5 and a6 alleles were 
overrepresented in the cases whereas the a2 was found to be less frequent. Subanalysis by 
gender demonstrated that the difference was only observed in females. An association 
with the allele 1 offnu4H l RFLP was also found in the overall sample (OR 1.45, 99.17% 
Cl 1.01-2.08). No association was found with the intron 1 GT repeat.
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An association study of the MAO-CA and/hm4HI polymorphisms in a sample o f 106 BP 
cases and 250 unscreened controls was performed (Furlong et al. 1999a). These results 
were then included in a meta-analysis o f these two markers. In total, seven non­
overlapping studies were identified. In contrast to Preisig et al, the family based study o f 
Nothen (Nothen et a l 1995) was included. The two studies using Asian populations were 
analysed separately, because of marked differences in allele frequencies for the MAO-CA. 
ORs were estimated by unconditional logistical regression within Statistical Package for 
the Social Sciences (SPSS). Rare alleles for the MAO-CA were pooled for the analysis 
and ORs calculated using allele 122 (a2) as the reference allele.
Significant association with the MAO-CA was found in both populations. The meta­
analysis of Caucasian studies comprised o f 412 BP cases and 489 controls and gave an 
overall OR o f 1.55 (95% Cl 1.06-2.28) comparing allele 116 (a5) against allele 122. 
Again, this association was only observed in females OR 2.13 (95% Cl 1.31-3.48). The 
meta-analysis o f the Japanese studies comprised 118 BP cases and 168 controls. The 
association was in this case observed when allele 114(a6) was compared against allele 
122, OR 2.65 (95% Cl 1.29-5.45). Association was also found with the fnu4E l RFLP. In 
Furlong et aV s report there is some discrepancy between the table (IIC) and the text 
below it. However, it seems that allele 2 is associated with decreased risk in females OR 
0.7 (95% Cl 0.49-0.99). If it were, indeed, in this direction it would accord with Preisig et 
aVs findings.
The MOA-CA and fnuAWl polymorphisms in 39 cases and 39 age/sex matched controls 
were analysed (Rubinsztein et al. 1996). A meta-analysis was then carried out which 
included this data. All data used in the meta-analysis was incorporated into the analyses 
above. Association with found with both markers which was attributable to females, in 
keeping with subsequent analyses.
Despite the lack o f evidence for Xp from linkage studies, the meta-analyses of 
association studies consistently demonstrate that variation at the MAO-CA polymorphism 
has a modest effect on susceptibility to BP in females. Analysis and interpretation o f
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association at microsatellites is slightly less straightforward but overall the results appear 
compatible. The MAO-CA polymorphism is not thought to be functional and therefore it 
is postulated that it is in LD with the aetiological change. The fnu4H l RFLP is functional 
with allele 1 (presence o f the RFLP site) being associated with lower MAOA activity. 
However, theories that invoke a reduction in enzymatic activity as the causative 
mechanism do not sit happily with the gender effect given that this is an X-linked gene.
4.4.4 Interpretation of meta-analysis
I think that it is reasonable to conclude from the discussion above that specific 
polymorphisms at the 5-HTT and MAOA genes do have a small effect on susceptibility 
to BP. However, it has not been adequately demonstrated whether these polymorphisms 
are aetiological or in LD with an aetiological change.
The associated alleles are common in the controls. Thus, one would have to invoke a 
theory of gene/gene or gene/environment interaction to account for the development of 
BP in a given individual. For the above loci an interaction is conceivable, as both 
associated alleles would be expected to increase 5-HT at the synaptic cleft. However, no 
evidence for such an interaction was found in a case-control sample from Sweden (Van 
Den Bogaert et al. 2006b). Alternatively, the alleles could be LD with a rare high-risk 
variant.
Yet, before one proceeds to such over-interpretation o f a positive result, caution is 
advised. Acknowledging the potential sources of error inherent in association studies, the 
above discussion, particularly with regard to 5-HTT, shows that meta-analyses are not 
necessarily consistent. Therefore, although it is tempting to consider a meta-analysis as 
the definitive result, it is important to critically evaluate its methodology. For instance, 
even a meta-analysis may have low power to detect a small effect and thus the problem of 
type II error remains.
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It is important to stress that 5-HTT and MAOA may not be the only genes in the literature 
for which there is good evidence of influence on BP susceptibility. It is simply that I have 
taken the approach of looking at these two genes as exemplars. Furthermore, I would not 
wish to give the impression that only loci which have been subjected to meta-analysis are 
worthy o f consideration. On the contrary, a rigorous large individual study is preferable 
to meta-analysis, as the potential danger of combining incompatible studies is avoided. 
However, for the loci above it is clear that associations found in individual studies have 
not been consistently reproducible. This phenomenon has been seen in association studies 
in other common diseases. Lohumeller et al (Lohmueller et a l  2003) made some 
important observations on this. Taking a sample of loci for which there were multiple 
published association studies it was possible to demonstrate that replication occurs much 
more commonly than expected by chance, suggesting that in general true associations 
were being found. Association studies for BP were not specifically analysed and so this is 
not necessarily applicable to the BP data, but nonetheless it is reassuring in terms o f the 
association methodology.
Lohmueller proposed three mechanisms which could account for inconsistency: 
population specific associations; false associations due to population stratification and 
underpowered replication samples.
For the loci above there is no evidence for ethnicity contributing to study heterogeneity, 
although the usual caveats about power to detect heterogeneity have to be made. There 
are, however, reasons to be concerned about population stratification. The majority o f 
earlier studies neither screened subjects for ancestry nor carried out any form of genomic 
control. However, lack o f difference in allele frequencies between control groups used in 
meta-analysis mitigates against this. Underpowered replication studies would certainly 
seem to be a cause o f non-replication. The majority of individual studies had poor power 
to detect an effect size observed in the original positive association even without taking 
into account the ‘winner’s curse phenomenon’, which predicts that the first positive 
association will overestimate the effect size.
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It was demonstrated that meta-analysis could be successful in overcoming inconsistency 
in results and this also seems to be true for 5-HTT and MAOA in BP. On one point of 
detail Lohmuller did not include the original positive association study in the meta­
analysis, considering the combined results of all subsequent studies as the replication 
study. This is at variance to the methodology used in the BP meta-analyses.
Even if an individual association study or meta-analysis has sufficient power to detect a 
small effect at a particular polymorphism it can be seen that only a very limited inference 
can be made about the gene’s role in BP. Lack of association at that polymorphism does 
not exclude a role for that gene, as an aetiological change may not be in LD with the 
marker. Historically, it has only been feasible to look at a limited set of markers for a 
given gene. Furthermore, the extent o f the haplotypic diversity captured is only now 
becoming apparent through the HapMap data.
However, association studies have very recently undergone a revolution. From being able 
to test a handful o f RFLPs or microsatellite markers - as seen in the studies above - SNP 
chip technology is now allowing 500,000 or even one million SNPS to be assayed at a 
time. This has very recently enabled genome wide association studies to be attempted.
4.5 Genomewide association studies
To date, two genome-wide association studies have been published for bipolar disorder 
(2007a; Baum et a l  2007).
In the first a test/replication case-control design was employed to address the issue of 
multiple testing (Baum et al. 2007). The ‘test’ sample comprised of 461 unrelated BPI 
cases from NIMH BP families and 563 controls. The independent ‘replication’ sample 
comprised of 772 German BPI cases and 876 controls randomly recruited from census 
data. Controls were screened for a personal history of schizophrenia or affective disorder. 
The test sample was matched for “exclusively European ancestry”. A subset o f the cases
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and controls was tested for population stratification and cryptic relatedness. 98% of the 
replication sample was of exclusively German ancestry.
Genomewide association testing was carried out using Human Hap 550 chips on pooled 
DNA samples. DNA pooling was used to reduce costs. 33,949 SNPs were associated at 
the /?<0.05 level in the test sample. Three criteria were set out to refine this result: 
OR>1.4, OR <0.71, #>0.05 in cases and controls, location in or near a gene. Of the 1,877 
SNPs which fulfilled these criteria 88 were replicated in the German sample at the p  
<0.05 level. 37 SNPs - mainly from this subset of replicated SNPs - were taken forward 
for individual genotyping in both samples.
Only modest effect sizes were observed, the largest being 1.67. The most convincing 
evidence for association was found at the genes SORCS2 and diacylglycerol kinase eta 
(DGKH). For each gene 3 SNPs were found to be associated in both samples. However 
only one SNP, in DGKH, remained positive after Bonferroni correction for multiple 
testing. SORCS2 and DGKH both lie in BP linkage regions, 4pl6.1 and 13ql4.11 
respectively, and are good biological candidates. DGKH encodes components of the 
phosphatidyl inistol pathway while the SORCS2 gene product is a developmentally brain 
expresessed VPS 10 domain containing receptor. Evidence for interaction between these 
loci was also found.
BP disorder was one of the seven common diseases chosen by the Welcome Trust Case 
Control Consortium (WTCCC) for genomewide association testing in a British 
population (2007a). Individual genotyping was performed on approximately 2,000 BP 
cases and 3,000 controls using the Affymetrix GeneChip 500 k Mapping Array set. Cases 
were derived from five centres. Unscreened controls were derived from the 1958 British 
birth cohort and UK blood donor service. Individuals with non-European ancestry were 
excluded. The sample was divided into 12 broad geographical regions and the allele 
frequencies between regions compared. On the basis o f this analysis it was concluded that 
there was little population stratification within the British population, although 13 
chromosoal regions did show geographical variation in allele frequencies.
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Only one SNP - rs420259, mapping to 16pl2 - exceeded the /?<5xl0-7 threshold set to 
declare genomewide significance. Interestingly, linkage of puerperal psychosis to this 
region has recently been reported by the Cardiff group, who contributed the majority o f 
the samples to the GWA (Jones et al. 2007). For most of the other common diseases 
studied - Crohn’s disease, rheumatoid arthritisis, type 1 diabetes and type 2 diabetes - the 
GWA results were remarkably consistent with previously replicated loci in these diseases. 
Unfortunately this was not evident for BP.
Despite the comparatively large sample sizes used in the GWA studies, power 
calculations demonstrate ability to detect association under certain scenarios may still be 
low. Therefore, meta-analysis o f GWA data is indicated. However the GWA results do 
argue that susceptibly genes operating in BP are individually of modest effect size.
4.6 Summary
I have presented the association findings for two major candidate genes rather than 
assessed the utility of LD for fine mapping in BP. There are many examples where ‘fine 
mapping’ by LD has been used to follow up linkage studies and resulted in findings of 
association. However, it is difficult to synthesise the results of this approach as no gene 
so identified has been unequivocally implicated in BP aetiology.
Overall, one could perceive that, so far, association studies in BP have had some success 
in identifying polymorphisms of small effect. It is possible that this is an example o f the 
predicted power o f association to detect genes o f small effect over linkage, as there was 
little evidence for linkage in either region. However, it is also apparent that the basis for 
studying functional candidates is often tenuous, and this may have contributed to the 
negative findings for many candidate loci. Thus, committing resources to study purely 
‘biological’ candidates may be a potentially inefficient strategy.
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Research at UCL Molecular Psychiatry laboratory, the subject o f the next chapter, has 
attempted to increase the prior probability of finding association by focusing only on 
regions where there is good evidence for linkage.
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Chapter 5: Background to Loci Studied
In this chapter I will put the experimental work I undertook in context. This work can be 
divided into that which stemmed from the previous linkage findings of the UCL 
laboratory and that which arose from meta-analysis of the linkage data.
Firstly, I will describe the linkage results from the UCL laboratory, which formed the 
basis for the subsequent fine mapping efforts on chromosomes 12, 21, 1 and 11. I will 
refer briefly to the preliminary association results on chromosomes 12, 21 and 11 as of 
the time I joined the effort. I will then go on to critique the evidence for the location of 
BP loci in these regions. Finally, I will explain why COMT and DAOA/G30 were chosen 
for attempted replication.
5.1 Regions implicated by the UCL research
The UCL laboratory has been engaged in linkage analysis and, more recently, association 
analysis in BP.
Since there appears to be considerable locus heterogeneity in BP, the UCL laboratory has 
chosen to focus on the linkage analysis o f large multiply affected kindreds. Such kindreds 
should favour the finding of linkage in this context. Linkage analysis has been performed 
on 23 pedigrees from the UK (17) and Iceland (6) or subsets o f these. The use of 
pedigrees from Iceland may further reduce locus heterogeneity in the sample as it is a 
relatively genetically isolated population. Families were interviewed using the SADS-L. 
Attempts were made to ensure that transmission was unilineal and that schizophrenia did 
not occur in the families selected.
The seven largest/most densely affected pedigrees (five Icelandic and two British 
pedigrees) were selected for a whole genome scan (Curtis et al. 2003). 365 microsatellites 
spaced at approximately 10 cM across the genome were typed. Initial two-point and
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three-point parametric and nonparametric analysis was performed. Regions yielding 
linkage at /?<0.01 level were subjected to four-point analysis under an assumption of 
heterogeneity. Overall the strongest evidence for linkage was found on 12q, lq, lp  and 3q. 
The highest LOD was obtained at D12S342 -  four-point heterogeneity LOD (HLOD) 2.8 
using broad affection status and dominant model, nominal significance 0.0007. D12S342 
maps to -124  Mb, in the 12q24.31 region. The telomeric lp  marker D1S243 gave a 
HLOD of 2.1, nominal significance 0.004. Both of the markers - D1S251 (lq42.2 at 
-30.0  Mb) and D3S1265 (3q29 at -197 Mb) - gave HLODs o f 2.0, p=0.005. The lq42 
marker D1S251 yielded a LOD of 2.5 in pedigree six.
Prior to the linkage scan, analysis had been performed in the full set of pedigrees with 
markers on l ip  and 21q (Smyth et al. 1996; Smyth et al. 1997). A maximum LOD of 
1.43 was obtained with a tetranucleotide repeat at the tyrosine hydroxylase locus, which 
maps to near the teleomere o f l i p  (Smyth et al. 1996). Subsequently three further 
markers across the 21q22 region were genotyped: pfkl, D21S171 and D21S49 (Smyth et 
al. 1997). An overall two-point LOD o f 1.28 was obtained at D21S171, with one of the 
Icelandic pedigrees individually giving a LOD of 1.74. Affected sib-pair (ASP) analysis 
demonstrated increased allele sharing at this marker (p=0.001) and analysis using 
MFLINK gave a MLOD/MALOD o f 2.25. A two-locus admixture linkage analysis was 
also performed. LOD scores from the 21q22 markers and the tyrosine hydroxylase 
markers were considered simultaneously. This analysis yielded a maximum LOD score of 
3.87.
The general approach of the laboratory has been to follow up its own linkage findings by 
LD mapping using a case-control design. These mapping efforts have, however, not only 
been guided by the strength o f the UCL linkage evidence, but due weight has also been 
accorded to the prior evidence for linkage in the implicated regions. This strategy has 
been adopted to maximise the chances o f identifying susceptibility loci.
Fine mapping has focused on the 12q24 and 21q22 regions. At the time of my joining the 
project, preliminary results indicated multiple associated markers in these regions
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(unpublished). Evidence for allelic association in the 12q24 region was first found by our 
collaborates in Aarhus in a small Danish association sample. Further evidence was 
found in a subset of the current UCL association sample. With regard to l ip ,  four 
markers across the tyrosine hydroxylase gene and one within the tryptophan hydroxylase 
gene had been tested but no association found (McQuillin et a l  1999a; McQuillin et al. 
1999b).
5.2 Other evidence for bipolar loci on chromosome 12q
In this chapter I will generally discuss the evidence for linkage to a chromosomal region 
of interest and then proceed to discuss association studies performed in this linked region. 
However, in this particular section it makes more narrative sense to consider the linkage 
and association results together.
A pedigree in which co-segregation o f major affective disorder and Darier’s disease, 
mapped to the 12q23-q24.1 region, has been described (Craddock et a l 1994). Dawson 
(Dawson et a l  1995) went on to investigate whether this region harbours a BP 
susceptibility locus by typing seven markers across the Darier’s locus in 45 BP pedigrees. 
Suggestive linkage (maximum LOD 2.11) was obtained under a heterogeneity model 
with a marker at the PLA2A gene. This marker was also found to be associated in a small 
case-control sample (Dawson et a l  1995). However, this finding was not replicated in a 
larger British case-control sample (Jacobsen et a l  1996). Furthermore, mutational 
screening and association analysis provided no support for the involvement of the 
Darier’s disease gene itself - ATP2A2 - in the susceptibility to BP.
A further pedigree exhibiting co-segregation of Darier’s disease and major affective 
disorder was reported (Jones et a l  2002). Recently, linkage and haplotype analysis using 
both o f these pedigrees has been performed (Green et a l 2005). Under a broad affection 
status model which included all mood disorders, multipoint parametric analysis gave a 
maximum LOD of 4.77 across the D12S1127-D12S1646 interval. This 6.5 Mb interval 
was found to delineate a haplotype which was shared by all affected individuals but did
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not occur in unaffected individuals. However, denaturing high performance liquid 
chromatography mutation screening and DNA sequencing o f 25 genes within this 
‘critical’ region did not reveal any likely aetiological variants.
The Cardiff group went on to investigate the critical D12S1127-D12S1646 interval by 
LD mapping o f the central 1.6 Mb portion (Glaser et a l  2005b). 17 microsatellites were 
genotyped using a DNA pooling technique in a UK population based sample consisting 
o f 347 cases and 374 controls. Individual genotyping was subsequently performed for 
seven of these microsatellites, o f which one - M l9 - showed alleleic association
(p=0.0016).
The region around M l9 was screened for polymorphisms and the LD structure 
interrogated using 22 SNPs. O f these, five SNPs were genotyped in the full sample. Four 
o f these - rs3847953, rs933399, rs933305 and the 9 bp insertion/deletion polymorphism 
rs3840795 - yielded nominally significant p-values (0.002, 0.004, 0.02 and 0.005 
respectively). The associations o f rs3847953 and rs933399 survived correction for 
multiple testing. rs3847953 maps to intron 18 o f the gene CUX2, while rs933399 maps to 
the promotor region of the adjacent hypothetical protein FLJ32356. The insertion allele of 
rs3840795 results in an insertion o f three glycine residues in FLJ32356. This finding was 
not formally supported by an attempted replication in a UK trio sample (n= 110).
The Cardiff group has also performed detailed association analysis of the transcription 
factor gene RFX4 (Glaser et al. 2005a). Although it lies just outside their critical region, 
it is within the broad region o f interest as defined by Green et al (Green et a l 2005). 
Furthermore, it was perceived to be a strong functional candidate based on the role of 
RFX4 proteins in the regulation of circadian rhythms.
Taking a similar approach to that for the M l9 region, RFX4 was screened for 
polymorphisms and the LD structure determined using 22 SNPs. Ten hapoltype-tagging 
markers were identified and genotyped in 676 cases and 690 controls. No individual 
allelic association was found. However, haplotypic analysis revealed association with the
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two-marker haplotype, rsl0778502-ss24735177. A significant difference was found 
between the global haplotype frequencies (p=0.017) and the specific haplotype C-ins was 
overrepresented in cases (p=0.002). Both these associations were restricted to male cases. 
Although only modest evidence o f association was obtained from the SNP analysis, 
testing of a microsatellite - D12S2072, located in intron 17 of the gene - did yield 
association at the /?=0.001 level.
Two other independent linkage studies, which have employed more traditional affection 
status models, have reported significant linkage with markers in the 12q24.2-3 region: 
(Ewald et al. 1998; Ewald et al. 2002); (Morissette et al. 1999); (Shink et al. 2005b).
Ewald et al (Ewald et al. 1998) genotyped 16 microsatellite markers across the 12q22-24 
region in two multiply affected Danish pedigrees. A two-point LOD of 3.37 at D12S1639 
was obtained under a dominant model with narrow affection status definition. These 
pedigrees were subsequently used in a genomewide linkage scan (Ewald et al. 2002). The 
results for the 12q24.3 region were generally consistent with Ewald et aV s original report, 
yielding a LOD of 3.63 at D12S1639 (-124.9 Mb). This slight increase may be 
attributable to the diagnostic changes made in light o f updated clinical information.
Morisette et al (Morissette et al. 1999) performed a genome scan on two large kindreds, 
termed VL and BM, from the Saguenay-Lac-St-Jean (SLSJ) population of Quebec. It was 
proposed that study o f this population would reduce the problem of genetic heterogeneity 
as the SLSJ region was settled by French immigrants in the 1830s and has remained 
genetically ‘rather’ homogenous. Multipoint nonparametric analysis yielded a Z-score o f 
3.92 (p<0.01) at D12S82. This marker maps to approximately 89.3 Mb which is probably 
not compatible with the UCL linkage signal. However, a further 18 families were 
recruited from this population and parametric analysis o f the pooled sample gave a 
maximum LOD of 3.35 at the telomeric marker D12S378 (Shink et al. 2005b). This was 
obtained under a recessive model with broad affection status, including individuals with 
recurrent major depression. Nonparametric analysis supported this finding with increased 
IBD allele sharing by affected sibs at D12S378.
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Shink et al (Shink et al. 2005a) genotyped a further 20 microsatellite markers in this 
region in the previously reported SLSJ families and an additional 21 small pedigrees. A 
MLOD of 3.85 was obtained at D12S1634 under a narrow affection status model. All but 
one of the markers which spanned the 7.7 Mb region yielded an MLOD with a /?<0.05.
Shink et al then undertook LD fine mapping of the 12q24.31 region implicated by the 
linkage results from the SLSJ families (Shink et al. 2005a). A population based sample 
consisting o f 213 cases and 188 controls was recruited from the same geographic region. 
The same 20 microsatellites as used in the linkage part of the study were typed. Allelic 
association was found with three o f these: D12S2075 (p=0.023), NBG6 (p=0.008) and 
NBG12 frO.OOOl).
In the NBG12 area, 32 genes were screened for the presence of polymorphisms in coding 
sequences and intron/exon junctions. 22 non-synonymous SNPs were found and 
genotyped. No significant allelic association was found. One uncommon polymorphism 
in the KIAA1595 gene and another in the FLJ22471 gene showed genotypic association 
with p-values <0.05 (T1 CLUMP statistic). However, the FLJ22471 polymorphism did 
not satisfy HWE in the control group -  no heterozygotes were observed. Haplotypic 
association was found (p=0.030) with the gene HM74.
NBG6 maps to intron nine of the gene P2RX7. This gene and the adjacent genes, P2RX4 
and CAMKK2, were screened for polymorphisms (Barden et al. 2006). 24 SNPs were 
selected on the basis of predicted functionality for association analysis. Allelic 
association (p=0.018) was found for one SNP - rsl 1065501, located approximately 75 bp 
downstream of P2RX4 in the slightly enlarged population based sample described above.
Haplotype analysis was performed both according to ‘blocks’ and using a sliding window 
approach. Analysis according to blocks revealed significant differences in haplotype 
frequencies of an eight-SNP haplotype spanning the last six exons o f P2RX7 and a four- 
SNP haplotype, including rsl 1065501 (global p-values o f 0.0410 and 0.0390
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respectively). The sliding window analysis also gave significant Likelihood Ratio 
Statistics for two seven-SNP haplotypes, which were broadly compatible with the block 
findings.
The study proceeded to type 12 SNPs in a family sample derived from the SLSJ 
pedigrees and perform association analysis using FBAT. Allelic association was found 
with the following non-synonymous SNPs: rs2230912 in exon 13 of P2RX7 (p=0.000708) 
and rs3817190 in CAMKK2 (p=0.01548). The rs2230912 association withstood 
correction for multiple testing. rs2230912 is a Gln460Arg substitution at position 460. 
This amino acid is localised in a SH-3 like domain. The glycine residue (A allele) is 
conserved between humans and rodents. The mutated G allele (arginine) was over­
transmitted to affected offspring. Recently, association has been found between the G 
allele and major depressive disorder in a large German case-control sample (Lucae et al. 
2006).
P2RX7 is a member of the ATP receptor family. Depending on the level of stimulation, it 
acts as a cation selective channel or a non-selective large conductance pore (Li et al. 
2005). P2RX7 agonism causes an increase in intracellular calcium that in some 
circumstances can lead to cell death (Zhang et al. 2005). Sites of brain expression include 
the hippocampus and pituitary gland. Study o f P2RX7 knockout mice has demonstrated 
that the receptor mediates ATP-induced GABA and glutamate transmission in the 
hippocampus (Papp et al. 2004). The functional effect of the arginine mutation is not well 
elucidated.
Degn et al (Degn et al. 2001) adopted a slightly different approach to mapping the 
12q23-24 region. The genetically isolated population of the Faroe Islands was studied in 
an attempt to identify chromosomal segments shared by BP subjects. 17 microsatellite 
markers across the region were typed in 14 distantly related BP patients and 43 controls. 
Significant allelic and haplotypic association were found using CLUMP. The most 
significant single marker association was found at D12S342 (0.007). Analysis of two-
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marker haplotypes gave two significantly associated regions: D12S1614-D12S342 (0.007 
and 0.003) and D12S2075-D12S1675 (pO.OOl).
In light of the increased rates o f UP depression in the relatives of BP probands, the 
finding of highly significant linkage of UP to markers in the 12q22-q23.2 may be relevant. 
Linkage analysis of a large cohort of families multiply affected with UP from Utah 
yielded a multipoint HLOD score o f 6.1 at D12S1706, at -97.4 Mb (Abkevich et al. 
2003). However, it should be noted that this impressive LOD was obtained under a 
phenotypic definition which only included affected males.
Overall, I conclude that there is strong evidence for linkage of BP to the 12q23-24 region, 
as summarised in figure 5.1 below. However, it has to be said that with three significant 
linkage studies the region is not supported by the meta-analyses of the linkage data.
Figure 5.1: Summary of linkage results compatible with UCL signal on 12q24.
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A number of other genes which are compatible with the linkage signal found in the UCL 
sample have been investigated by association analysis. These include DAO (107.8 Mb), 
NOS1 (116.1 Mb) and Citron (118.6 Mb).
DAO was identified as an interacting protein with the G72 gene implicated in 
schizophrenia (Chumakov et al. 2002). Five SNPs across the DAO region were tested as 
part of a screen o f 64 candidate genes in BPI and schizophrenia (Fallin et al. 2005). In an 
attempt to reduce genetic heterogeneity, family samples o f Ashkenazi Jewish descent 
were used. The BP sample consisted o f 323 trios. Single SNP and haplotype based TDT 
analysis was performed. Association o f single SNPs or haplotypes at the <0.01 level was 
reported as highly suggestive, while association at the <0.05 level was reported as 
suggestive. On this basis, DAO was reported as showing highly suggestive association in 
BP. Flowever, I was unable to glean from the report any details of the association. In this 
study nine SNPs were also tested across the NOS1 gene and suggestive association was 
found.
Citron has been identified as a functional candidate within the 12q24 region, through its 
interaction with DISCI (Lyons-Warren et al. 2005). The evidence for the role of DISCI 
in BP will be discussed in a later section of this chapter. Association was tested with 
seven SNPs across the Citron gene in a sample of NIMH pedigrees. Significantly 
distorted transmission was found for two individual SNPs: rs203368 {p=0.020) and 
rs435136 {p=0.012). These findings were supported by significant transmission distortion 
of multiple haplotypes, which included at least one of these markers.
Hence, association with BP has been found with multiple loci spanning approximately 20 
Mb of 12q23-24. These associations are summarised in the figure 5.2 below. However, 
none of the associations have to date been replicated. While the possibility of multiple 
false positive association results in this region has to be considered, it seems unlikely that 
only a single BP susceptibility locus is present on 12q23-24.
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Figure 5 2 :  Summary of association results for the 12q23-24 region
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5.3 Other evidence for a bipolar locus on chromosome 21 q
5.3.1 Linkage findings for 21q
Significant linkage on chromosome 21q to BP was first reported by Straub et al (Straub et 
al. 1994). A LOD of 3.41 was obtained with the PFKL locus in a single large pedigree 
(family 01001). Analysis of PFKL and the more distal marker D21S171 was undertaken 
in a further 46 families. The PFKL finding was supported, /?<0.003, using the affected 
pedigree number method but not by parametric analysis -  at least not when the whole 
dataset was considered. The same group went on to type 31 markers on 21 q in 373 
individuals from 40 families (Aita et al. 1999). It is not clear to me to what extent the 
families overlapped. It was stated that some, but not all, o f the individuals from family 
01001 were included in the later study. Significant linkage was obtained at the more 
proximal marker D21S1260, with a two-point LOD 3.35 under the assumption of 
heterogeneity. Analysis excluding the individuals from family 01001 indicated that the 
linkage was not restricted to this family alone.
Investigation o f linkage to 21q in the Aita et al sample was subsequently extended (Liu et 
al. 2001b). The sample was enlarged, with 331 more individuals from the 40 families 
(denoted ‘core pedigrees’) and 16 ‘new’ families. A total of 11 markers spanning the 
previously linked region were genotyped, and included 3 additional markers to provide 
more uniform coverage. Comparison of the results is complicated by the introduction o f a 
broader range o f disease phenotypes. Separate analysis of the core pedigrees 
demonstrated slightly increased evidence for linkage at D21S1260 with a maximum two- 
point LOD of 3.56. The threshold for suggestive linkage was almost achieved in the new 
pedigrees at the slightly proximal marker D21S266, LOD 1.89. Combined analysis of the 
pedigrees did not result in an appreciable change of the LOD score at D2 IS 1260.
Linkage to 21q has been supported by multiple subsequent linkage studies. Detera- 
Wadleigh et al (Detera-Wadleigh et al. 1996) initially genotyped 18 markers on 
chromosome 21q in 22 multiplex families -  the Clinical Neurogenetics Initiative (CNG)
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pedigrees. ASP analysis demonstrated increased allele sharing at nine of these marker 
loci (p=0.049-0.0008). Multilocus ASP analysis revealed two intervals showing excess 
allele sharing: D21S270-D21S171 and D21S1436-D21S65. Subsequently, a high density 
genome scan was performed using these 22 families (Detera-Wadleigh et al. 1999). In 
this analysis the maximum evidence for linkage on 21q came from the proximal region 
bounded by the markers D21S1254-D21S65 (LOD 1.85, /?=0.0018). Detera-Wadleigh et 
al also carried out linkage analysis in an independent sample of 97 families from the 
National Institute of Mental Health Genetics Iniative (NIMHGI). Four markers - 
D21S1254, D21S65, D21S1440 and D21S1255 - exhibited excess allele sharing with p- 
values ranging from 0.041-0.008. These markers overlap both the proximal and distal 
intervals identified in Detera-Wadleigh’s original study. Multilocus analysis provided 
stronger evidence for increased allele sharing with a minimum p-value of 0.0009.
Independent evidence was found for linkage to the original marker, PFKL (Kwok et a l  
1999; Kelsoe et al. 2001). Kwok et al performed analysis o f six 21q markers in 12 
Australian pedigrees. Nonparametric analysis using SIMIBD gave linkage at the /?<0.001 
level. However, other nonparametric and parametric analyses did not support this result. 
Kelsoe et al obtained a maximum two-point LOD score o f 2.04 under a broad phenotype 
definition and dominant model at PFKL in a genome survey o f 20 North American 
families.
Linkage analysis o f families from Eastern Quebec has also provided support for a 21q 
locus. As referred to in section 5.2, a genomewide scan was performed on a single very 
large pedigree from the SLSJ region (Morissette et al. 1999). Multipoint nonparametric 
analysis using GENEHUNTER yielded a Z score of 4.81 (/?<0.01) at D21S263. This peak 
was found to be mainly due to one branch of the pedigree. Furthermore, linkage analysis 
to BP and schizophrenia was carried out in 21 multi-generational pedigrees using 220 
markers on 13 ‘target’ chromosomes (Maziade et al. 2001). Seven of the pedigrees were 
predominately schizophrenic, six predominately BP and eight mixed. Linkage to BP was 
tested in the BP and mixed pedigrees. A maximum LOD score of 2.03 was obtained at
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D21S1893 using a narrow phenotypic definition. However, this did not reach the 
threshold for suggestive linkage according to their correction for multiple testing.
Linkage analysis was performed using 11 markers across the 21q22-23 region in 18 small 
to medium sized Bulgarian pedigrees (Kaneva et al. 2004). Suggestive linkage was 
observed with the marker D21S1252, with a multipoint LOD of 2.1, p=0.0003 under a 
narrow phenotype definition.
Most recently, the combined linkage data from the first and second waves o f the 
NIMHGI for BP was re-analysed incorporating age o f onset as a covariate (Lin et al. 
2005). Analysis using the affected relative pair approach produced a LOD of 3.29 near 
D21S1252, with increased linkage among subjects with early age of onset (defined as 
below 21). This result was corroborated by the reanalysis o f an independent replication 
sample of 65 pedigrees with a maximum LOD of 2.88 near D21S156. However, this 
finding was not supported by a genome scan of 70 European families ascertained through 
early onset probands (Etain et al. 2006).
Meta-analysis yielded a single analysis MSP of 0.006 and a best analysis MSP of 0.01 at 
31 cM on 21q (Badner and Gershon 2002a). However, neither replication analysis gave 
significant results, suggesting the linkage may be due to one study. Furthermore, 
subsequent meta-anlyses have not implicated this region.
The linkage results are summarised in figure 5.3 below. Care needs to be exercised in 
interpreting the linkage results for 21q, as there is some overlap of samples between 
studies. Furthermore, while there is often large variation in the LODs obtained with 
different analyses this seems particularly pronounced in relation to the 21q results. 
Having said this, the overall evidence for a susceptibility locus in the 21q22 region is 
compelling.
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Figure 53. Summary of linkage results compatible with UCL signal on 21q22
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5.3.2 Association findings for 21 q
LD mapping o f the 21q22 linkage region has not, to date, been extensive. Association and 
mutation analysis has been undertaken for three genes which would be compatible with 
the UCL linkage results: synaptojanin 1 gene (SYNJ1), ATP-binding cassette transporter 
G1 gene (ABCG1) and AD ARBI.
SYNJ1 is an inositol 5-phosphatase and maps to -32.9 Mb. 11 polymorphisms were 
identified by mutation screening (Saito et al. 2001). These polymorphisms were analysed 
in 149 unrelated BP cases and 148 controls. Four variants were found only in the case 
sample. Two variants, occurring in putative TF binding sites, -1898T>C and +58C>A, 
were found in one case each. It was postulated that the variant in intron six, 49G>A, gives 
rise to a cryptic branch-point site and was identified in two cases. An exon 8 variant, 
resulting in a conservative amino acid change, was found in one patient. However, this 
individual had two siblings with BP, neither of whom had the variant. Subsquently, 84 
BP patients were screened for the -1898T>C, +58C>A and -49G>A variants (Stopkova et 
a l  2004). No changes were found.
ABCG1 maps to -42.5 Mb and codes for a transported protein which may play a role in 
the uptake o f tryptophan. DHPLC screening identified a total o f 16 polymorphisms 
(Kirov et al. 2001). The extended TDT was performed using 11 of these polymorphims 
and 2 known intragenic microsatellites in a trio sample («=110). No transmission 
distortion was found.
ADARB1, at -45.3 Mb, is thought to influence neuronal calcium signalling through 
editing of glutamate receptor subunit b pre-RNA. No novel polymorphisms were found in 
a mutational screen of 60 BP patients and 66 controls using Single Strand Conformational 
Polmorphisms (SSCP) and sequence analysis (Kostyrko et al. 2006). Furthermore, no 
significant difference was found between cases and controls for the previously identified 
synonymous exon ten variant, +2234A>G.
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While testing o f rare SYNJ1 variants in larger samples would seem to be warranted, none 
of the genes above have been associated with BP.
5.4 Other evidence for a bipolar locus on chromosome lq
5.4.1 Linkage findings on lq
Under traditional diagnostic models no individual linkage study or meta-analysis of 
linkage studies has, to date, yielded genomewide significant LOD scores on lq. However, 
multiple studies have reported suggestive linkage that would be compatible with the 
telomeric signal obtained by the UCL laboratory (Curtis et al. 2003).
A LOD of 1.98 at D1 S I03 (-229 Mb) was obtained in a series of moderately sized North 
American pedigrees (Gejman et al. 1993). Increased allele sharing was found between 
affected individuals at the same marker, p<0.0001, in the Old Order Amish (LaBuda et al. 
1996). A linkage scan of 22 multiplex pedigrees yielded suggestive LODs in the lq32- 
lq41 region under both nonparametric and parametric analysis (Detera-Wadleigh et al. 
1999). Multipoint analysis using GENEHUNTERPLUS(fam) gave a LOD of 2.67 
(p=0.00022) at the D1S1660-D1S1678 (196.9-201.8 Mb) interval and a parametric LOD 
of 2.37 at GATA124F08 (-207 Mb).
An attempt was made to identify genetic subtypes o f BP by analysing the linkage data 
under affection models with greater phenotypic specification (Cheng et al. 2006). The 
presence of psychosis, suicidal behaviour and panic disorder were used to subdivide the 
traditional diagnostic models. Multipoint nonparametric analysis yielded an NPL score of 
2.01 near D1S1609. NPL scores o f >1.63 were considered suggestive of linkage on the 
basis of their own simulations. This NPL score was obtained under a traditional model 
which included BPI and BPII individuals as affected. In this region phenotypic dissection 
did not reveal a possible genetic subtype.
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The debate continues as to whether schizophrenia and BP often occur in the same family. 
However, analysis o f families where this seems to have occurred has yielded positive 
results on lq.
Most recently, a genome scan was performed on families originating from the old 
Choggia population - a town on an island of the Venetian lagoon - with either 
schizophrenia or BP (Vazza et al. 2007). A single affection model classifying individuals 
with schizophrenia, BP or schizoaffective disorder as affected was employed. Non­
parametric analysis yielded a NPL score of 1.51 on lq43 but this did not reach the 
threshold for suggestive linkage based on their own simulations.
Linkage was performed on 22, predominately extended, Scottish families affected by BP 
or schizophrenia (Macgregor et al. 2004). Analysis o f the ‘BP’ families yielded a 
maximum two-point LOD of 2.63 at the marker D1S103 (-229 Mb) under a recessive 
model with broad phenotypic definition. ‘BP’ families in which cases of schizophrenia 
occurred were included in this analysis. Multipoint variance component linkage analysis 
was also carried out for the chromosome 1 markers. This gave a maximum LOD at a 
slightly more centromeric location near D1S419 (-213 Mb). Interestingly, no evidence 
for linkage was found in the ‘schizophrenic’ families. However, the effect of analysing 
linkage data using more lax diagnostic boundaries was dramatic.
Pedigrees containing at least one member with a diagnosis of schizoaffective disorder 
(manic type) were selected from a collection of pedigrees ascertained for schizophrenia 
and BP linkage scans (Hamshere et al. 2005). An affection status model which included 
schizophrenia and BPI as well as schizoaffective disorder (manic type) was then applied 
to these pedigrees. Genomewide significant linkage, LOD=3.54, was obtained on lq42 
near the marker D1S2800 (-233 Mb). Further analysis o f LOD scores from individual 
families suggested that both BP and schizophrenic families were contributing to this 
significant finding. Sex covariate linkage analysis was also performed which led to a 
significant increase in the LOD score with increased allele sharing in same sex sib-pairs 
(either male or female).
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In light of these findings, it is worth noting the consequence of varying the affection 
models on the linkage results from the Scottish (1 ;11) (q42;ql4.3) translocation family. 
The highest LOD, 7.1, was obtained with the broadest model, including individuals with 
schizophrenia, BP and recurrent major depression as affected (Blackwood et a l  2001). 
More restricted models: schizophrenia only and affective disorders only gave LODs o f
3.6 and 4.5 respectively.
The linkage results are summarised in figure 5.4 below. Considering only those linkage 
studies which have respected traditional diagnostic boundaries, there is reasonable 
evidence for a ‘pure’ BP susceptibility locus in the region. However, with reference to 
Hamshere and Blackwood’s findings it is difficult to escape the conclusion that a 
susceptibility locus for a non-traditional phenotype, encompassing the schizophrenia, 
schizoaffective, BP and recurrent depression phenotypes exists in this region. It is also 
plausible that a linkage signal is being detected from more than one locus in the region. It 
is of significance that linkage analyses o f schizophrenia performed at the UCL laboratory, 
in which an identical set o f markers to those used by Curtis et al was utilised, gave a peak 
LOD on lq  in a more proximal position with no overlap with the positive LODs for BP 
(Gurling et al. 2001). In other words, in the UCL data, at least, there is evidence for 
separate susceptibility loci for schizophrenia and BP on lq.
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Figure 5.4. Summary of linkage results compatible with UCL signal on Iq31^ l4
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5.4.2 Association results for DISCI
Analysis o f the breakpoint on chromosome lq42 o f the Scottish translocation family 
revealed direct disruption of two genes, denoted DISCI and DISC2 (Millar et al. 2000b). 
This finding has led to the testing of association of both schizophrenia and BP with the 
DISCI locus. I will predominantly restrict the discussion to BP.
Studies have concentrated on DISCI as it has been demonstrated to code for a translated 
protein, whereas no equivalent protein has been demonstrated for DISC2. The DISCI 
product has been shown to be a multifunctional protein involved in both cell signalling 
and neurodevelopment. DISCI influences cAMP-dependent cell signalling through its 
interaction with the cAMP-degrading enzyme PDE4B (Millar et a l 2005). Neuro- 
developmentally, DISCI plays a role in microtubule dynamics, neuronal migration and 
neuronal outgrowth. It interacts with components of the dynein motor complex including 
lissencephaly (LIS1) and nuclear distribution element-like (NDEL1/NUDEL) (Kamiya et 
al. 2006).
The first association study of DISC 1 and BP was performed by Devon et al (Devon et al. 
2001). Polymorphism detection was carried out by sequencing of DISCI in schizophrenic 
individuals and of multiple cDNA clones. One microsatellite and 15 SNPs were thus 
identified. Association with BP and schizophrenia was tested using four of these SNPs 
and the microsatellite in a case-control sample. The number of cases and controls 
genotyped varied between marker: cases (152-175) and controls (426-726). Cases were of 
Scottish descent and controls were recruited from the Edinburgh/SE Scotland blood 
transfusion service. No single marker or haplotypic association was found with either BP 
or schizophrenia. However, the authors note that significant LD was only found between 
A844G and T11870C. The implication here is that the result could be a false negative, as 
more markers would be required to comprehensively test for association across DISCI.
A population based association analysis of 39 SNPs in BP, schizoaffective disorder and 
schizophrenia was reported (Hodgkinson et al. 2004). All participants were North
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American Caucasians of European descent. The BP group consisted of 82 individuals, 
which was compared against a control group of 217. None o f the markers were 
individually associated with BP. However, allelic association was observed with 
schizophrenia (five markers) and schizoaffective disorder (one marker).
The authors proceeded by identifying seven ‘haplotype blocks’ for which the average D ’ 
was >0.9. Haplotype analysis was carried out with respect to each block. Disease 
association was found detected for haplotypes from the first four consecutive blocks. For 
BP, association was found with haplotypes from block one and block four. Two rare 
block one haplotypes, denoted hap8 and hap 14, were found in cases but not controls 
(both p=0.0192). One rare block four haplotype, hap7, was found in cases but not 
controls (/?=0.0048) while the common hapl was underrepresented in BP cases (p=0.027). 
None of the BP associations remained after Bonferroni correction, although the authors 
argue that its application is overly conservative. Haplotypic association was also detected 
with schizophrenia.
A comprehensive association analysis of a 510 kb region, which included DISCI and the 
immediately centromeric gene translin-associated factor X (TRAX), in BP and 
schizophrenia was attempted (Thomson et al. 2005). The region of study was extended to 
include the TRAX gene as intergenic splicing with DISCI has been shown to occur 
(Millar et al. 2000a). To optimise SNP selection an LD map of the region was first 
constructed using the information from 45 SNPs genotyped in 29 Scottish BP parent- 
offspring trios. Tagging SNPs thus identified were supplemented with SNPs showing 
association in previous studies, giving a total of 30 SNPs which were carried forward to 
the association testing. The case-control groups were drawn from the same populations 
and numbered 381 BP cases and 478 controls. Following the observation in schizophrenia 
that the under-transmission o f a DISCI haplotype was only significant in affected 
females (Hennah et al. 2003), sex specific analysis was undertaken.
Only one marker, r s l030711, showed allelic association with BP (p=0.032). This marker 
is not located within DISCI but maps to intron 5 of TRAX. No single markers showed
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association with schizophrenia. Analysing the sexes separately yielded one associated 
marker, rs821663, with BP males (p=0.047). By contrast, rs821663 is located towards the 
3’ end of DISCI within exon 10.
Several haplotypes across the TRAX/DISC1 showed global and/or individual association 
with BP. Interpretation of these haplotypic associations is not straightforward. The 
strongest association was found with haplotypes from what can loosely be described as 
the central portion o f DISCI spanning rsl954175 to rs6675281 (Thompson et aVs region 
3). Analysis by sex revealed that association is restricted to affected females. This region 
was also the only region to show association with schizophrenia.
However, association with BP was also found at both the ‘ centromeric ’ region 1 and 
‘telomeric’ region 2. Thompson et aV s region 1 refers to the interval spanning TRAX and 
exons 1 and 2 of DISCI, rsl630250-rs3738401. The global and individual haplotypic 
associations indicate that this region is associated with BP males. Thompson et aV s 
region 2 refers to the interval spanning rs821663-rsl 1122396. The gender effect observed 
with the individual marker rs821663 was not supported by the haplotype analysis. The 
only haplotypic associations found in this region were for a number o f individual 
haplotypes which occurred in the female BP group and not the control group. Thompson 
was unable to test the haplotypes associated with BP in the Hodkingson et al study, as the 
constituent SNPs were not typed. However, it can be seen from figure 5.5 (after Maeda et 
al) below that the regions do not overlap.
A family based association study o f DISCI was conducted (Maeda et al. 2006). Fifty- 
seven pedigrees from the Hopkins/Dana collection were selected and 12 SNPs genotyped 
in a total of 297 subjects. The SNP set included one novel SNP which had been 
discovered by direct sequencing o f ten BP subjects prior to the association phase o f the 
study. These subjects were identified from pedigrees with the strongest evidence for 
linkage to lq42. Tests o f allelic and haplotypic association were performed using FBAT. 
Sex specific analysis was also carried out. No individual marker showed association with 
BP. ‘Various’ haplotypes were tested. Two ‘common’ 12 marker haplotypes, denoted
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HP1 and HP2, showed association. HP1 was over-transmitted to affected females 
(p=0.004) while HP2 was under-transmitted. Maeda et al proceeded to examine the 
relationship between the 12 SNP haplotypes and DISCI expression in human 
lymphoblasts. Consistent with the association results, DISCI mRNA in females was 
found to be significantly lower in affected individuals carrying the HP1 haplotype as 
compared with unaffected individuals with the ‘protective’ HP2 haplotype (p=0.001). 
The correlation of mRNA levels with a number of clinical variables was then investigated. 
A statistically significant inverse correlation was found with a number of manic 
symptoms
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Figure 5.5: Summary of haplotypic associations with DISCI.
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The evidence from association studies does not strongly support DISCI as a 
susceptibility locus for BP. No individual marker has been associated in any o f the 
studies. However, it is conceivable that this represents a false negative result. The earlier 
studies lacked power to detect association, as only a small number of markers (Devon et 
a l 2001) or small sample (Hodgkinson et a l 2004) were tested. Although three separate 
studies found associated haplotypes, only one of these associations survives correction 
for multiple testing. The finding o f haplotypic association in the absence of single marker 
association does raise concerns over false positives. Estimation o f haplotype frequencies 
using the EM algorithm is inherently imperfect. In particular, rare haplotypes that do not 
exist in nature may be constructed. Genotyping error has a disproportionately large effect 
of haplotypic association analysis compared with single marker analysis. Such 
genotyping error may compound the problem of frequency estimation.
Interpretation o f haplotypic associations is hampered because the originally associated 
haplotypes have not been reconstructed in subsequent studies. Overall, there does not 
appear to be a good overlap between associated haplotypes. If one accepts the association 
to be real then the sex effect observed in schizophrenia also seems to be operating in BP, 
with the association largely being restricted to females.
The findings in schizophrenia are similarly equivocal and it is hard to know how they 
relate to the BP findings at the present time. Phenotypic subtypes that cross traditional 
boundaries have not been explored to the same extent as will be seen for the DAOA locus.
However, very recently association with a ‘bipolar spectrum disorder’ and ‘psychotic 
disorder’ has been reported (Palo et a l 2007). The association was found in a family 
sample derived from four extended Finnish pedigrees. The ‘bipolar spectrum disorder’ 
phenotype included BPI, BPII, BP NOS and cyclothymia. The ‘psychotic disorder’ 
phenotype included BPI with psychotic symptoms, psychotic depression, schizophrenia, 
schizoaffective disorder and psychosis NOS.
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One marker, rsl655285, showed individual association (p=0.025). SNP rsl655285 maps 
to intron 5 o f TRAX (referred to as TSNAX in the paper). Analysis o f 2-SNP haplotypes 
supported the association of TRAX with ‘bipolar spectrum disorder’. Haplotypic 
association was also found with 2-SNP and 3-SNP haplotypes at the 3’ end o f DISCI. 
This pattern o f association is similar to that obsevered by Thomson et al.
No individual marker association was found with ‘psychotic disorder’. Furthermore 
analysis of 2-SNP haplotypes did not yield association in the whole dataset. However, 
analysis by gender revealed association with 2-SNP and 3-SNP haplotypes at the 5’ end 
of DISCI. This male specific association in the 5’ region o f DISCI was also observed by 
Thomson et al.
The question of which phenotype is o f primary relevance at the DISCI locus is further 
thrown into question by the finding that a single non-synonymous SNP is associated with 
major depressive disorder (MDD) (Hashimoto et al. 2006).
While DISCI has received most attention in this region other genes that are compatible 
with the UCL linkage have been investigated by association analysis. Eleven 
polymorphisms across the adenosine A l receptor were genotyped in a very small case- 
control sample (Deckert et al. 1998). No association was found. However, allelic 
association was found with a functional polymorphism in the angiotensinogen gene in a 
case-control sample from Brazil, p=0.009. The angiotensinogen gene maps very close to 
DISCI at 229 Mb (Meira-Lima et al. 2000).
5.5 Other evidence for a bipolar locus on chromosome l ip
5.5.1 Linkage findings on l ip
The first significant linkage to BP was found with the HRAS1 locus which maps to the 
teleomere of l ip ,  at ~0.5 Mb (Egeland et al. 1987). While this finding has subsequently
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been brought into question, other independent studies have reported supportive linkage in 
this region.
Egeland et al performed linkage analysis of a large composite pedigree (family 110) from 
the Old Order Amish community of Pennsylvania using RFLP markers. Comprehensive 
genealogical records were available for the community and indicated that the entire 
community o f 12,000 was descended from 30 founders who emigrated from Europe in 
the 18 Century. Analysis under a dominant model with the penetrance value set to 0.63, 
in accordance with the segregation analysis, gave a two-point LOD of 3.34 at HRAS1. 
Three point analysis, including data from the nearby insulin locus, yielded a peak LOD 
score of 4.90 at HRAS1. Subsequent analysis of linkage to these markers using a three- 
allele model resulted in an increase in the LOD scores (Sandkuyl and Ott 1989).
Diagnostic revision, additional genotyping and extension o f the original ‘core’ pedigree 
would seem to have negated the evidence for linkage to the 1 l p l 5.5 region. The ‘core’ 
pedigree was re-analysed using updated information (Kelsoe et al. 1989). Missing 
genotypes for ten unaffected individuals were obtained, two new unaffected individuals 
were added to the pedigree and two individuals reclassified as affected, having developed 
affective disorder in the interim. Evidence for linkage to HRAS1 and INS was markedly 
reduced following these amendments. Extension of the ‘core’ pedigree, right and left 
lateral extensions, further reduced the evidence for linkage. In fact, linkage to HRAS1 or 
INS was excluded in the large right lateral extension. Linkage to l ip  was also excluded 
in a second large lateral extension of the ‘core’ pedigree (Pauls et a l  1991).
Theoretically, genotyping error could contribute to the discrepancy between results. The 
genotyping of individuals from the ‘core’ pedigree was repeated (Law et a l  1992). Due 
to the difficulty o f resolving some o f the alleles of the INS marker an alternative assay 
was designed. Scoring of INS alleles and diagnostic models differed somewhat from 
those of Kelsoe et al but the linkage findings were in general agreement.
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Under a heterogeneity model, suggestive linkage was found - maximum LOD 2.89 - with 
a marker p]4.1/taq\ which flanks the tyrosine hydroxylase locus (Malafosse et al. 1997). 
The tyrosine hydroxylase gene is located at approximately 2 Mb. Four markers spanning 
tyrosine hydroxylase, INS and HRAS1 loci were typed in 11 French pedigrees. Analysis 
was performed using a broad disease definition. Two o f the families yielded positive 
LOD scores when analysed individually.
Analysis of the second wave of the NIMH collection provided evidence o f linkage to the 
1 l p l 5 region (Zandi et al. 2003). This sample comprised of 56 families from the USA. 
NPL scores of more than two were found for the region extending from D11S1984 to 
D11S2362 using an intermediate phenotypic model. The peak score, 2.96 (p=0.002), 
occurred at D11S1923. The results o f a parametric analysis, allowing for heterogeneity, 
were consistent with this finding.
Subsequent analysis of the combined NIMH wave 1 and wave 2 datasets, comprising o f a 
total o f 153 families, supported the l lp l5  finding (Mclnnis et al. 2003a). The peak NPL 
score was again found at D11S1923, but was somewhat reduced at 2.2 (p=0.01). Possible 
heterogeneity or epistatic effects were tested but the analyses did not increase the 
evidence for linkage on 1 l p l 5.
Other investigators have implicated a slightly more centromeric region, although it is 
possible they have detected the same linkage signal. Suggestive linkage, two-point LOD 
1.95, was obtained with the 1 lp  14 marker D11S1312, which maps to approximately 30 
Mb (Mclnnes et al. 1996). This result emanated from a genomewide linkage scan of two 
large Costa Rican pedigrees, CR001 and CR004, ascertained from the genetically 
homogenous population o f the Central Valley. A narrow definition o f affection, including 
only those individuals with BPI or schizoaffective disorder (manic type) was employed.
Positive LODs were also obtained in the more centromeric region under a dominant 
model and narrow phenotype definition (Detera-Wadleigh et al. 1999). However, the 
LODs of 1.89 and 1.62 at D11S915 and D11S904 respectively cannot be considered as
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confirming linkage in light of the re-evaluation o f Egeland et aVs findings. This genome 
scan of the CNG families has been described in the section 5.3.1. It is o f note that the 
pedigrees included the ‘right extension’ of the Old order Amish family 110.
In summary, the linkage evidence for the llp l4 -15  region is not as compelling as for the 
other regions discussed so far. Suggestive rather than significant linkage has been found, 
with a telomeric position being favoured.
5.5.2 Association findings on llp l4-15
Association studies in the l i p  14-15 region have focused on four promising functional 
candidates: tyrosine hydroxylase (TH), dopamine D4 receptor (DRD4), tryptophan 
hydroxylase (TPH) and brain-derived neurotrophic factor (BDNF). The association 
literature relating to these loci, particulary TH, is very large. I will discuss the BDNF 
findings in the most detail, as I tested this association in the UCL sample. Thus for the 
other loci I will, where appropriate, restrict the discussion to meta-analyses or reviews 
rather than individual studies.
Tyrosine hydroxylase
TH catalyses the hydroxylation of tyrosine to L-Dopa. It is the first, and importantly, the 
rate-limiting step in the synthetic pathway of dopamine and noradrenaline. 
Catehcolamines have widely been implicated in the aetiology of BP. For instance, anti- 
dopaminergic drugs are effective against mania and dopaminergic drugs, such as 
amphetamine, cause behavioural changes which, to some extent, mimic those seen in 
mania. Hence, TH has been thought to be an excellent functional candidate for BP.
Association with TH was first reported by Leboyer et al (Leboyer et al. 1990), who tested 
two RFLPs - a 5’ Taql site and 3’ BgUl site - in a small French sample. The same group 
subsequently reported genotypic association with a tetranucleotide VNTR in intron one 
(Meloni et al. 1995). Several association studies of the TH locus have now been 
performed. The Taql and tetranucleotide (now referred to as HUMTH01) have been the
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most commonly studied polymorphisms. The tetranucleotide polymorphism is thought to 
be functional. It was demonstrated that allelic variation had a quantative silencing effect 
on TH expression through differential binding of the zinc finger protein ZNF 191 
(Albanese et a l  2001).
Three meta-analyses have now been performed. The most recent is that o f Furlong et al 
(Furlong et al. 1999b). The meta-analysis was restricted to the intron one tetranucleotide 
VNTR. The group searched the Bath Information and Data Services database in March 
1998. They identified 12 studies, including their own findings, o f which 11 were included 
in the analysis. One Japanese study (Kawada et a l  1995b) was omitted due to uncertainty 
over how the alleles they reported corresponded to other published alleles. The rare allele 
(termed 6 or F), found only by Furlong et al and Todd (Todd and O'Malley 1989), was 
also omitted from the analysis. Both case-control and family based studies were included. 
In total, the meta-analysis comprised of 583 BP(I or II) cases and 745 controls. Meta­
analysis was performed using unconditional logistic regression as implemented in the 
SPSS. The authors claimed such analysis was robust to differences to control allele 
frequencies in the different studies. No evidence of association was found. A further 
meta-analysis, including UP cases as affected, also failed to show association.
A meta-analysis had previously been performed (Turecki et a l  1997), but a number of 
methodological issues were subsequently highlighted (Bellivier et a l  1998b). Turecki et 
aVs primary analysis was of association of either the Taql RFLP or intron 1 VNTR with 
BP. Separate analyses o f the two markers were also performed. The group carried out a 
search which encompassed published data up to January 1996. They included eight 
studies, totalling 547 cases and 522 controls. There was some variation in the studies 
included in this meta-analysis compared to that of Furlong et a l  For example, the study 
by Kawada et al (Kawada et a l  1995b) was not excluded.
On the basis o f a homogeneity test, Turecki et al considered the analysis o f pooled data to 
be valid. No evidence for association was found when the markers were considered 
together or separately. However, Belliever et al objected to the pooling of studies using
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different markers, as the LD between the marker and putative aetiological change may 
differ. Turecki et al argued that it was valid to pool because meta-analysis combines a 
“relative measure of the observed effect towards or against a hypothesis”. Furthermore, 
the studies were testing the same hypothesis, i.e. that variation at the TH locus influences 
susceptibility to BP.
Belliever et al (Bellivier et al. 1998b) performed their own meta-analysis o f the Taql and 
BglII polymorphisms. However, they found significant heterogeneity o f allele frequencies 
between centres for the Taql marker, and between control groups for the Bglll marker. 
The group did not perform meta-analysis for the intron 1 VNTR, arguing that the 
variation in tests o f association applied in the constituent studies rendered this 
“unfeasible”. In line with Turecki et al, they found no association with Taql. They found 
a significant association with Bglll (p=0.02).
Since these meta-analyses, a number of individual studies o f TH have been published, all 
o f which have been negative: (McQuillin et al. 1999a), (Muglia et al. 2002) and (Serretti 
et al. 2003).
The sizes o f these meta-analyses are not great and they may not have sufficient power to 
detect small effects. As discussed in chapter 4, the issue o f variation in studies included 
and, importantly, heterogeneity in allele frequencies is highlighted by the TH example. 
The findings o f Belliever et al indicate that such heterogeneity can occur even if the 
analysis is restricted to samples from populations assumed to be broadly comparable. The 
implications o f such heterogeneity are unclear, but do raise concerns regarding the 
possibility of population stratification inducing error.
Dopamine D4 receptor
The DRD4 gene maps to 1 l p l 5.5 at approximately 0.6 Mb. It encodes the D4 subtype of 
the dopamine receptor, which is highly expressed in the limbic system. The most 
commonly studied polymorphism in this gene has been the exon 3 VNTR. The 
polymorphism is an imperfect 48 bp tandem repeat. Repeat numbers o f 2-10 have been
120
observed. Certain repeat numbers have been shown to influence the pharmacological 
properties o f the receptor (Muglia et al. 2002).
Association studies have provided little evidence for DRD4 being involved in the 
aetiology of BP. Eight studies have failed to find association: (Lim et al. 1994); (Perez de 
Castro et al. 1994); (Kawada et al. 1995b); (Di Bella et al. 1996); (Oruc et al. 1997); (Li 
et al. 1999); (Bocchetta et al. 1999); (Serretti et al. 2001); (Leszczynska-Rodziewicz et al. 
2005). However, sample sizes were mostly small.
Only one positive association has been reported with BP (Muglia et al. 2002). Muglia et 
al tested for association with the exon 3 VNTR in a sample of 145 trios from Canada. 
Transmission distortion was observed for two alleles. The two-repeat allele was under­
transmitted to probands (p=0.0114), while the four-repeat allele was over-transmitted 
(p=0.0278). Separate analysis of maternal and paternal transmissions revealed that the 
transmission was restricted to the maternal meiosis. The authors note that the DRD4 gene 
is a region where genomic imprinting is known to operate.
One other study has reported association with alleles at the exon 3 VNTR (Manki et al. 
1996). However, the case group included UPD. When the BP cases were analysed 
separately no association was found.
While Muglia et aVs result should not be ignored, the weight o f evidence does not favour 
a role for the exon three polymorphism in BP. I was unable to find any meta-analyses of 
association results for this polymorphism. However, one cannot exclude DRD4 in the 
aetiology o f BP as the study of this marker alone will not capture all the haplotypic 
variability at the locus.
Tryptophan hydroxylase
The tryptophan hydroxylase 1 gene (TPH1) maps to 1 l p l 5.1 at approximately 18 Mb. 
TPH1 catalyses the conversion of tryptophan to 5-hydroxytryptophan, which is the rate-
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limiting step in the synthesis of 5HT. The most commonly studied marker has been the 
intron 7 A218C RFLP.
Belliever et al (Bellivier et al. 1998a) initially reported allelic association between the A 
allele of the A218C polymorphism and BP (p<0.001) in a small case-control sample from 
France. However, attempts to replicate this finding have not been successful: (Furlong et 
a l 1998a); (Kirov et a l  1999b); (McQuillin et a l 1999b); (Vincent et a l  1999); (Kunugi 
et a l  1999); (Rietschel et a l 2000); (Souery et a l  2001); (Rotondo et a l  2002). A more 
systematic association analysis of the TPH1 locus was attempted (Lai et a l  2005). Ten 
SNPs were tested in a relatively small Taiwanese case-control sample. No allelic or 
genotypic association was found for individual markers. Haplotype analysis revealed one 
10-marker haplotype which occurred in cases but not controls. However, the significance 
o f this finding did not survive correction for multiple testing.
It is clear that there is scant evidence to suggest a role for TPH1 in BP. However, despite 
Lai et a /’s more extensive coverage of the TPH1 locus, association cannot be confidently 
excluded. More recently attention has shifted to the study of the other TPH isoform, 
TPH2, which maps to chromosome 12. TPH2 is solely brain expressed and some 
promising association results have emerged, e.g. (Van Den Bogaert et a l  2006a).
Brain-derived neurotrophic factor
The BDNF gene maps to llp l4 .1  at approximately 27.6 Mb. BDNF promotes survival, 
growth and differentiation of neurons. A number of lines o f evidence suggest it is an 
excellent functional candidate for BP. Antidepressants and mood stabilizers have been 
shown to increase BDNF transcription. In animal models o f depression, decreased BDNF 
expression and hippocampal atrophy have been demonstrated. In drug naive patients with 
MDD, serum BDNF has been shown to be lowered (Hashimoto et a l  2004).
The most intensively studied marker at the BDNF locus is the Val66Met polymorphism. 
This amino acid is present in the pro-peptide but cleaved in the formation o f the mature
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peptide. However, variation at this position affects BDNF secretion in vitro and memory 
in human subjects (Egan et al. 2003).
Association of BDNF with BP was first described by Sklar et al (Sklar et al. 2002). This 
association was identified in the course o f a screen o f 76 candiadate genes using 90 SNPs. 
The test sample consisted of 136 American trios. Only the Val66Met polymorphism was 
tested at the BDNF locus. Association with the valine (G) allele was found at the 0.042 
level. Replication o f the association was attempted in two independent trio samples, 
NIMH («=189) and UK («=145). A trend for over-transmission was observed. 
Resequencing o f the gene in cases and controls identified 44 SNPs. Eight of these were 
successfully genotyped. Three additional SNPs showed transmission distortion: a40 
(p=0.0047), a20 (p=0.0021) and al3  (p=0.0124). a40 is 5’ while a20 and al3  are both 3’ 
of the coding sequence. Haplotype analysis demonstrated significant global transmission 
distortion of the six eight-marker haplotypes with frequencies above 2% (p=0.034). With 
regard to individual haplotypes there was significant under-transmission o f haplotype 3 
(p=0.03013) and over-transmission of haplotype 6 (p=0.00096).
In the same year, association was reported in an independent family based sample 
(Neves-Pereira et al. 2002). A 5’ dinucleotide repeat, -1040bp (GT)n, and the Val66Met 
were tested in 283 Canadian trios. The Val66Met valine allele was again over-transmitted, 
/?=0.00064. Preferential transmission of allele 3 (A3) o f the -1040bp (GT)n 
polymorphism was also observed, p=0.042. Haplotype analysis supported this association 
with over-transmission of the A3-G haplotype, /?=0.000394.
This sample was extended and further markers tested (Muller et al. 2006). A small 
number of families were added and siblings included, giving a total o f 350 BP cases and 
693 non-affected relatives. The association with the valine allele at Val66Met and allele 3 
o f the -1040bp (GT)n repeat remained, /?=0.001 and /?=0.008 respectively. Four 
additional SNPs were typed of which two showed significant association: hCVl 1592756 
and rs2049045. Muller et al proceeded to demonstrate that the associations were only 
observed in patients with the rapid cycling form of the disorder.
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This finding o f association with rapid cycling BP was consistent with the results from a 
very large UK case-control sample (Green et al. 2006). The Val66Met polymorphism 
was typed in 962 cases and 2,100 controls. No association was found in the primary 
analysis. Six subtypes of BP were defined according to phenotypic variables, e.g rapid 
cycling, on the basis that these variables may equate to distinct genetic subtypes. Testing 
of the rapid cycling subtype «=131 revealed association with the valine allele at the 0.004 
level (uncorrected). Green et al therefore re-analysed the data for the Cardiff trio sample 
used for replication in the original Sklar et al paper. By restricting the analysis to only 
those trios with rapid cycling probands, significant over-transmission of the valine allele 
was found, /?<0.03 (one tailed).
Replication of the Val66Met association has now been reported in both family based and 
case-control samples. Excess transmission of the valine allele, /?=0.001, was found in a 
sample of 212 nuclear families from the historically isolated Antioquina region o f North 
West Colombia (Kremeyer et a l  2006). The -1040bp (GT)n repeat, which was denoted 
BDNF-CA in this study, was also tested. Association at this marker was not replicated, 
but transmission of the same two-marker haplotype as Neves-Pereira et al was observed, 
(p=0.025). O f note, Kremeyer et al found the microsatellite alleles to be 57 bp larger than 
reported in previous studies. However, they were confident that the alleles corresponded, 
e.g. Kremeyer et aVs 227 bp allele=Neves-Pereira et aVs 170 bp allele.
A case-control design was employed to test association at the Val66Met polymorphism 
(Lohoff et al. 2005). 621 unrelated BPI cases of European descent were identified from 
the NIMHGI collection. By definition, all had a family history o f BP. The control group 
consisted of 998 individuals. Association with the valine allele was found at the 0.028 
level.
Schumacher et al (Schumacher et al. 2005a) also used a case-control design to test for 
association with BP, MDD and schizophrenia. The Val66Met, -1040bp (GT)n repeat and 
additional SNP, rs988748, were genotyped. The BP sample numbered 281 and the control
124
sample, 1,097. Although no single marker association was found for BP, a significant 
difference in the global frequencies of the three marker haplotypes was observed between 
BP cases and controls, p=0.0057. However, the most robust findings o f association with 
BDNF were for MDD.
Association results have suggested that variation at the BDNF locus confers susceptibility 
specifically for BP o f early onset. Children and adolescents, mean age 10.7, with a 
“bipolar disorder phenotype” were studied (Geller et al. 2004). Case attribution included 
the requirement that euphoria or grandiosity had been present. One could question how 
exactly this “bipolar disorder phenotype” relates to the traditional adult BP construct. 
Certainly, the mean duration o f baseline manic episodes o f 3.2 years seems very long 
considering the mean age o f the sample group. However, longitudinal validation of the 
phenotype was claimed. The Val66Met polymorphism was tested in 53 American trios. 
Over-transmission o f the valine allele was found, p=0.014.
Some support has been provided for this association between BDNF and early onset BP 
(Strauss et al. 2004). However, there were important differences between the studies. 
Strauss employed a much broader phenotypic definition -  childhood onset mood 
disorders (COMD). In fact, only 23 of the 99 subjects had a diagnosis of BP. Furthermore, 
subjects were recruited as adults -  some had been diagnosed in childhood while the 
others were diagnosed retrospectively. A case-control design was used. The cases had 
different ethnic backgrounds. To reduce the potential for population stratification the 
controls were ethnically matched and genomic control was performed. The dinucleotide 
repeat -1040bp (GT)n and Val66Met polymorphism were tested. A significant difference 
in the distribution o f -1040bp (GT)n alleles was observed, /?=0.0032. The 168 bp allele 
was overrepresented in the cases. The Val66Met polymorphism did not individually show 
association but haplotypic analysis supported the implication o f the BDNF locus.
Subsequently, Strauss et al was able to demonstrate the association o f COMD with 
BDNF in an independent sample o f 258 Hungarian trios. However, the authors comment
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in the conclusion that they “were not able to test for association with bipolar disorder”. 
This was due to the very small number of subjects with a diagnosis of BP in the sample.
It is important to recognize, however, that there have been a number o f negative findings: 
(Hong et al. 2003); (Oswald et al. 2004); (Kunugi et al. 2004); (Skibinska et al. 2004); 
(Nakata et al. 2003). Furthermore, meta-analysis o f the Val66Met polymorphism 
published since the commencement o f this work failed to find association (Kanazawa et 
al. 2007). The numbers involved in the meta-analysis were large -  3,143 cases and 6,347 
controls. However, o f the l i p  candidate loci BDNF would still seem worthy of further 
study given the association in multiple independent samples using different study designs 
and populations.
5.6 Loci implicated by meta-analysis of the linkage data
There is a natural desire to follow up ones own linkage results in the hope that they will 
lead to the identification o f novel susceptibility loci. However, independent replication of 
findings is crucial to the advancement of the field. Therefore, the UCL laboratory has 
tried to contribute to replication studies. It would be logistically impossible to follow up 
all the positive findings reported for BP. Hence, the laboratory has concentrated on 
attempting to replicate association findings in regions where there is strong a priori 
evidence for a susceptibility locus from the linkage data. At the time my work 
commenced, there had been only one meta-analysis of the linkage data for BP which 
found 13q and 22q to be the regions with the best evidence for harbouring a BP 
susceptibility locus.
5.6.1 Evidence for 22q bipolar locus
Both cytogenetic abnormalities and linkage studies have provided evidence that an 
aetiological gene maps to 22q. While I will essentially confine the discussion to BP, it is
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important to state that these lines of evidence have also implicated a 22q schizophrenia 
susceptibility locus.
Cytogenetic evidence
Velo-cardio facial syndrome, also known as 22q ll.2  deletion syndrome, is an autosomal 
domimantly inherited condition which is characterised by cardiac malformations, cleft 
palate and learning disabilities. Investigators have variously reported an association with 
schizophrenia or BP.
A very high rate o f early onset BP was found amongst VCFS patients (Papolos et al.
1996). Twenty-five unselected patients diagnosed with VCFS were recruited and 
underwent diagnostic psychiatric interviews. Ages ranged from 5 to 34. 64% were 
diagnosed with BP and all had onset in late childhood or early adolescence.
The characteristics o f the deletions seen in VCFS with psychiatric disorders were 
investigated (Carlson et al. 1997). Loss of heterozygosity analysis revealed that a 1.5 Mb 
deletion bounded by the markers D22S427 (-17.0 Mb) -  D22S264 (-19.1 Mb) was 
common to all the patients in which there was evidence of a deletion.
Therefore, it is hypothesised that both the physical and psychiatric manifestations of 
VCFS are due to haplo-insufficiency of gene(s) that map to this minimally deleted 
interval.
Linkage
Many of the studies referred to below have been discussed in previous sections. I will 
therefore try not to repeat descriptions of these studies. I have indicated such studies with 
an asterisk.
The first report o f linkage compatible with a susceptibility locus in the VCFS deletion 
region was that o f Lachmann et al (Lachman et al. 1997). 22q microsatellites were typed 
in 17 BP families. 13 of the families were derived from the University of California, San
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Diego/University o f British Columbia (UCSD/UBC), 2 from New York and the other was 
a branch of the Old Order Amish pedigree 110. The strongest evidence for linkage was 
obtained when the UCSD/UBC families were analysed separately. Under a dominant 
model a maximum LOD of 2.51 was found at the 22ql 1 marker D22S303 (at -21.6  Mb).
Subsequently, a genomewide survey of 20 North American familes was reported which 
included the 13 UCSD/UBC families above (Kelsoe et a l  2001). Significant linkage, 
maximum LOD 3.8, to the slightly more telomeric marker D22S278 (at -34.7 Mb) was 
found. However, the authors noted a broad linkage region, LODs >1.0, spanning 32 cM 
with a possible second linkage peak at D22S419 (-24.3 Mb). A maximum LOD of 2.19 
was found at this marker under a recessive model.
Linkage to the 22ql 1-12 region is supported by results from the NIMH (both NIMHGI 
and CNG) pedigrees. Analysis o f the first wave of 97 NIHMGI families revealed 
increased allele sharing at the marker D22S533, at -24.2 Mb (Edenberg et a l  1997). 
Under a broad affection model a maximum LOD of 2.46 was obtained. Using the same 
chromosome 22 markers and analysis employed in the genome survey, 57 o f these 
families were examined (Kelsoe et a l  2001). The results were consistent with those 
reported by Edenberg et al, with the peak LOD 2.72 occurring at D22S419 which maps 
very closely to D22S533.
The CNG families are entirely separate from the NIMHGI pedigrees but do include the 
right extension o f the Old Order Amish pedigree 110. Under a broad affection status 
model, excess allele sharing was observed in a region delineated by D22S689 and 
D22S685, LOD 2.1 (Detera-Wadleigh et a l 1999).
Implication o f the 22q region by these individual studies is strengthened by meta-analysis 
o f the linkage data (Badner and Gershon 2002a). Signifcant linkage was found at 36 cM 
on 22q, p< 1 x 10'5. This represented the region with the second strongest evidence for 
linkage after 13q. O f note, significant evidence for linkage to schizophrenia was also 
found on 22q (at 32 cM).
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Since the publication o f the meta-analysis a number o f studies have supported 22q 
linkage. Linkage has been reported in two independent large multiply affected pedigrees. 
Two-point parametric analysis of the entire Costa Rican kindred cr201 did not yield 
evidence for linkage to 22q (Service et al. 2006)*. However, division o f the pedigree to 
enable multipoint analysis revealed a linkage peak, /?=0.00732, at approximately 40 cM 
on 22q in one section of the family.
A genomewide scan on a kindred from Eastern Cuba with 28 affecetd members was 
performed (Marcheco-Teruel et al. 2006)*. Nonparametric analysis yielded suggestive 
linkage in both the entire family and one individual branch under a broad phenotypic 
model. The peak NPL score was observed at 46.4 cM for the complete family, /?=0.015 
and 51.56 cM,/?=0.005, in section la  of the family.
Linkage analysis o f potential subtypes of BP has produced some promising results on 22q, 
particularly with regard to a psychotic subtype. Suggestive linkage, /?=0.005 at D22S277 
(34.6 Mb), was obtained when the linkage analysis was restricted to families with at least 
3 members with psychotic mood disorder (Potash et al. 2003)*. Linkage analysis of 
pedigrees containing at least one member with schizoaffective disorder (BP type) gave a 
maximum LOD of 1.96 at D22S420, at -16.2 Mb (Hamshere et al. 2005)*.
Turecki et al (Turecki et al. 2001) postulated that a lithium response subtype o f BP exists 
and attempted mapping by linkage analysis. A cohort o f patients with BP attending an 
affective disorder clinic in Canada was followed prospectively. Families were ascertained 
through patients that showed an excellent response to lithium. In total, 31 families were 
included in the linkage analysis. Again, suggestive linkage was found at the marker 
D22S420, LOD 1.91 under a recessive model in which only lithium responders were 
considered affected.
An attempt was made to identify chromosomal segments shared by distantly related BP 
subjects in the isolated population of the Faroe Islands (Jorgensen et al. 2002). This
129
follows the approach of Degn et al in mapping o f the 12q23-24 region, referred to in 
section 5.2. Thirty-five microsatellite markers across 22q were typed in 14 BP patients, 
10 schizophrenia patients and 44 unrelated controls. Where possible, parents of both 
patients and controls were genotyped so as to reconstruct haplotypes. The most 
significant result was for the telomeric two-marker haplotype, D22S1161-D22S922. 
Haplotype frequencies were significantly different at the 0.0081 level.
Overall, the linkage of BP to 22q is convincing. Given that 22q has also been implicated 
in schizophrenia, the recent findings of Potash et al and Hamshere et al are consistent 
with the hypothesis of a common susceptibility locus. However, the results could 
alternatively be explained by the presence of separate susceptibly loci in this region.
Association studies o f  catechol-o-methyltransferase
Association studies have implicated multiple BP susceptibility loci along chromosome 22 
at positions which would be consistent with the linkage evidence. However, within the 
VCFS deleted region only catechol-o-methyltransferase (COMT) has shown association. 
Therefore, I will limit the discussion to this locus.
COMT maps to 22ql 1.21 at approximately 18.3 Mb. COMT is considered an excellent 
functional candidate due to its role in catecholamine metabolism. The first step of 
catecholamine neurotransmitter degradation proceeds either by oxidation or methylation. 
MAO catalyses the oxidation while COMT catalyses the methylation. The relative 
importance of theses pathways varies between brain regions but COMT degradation is 
pronounced in the frontal cortex.
COMT exists in two isoforms -  a membrane bound form, MB-COMT and a shorter 
soluble form, S-COMT. It has been demonstrated that the expression o f each isoform is 
under the control o f separate promotors, P2 and PI respectively (Tenhunen et al. 1994). 
While overall expression of S-COMT predominates, the MB-COMT is the more common 
isoform in the CNS.
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The most extensively studied COMT polymorphism has been the exon 4 Vall58M et 
substitution. I will refer to it as rs4680 from now on. The presence o f the methionine 
residue results in heat lability of the protein and a dramatic decrease in enzymatic activity 
(Lachman et al. 1996b). It is o f relevance to genetic association studies that allele 
frequencies at this polymorphism have been shown to vary between populations (McLeod 
etal. 1998).
A gender difference in COMT activity has also been demonstrated, with lower activity in 
females (Floderus et al. 1981). It appears that this effect is mediated by oestrogen 
response elements and C/EBP binding sites within the promotor regions. A region 
between -1405 and -1083, with respect to the MB-COMT transcription start site, was 
found to be critical for the oestrogen-dependent repression o f the P2 promotor (Xie et al. 
1999). A H indlll RSP was identified within this critical region, at -1217 bp (DeMille et al. 
2002).
Association of the rs4680 methionine allele with BP was initially found in a sample of 
VCFS patients with psychiatric disorders (Lachman et al. 1996a). The rs4680 
polymorphism was typed in 23 patients and a screened control group, n= 89. Association 
of the methionine allele with rapid cycling BP was found, although no correction was 
made for multiple testing o f diagnostic categories. Since this original report, multiple 
studies have tested the association between BP and COMT.
Craddock et al (Craddock et al. 2001) performed a meta-analysis for the rs4680 
polymorphism which included the following studies: (1997); (Gutierrez et al. 1997); 
(Lachman et al. 1997); (Kunugi et al. 1997); (Mynett-Johnson et al. 1998); (Li et al.
1997); (Ohara et al. 1998). These studies contributed a total o f 910 BP cases and 1,069 
controls to the analysis. Association with the methionine allele was confirmed, albeit with 
a very modest pooled OR of 1.18 (Cl 1.02-1.35).
Three subsequent studies have supported association with the COMT locus. Analysis of a 
population based sample from Italy, cases= lll, controls=127, gave association with the
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methionine allele at the /?=0.004 level (Rotondo et al. 2002). Subdivision o f the case 
sample by comorbid panic disorder revealed that the association was only seen in the 
group without comorbid panic disorder. This finding is somewhat unexpected since the 
met allele has been implicated in the aetiology of panic disorder itself, e.g. (Woo et al. 
2002).
Association with three COMT SNPs - rs737865, rs4680 (referred to as r s l65688 in the 
article), and r s l65599 - was tested in an Ashkenazi Jewish sample (Shifman et al. 2004). 
Allele frequencies of 217 BP cases were compared with over 4,000 controls. No 
association was found with rs4680 alleles. However, both o f the other SNPs showed 
association, p=0.049 and /?=0.0015. Haplotypic analysis produced two intriguing results. 
Firstly, haplotypic association was restricted to BP women. Secondly, the G-G-G 
haplotype was found to be associated. The G allele at rs4680 corresponds to the high 
activity valine residue, which is at odds with the hypothesis that low COMT activity 
predisposes to BP.
Further evidence o f allele switching comes from the study o f Funke et al (Funke et al.
2005), although the results are rather difficult to interpret. In addition to the 3 SNPs tested 
by Shifman et al, a SNP located in the P2 promotor region, rs2097603 was genotyped. 
Variation at this SNP had previously been shown to have a small effect on enzyme 
activity. Individual marker association was found at rs2097603, rs4680 and r s l65599 in a 
US Caucasian sample o f 394 cases and 467 controls. Again the valine allele o f rs4680 
was associated. However, the case group included patients with diagnoses o f BP, 
schizophrenia, major depression, depressive disorder, NOS and psychotic disorder NOS. 
When the BP cases were analysed separately n=82 no single marker associations 
remained.
Most recently association of BPI with SNP rsl65599 was supported, p=0.02 in a small 
case control study from the US (Burdick et al. 2007). The risk allele (G) was 
subsequently shown to predict poorer performance on tests of verbal memory in both 
cases and controls. Association with rs4680 was not, however, replicated.
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Some additional evidence that the methionine allele at rs4680 increases susceptibly to the 
rapid cycling (RC) form of BP has emerged. However, this association has only been 
observed when BP cases with RC are compared to BP cases without RC, rather than 
controls (Papolos et al. 1998); (Kirov et al. 1998). Furthermore, the association was 
restricted to a subgroup of RC, ultra-ultra RC, in the Papolos et al study.
It needs to be recorded that there have also been multiple negative studies since Craddock 
et aVs meta-analysis: (Kirov et al. 1999a); (Geller and Cook 2000); (Serretti et al. 2003); 
(Massat et al. 2005); (Van Den Bogaert et al. 2006b); (Prata et al. 2006; Serretti et al.
2006).
Revised meta-analysis is awaited, but the methionine allele at rs4680 does seem to confer 
a small increase in risk o f BP. Although this is a functional polymorphism it is not 
necessarily responsible for the increased risk, as the methionine allele may be in LD with 
the true aetiological variant. It has been suggested that variation at the COMT locus alters 
risk of psychiatric illness in some generic way as, in addition to panic disorder, COMT 
has also been implicated in schizophrenia and alcoholism.
5.6.2 Evidence for bipolar loci on 13q
Linkage
Several studies have found linkage between BP and markers on the long arm of 
chromosome 13. The distribution o f these linked markers would suggest at least two 
distinct regions o f linkage: 13ql 1-13q21 and 13q22-13q32.
The more telomeric 13q22-13q32 region is robustly supported by the linkage data. As 
discussed in chapter 3, the first meta-analysis o f linkage scans in BP found the strongest 
evidence for a susceptibility locus on 13q at 79 cM (Badner and Gershon 2002a). 
Subsequently, significant linkage with markers mapping to this region has been reported 
(Shaw et al. 2003). A parametric multipoint analysis using a BP-only, autosomal
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dominant, medium penetrance model yielded a peak LOD of 3.4, approximately 7 cM 
centomeric to D13S154. The relative position o f this marker is indicated on figure 5.6 
below. In addition, there have been a number of independent reports which support 
linkage to the 13q22-13q32 region: (Detera-Wadleigh et al. 1999); (Liu et al. 2003); 
(Potash et al. 2003); (Cheng et al. 2006).
Under multipoint nonparametric analysis suggestive linkage at the D13S1252-D13S1271 
interval, /?=0.000028, with a broad phenotypic definition was obtained (Detera-Wadleigh 
et al. 1999). Subsequently, additional microsatellite markers were genotyped in this 
sample and a slight telomeric shift in the interval showing strongest evidence for linkage 
(D13S779-D13S225) was found (Liu et al. 2001a).
Multipoint ASP analysis yielded a suggestive linkage signal near D13S779, LOD score of 
2.2, in a large sample of American and Israeli pedigrees (Liu et al. 2003). When this 
dataset was reclassified to include only individuals exhibiting psychotic symptoms as 
affected, suggestive evidence for linkage persisted at this marker, multipoint, LOD=1.96 
under a dominant model (Park et al. 2004). Attempts have also been made to identify 
susceptibility loci for ‘psychotic’ BP by sub-dividing BP pedigrees according to the 
number of members with psychotic symptoms (Potash et al. 2003). In families with three 
or more members exhibiting psychotic mood disorder a nonparametric LOD score of 2.52 
at D13S317 was obtained using ASPEX SIBIBD.
More recently, the effect of different phenotypic definitions on the linkage results has 
been further explored (Cheng et al. 2006). No evidence was found to support linkage of 
‘psychotic’ BP to this region, but a nonparametric LOD of 1.78 at D13S793 was obtained 
when a standard narrow affection status model was applied. Although this LOD did not 
reach the Lander and Krugylak threshold for suggestive linkage, the authors argued that it 
should be considered as such, as it exceeded the threshold derived from simulation 
analysis of their dataset. Since approximately 16% o f people with BP develop panic 
disorder at some point in their lives (Henry et al. 2003), it is interesting to note that
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significant linkage of panic disorder to this marker (LOD 3.57) has been published 
(Hamilton et al. 2003).
Figure 5.6: Summary of linakge results on 13q31-33
D13S317, 81.6 Mb 
Potash et al, NPL2.52
~7cM proximal to 
D13S154, 95.1 Mb 
Shaw et al, LOD3.4
D13S793, 96.7 Mb 
Stine et al, p= 0.02, 
Cheng et al, NPL1.78
D13S1252-D13S1271, 
97.3-98.7 Mb 
Deteria-Wadleigh et al, 
LOD3.5
Gershon, p=6x!0 -6
D13S779, 13q32.3,
100.3 Mb 
Lui et al, LOD2.2
___
Three independent genomewide linkage scans have provided suggestive linkage evidence 
for the more centromeric 13qll-13q21 region: (Badenhop et al. 2002); (Cichon et al.
2001); (Mclnnis et al. 2003b). These studies defined a broad region - spanning 
approximately 30 Mb - but one that could still be compatible with a single locus.
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Association findings fo r  DAOA/G30
Multiple studies have also demonstrated linkage of schizophrenia to the 13q22-34 region. 
Indeed, Badner and Gershon’s (Badner and Gershon 2002a) meta-analysis of 
schizophrenia linkage scans yielded remarkably similar results to that o f their BP meta­
analysis. Again, the strongest evidence for linkage of a susceptibility locus was found on 
13q. The location was slightly more distal for schizophrenia at 85 cM, but is entirely 
compatible with the same loci being responsible for the signal in both disorders. These 
findings added weight to the possibility that a common susceptibility locus exists in the 
region. Around the same time as this meta-analysis was published, the gene G72 was 
implicated in the aetiology of schizophrenia (Chumakov et al. 2002).
Chumakov et al undertook systematic fine mapping of a 5 Mb region o f 13q34 by SNP 
association analysis. Two associated sub-regions were defined. Two novel genes - G30 
and G72 - were identified in one o f these sub-regions. G72 was found to be expressed in 
the brain and could be translated in vitro. Furthermore, G72 was found to interact with D- 
amino acid oxidase (DAO). This was an important finding, as it linked G72 with NMDA 
function. DAO oxidises D-serine, which is a potent activator o f the NMDA receptor. G72 
was found to increase the oxidation of D-serine by DAO. Therefore, G72 has come to be 
referred to as D-amino acid oxidase activator (DAOA). I will use this terminology from 
now on.
DAOA maps to approximately 105 Mb, a position that is also compatible with the linkage 
data for BP. On this basis, DAOA was tested for association with BP (Hattori et al. 2003). 
The study examined 16 SNPs across a 157 kb region, which encompassed the 
DAOA/G30 locus, in two family based samples. The CNG sample consisted o f 83 
individuals from pedigrees in which linkage to 13q32 had previously been found. The 
NIMH samples comprised of 474 individuals. TDT and haplotype analysis was 
performed. It was stated that both tests controlled for the presence o f linkage which could 
potentially confound association.
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Five SNPs showed individual association with BP in the CNG sample: r s l815686 
(p=0.041), rsl935058 (p=0.00077), rsl341402 (p=0.0075), rsl935062 (p=0.0078) and 
rs778294 (p=0.018). No individual association was found in the NIMH sample, although 
rsl935058 approached significance a tp=0.055. Haplotype analysis was performed for the 
seven SNPs in LD with one another. Significant perturbations from the expected 
transmission frequencies were found for the two most common haplotypes in the CNG 
sample. Furthermore, significant results were obtained for the global test o f transmission 
disequilibrium in both datasets.
Subsequently, a number o f groups have attempted to replicate the association of DAOA 
with schizophrenia, BP, a psychosis phenotype and panic disorder. I will restrict my 
consideration to those that have studied BP.
Six SNPs - rs2027446, rsl935058, rs2391191, rsl935062, rs947267 and rs954581 - were 
tested in a population based sample of 139 cases and 113 ethnically matched controls 
(Chen et a l 2004). Only two of the five associated SNPs in the Hattori et al study were 
tested. Attempts were made to genotype two more of the Hattori et al associated SNPs - 
rsl341402 and rs778294 - but the assays failed quality control. Significant association 
was found with two adjacent SNPs: rsl935062 (p=0.007) and rs947267 {p=0.04). 
However, here the A allele of rsl935062was found to be associated, whereas it was 
under-transmitted to cases in the Hattori et al study.
Because o f the assay failure, Chen et al were unable to reconstruct the Hattori et al 
haplotypes. However, analysis o f five SNP haplotypes provided further evidence for 
association, with significant results for both individual haplotypes and the global 
distribution of haplotypes (p=0.004). The associated haplotypes did not correspond 
between the two studies. Of the three individually associated haplotypes in the study of 
Chen et al, two were not reported in that of Hattori et al. It is possible that these rare 
haplotypes did not exist in the Hattori et al samples, or that they were an artifact o f 
haplotype estimation.
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Seven SNPs in schizophrenia and BP case-control samples from Germany were 
genotyped (Schumacher et a l  2004). 300 BP cases and 300 controls were included. As 
can be seen from table 5.1 below, not all o f the SNPs which Hattori et al found to be 
associated were typed and it was not possible to reconstruct the original seven SNP 
haplotypes. One SNP, rs3918342 (M23), was associated at the 0.013 level. A four-marker 
haplotype was tested. No difference in the overall distribution o f haplotypes between 
cases and controls was observed. However, one individual haplotype was found to be 
significantly less frequent in the cases (p=0.032).
On the premise that the DAOA/G30 locus confers susceptibility to both disorders, the 
hypothesis that a psychotic subtype of BP is accounting for the association observed in 
the above dataset was examined (Schulze et a l 2005). Logistic regression was performed 
to identify variables from the 21 OPCRIT symptoms of psychosis, which influenced M23 
genotype. Lifetime history o f persecutory delusions was found to be the only significant 
variable. A case group o f BP with persecutory delusion was thus defined («=90) and the 
association data re-analysed for the four markers that made up the associated haplotype in 
the Schumacher et al study. Two of these markers showed association - rs3918342 (M23) 
and rsl421292 (M24), with p-values of <0.0004 and <0.007 respectively. No association 
was found at any o f the markers for BP without persecutory delusions. Haplotype 
analysis supported the association with BP with persecutory delusion, yielding significant 
results for global and individual haplotypes.
Replication o f this finding was attempted in a Polish sample o f 294 BP cases and 311 
controls. Only the positively associated rs3918342 (M23) and rsl421292 (M24) markers 
were genotyped in this sample. Individually neither marker was found to be significantly 
associated, but a modest association was observed with one haplotype (p<0.04). This 
haplotype was consistent with one of the associated four SNP haplotypes in the German 
sample.
As described in relation to DAO, a screen of 64 candidate genes in Ashkenazi Jewish 
trios was conducted (Fallin et a l 2005). Fourteen SNPs across the DAOA/G30 locus
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were tested and the suggestive association with BP reported. However, I was unable to 
glean from the report any details of the association.
A meta-analysis o f the association findings in schizophrenia and BP was performed 
(Detera-Wadleigh and McMahon 2006). For BP it included the studies of Hattori et al, 
Chen et al and Schumacher et al. Three markers - rsl935058, rsl935062 and rs3918342 
(M23) - were found to be significantly associated. However, the results were combined 
“without regard to the allele identity”.
An attempt was made to systematically test for association o f the DAOA/G30 locus with 
BP and schizophrenia (Williams et al. 2006). Initially, mutation screening of 14 unrelated 
schizophrenic individuals was performed. Exonic 5’ and 3’ untranslated regions and the 
flanking intronic regions were sequenced. Nineteen sequence variants were identified. 
Thirteen of these were not analysed further because they captured the same information 
or had minor allele frequencies o f <10%. The remaining six SNPs and three intronic 
SNPs chosen from dbSNP were used to define the LD structure using a sample o f 96 
unrelated individuals. From this, six tag SNPs were identified. These were supplemented 
with three SNPs that had previously been associated with schizophrenia for the 
association testing stage. Case-control samples were used comprising o f 706 BP cases, 
709 schizophrenics and 1,409 controls. Three SNPs showed association with BP: 
rs3916965 (M12), DAOA_3’UTR_SNP12 and rsl341402. The results o f haplotype 
analysis were not shown.
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Table 5.1: Summary of published association studies for DAOA in BP
Hattori et a l Chen et al Schumacher et al Williams e t a l
rs3916965 (Ml 2) - - 0.225 0.047
rsl 815686 0.041 - - -
rs2027446 - NS - -
rsl 935058 0.00077 NS - 0.30
rsl 341402 0.0075 - 0.437 0.03
rs2391191 (M15) 0.08 NS 0.222 0.09
rsl 935062 0.0078 A 0.0072 A 0.715 -
(controls) (cases)
rs947267 0.17 0.0403 A - -
DAOA 3TJTR SNP 12
rs778294 (M19) 0.018 - 0.337 0.35
rs954581 0.62 NS - 0.88
rs778293 (M22) - - - 0.36
rs3918342 (M23) - - 0.013 -
rsl421292 (M24) - - 0.064 0.59
Abbreviations: NS=not statistically significant, A=associated allele. Results that a re statistically significant are 
indicated in red and SNPs used as part o f  Hattori et a l’s 7-SNP haplotype are shown in blue.
It is difficult to know how to interpret the DAOA/G30 results. The difficulty emanates 
from two sources: firstly, the variation in markers tested between individual studies and 
secondly, the fact that different alleles at the same marker were found to be associated.
No study tested all the markers that were found to be associated by Hattori et al (Hattori 
et al. 2003). Consequently, it is particularly difficult to interpret the haplotype findings 
for subsequent studies. The example of DAOA association studies raises the more general 
point of what constitutes a formal replication. It could be argued that if the LD structure 
of the region is first delineated then it may not be necessary to type the exact same SNPs, 
as tagging SNPs will be able to capture the information. This is broadly the approach 
taken by Williams et al (Williams et a l 2006).
Individual association was found with the marker rs l935062 by Hattori et al and then by 
Chen et al. The p-values were similar and impressive, but unfortunately for different 
alleles. However, such findings are not necessarily incompatible with DAOA being a 
susceptibility gene for BP. One explanation is that there were a number o f aetiological
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mutational events which occurred on different haplotypic backgrounds. Hence, patterns 
of association could differ between populations. This argument has been used to explain 
the findings for Dysbidin in schizophrenia (Schwab et al. 2003).
While I have avoided detailed discussion of the findings in schizophrenia, I think it is 
pertinent to note that there have been similar inconsistencies in the associated alleles but 
overall the evidence for association is much stronger (Detera-Wadleigh and McMahon 
2006). Detera-Wadleigh and McMahon also performed a meta-analysis where 
schizophrenia and BP studies were combined, which in fact yielded the strongest 
evidence for association. Susequently Williams et al performed analysis across traditional 
diagnostic boundaries (Williams et al. 2006). No association was found when cases were 
defined by the presence of psychosis, but the evidence for association was increased 
when the definition was according to the presence of major mood disorder.
Although association studies on the telomeric region of 13q have focused on the DAOA 
locus, it should be remembered that the linkage results implicate a wide region. 
Furthermore, the possibility exists that there is more than one susceptibility locus in this 
region. The parametric multipoint linkage analysis of Shaw et al (Shaw et al. 2003) 
showed two peaks. O f these, the distal peak is more compatible with the DAOA locus, 
while it was the proximal peak that showed the greater evidence for linkage.
To follow up the more proximal findings at D13S280, three genes - KDELC1, BIVM, 
ERCC5 - and the hypothetical gene LOC93081 were screened (Ferraren et al. 2005). No 
convincing evidence for association was found, but nonetheless this study serves as a 
reminder that the search may need to extend beyond the DAOA locus.
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Chapter 6: Aims
The overall intention of the work was to identify novel, and further investigate previously 
implicated, BP susceptibility loci by LD mapping. Within this framework the aims were 
three-fold:
1) To follow up the preliminary association findings on the 12q24 and 21q22 regions 
identified through linkage studies at UCL in a larger case-control sample.
2) To follow up the UCL linkage findings on lq42.
3) To attempt to replicate association findings at loci within regions either implicated 
by linkage studies at UCL or by meta-analysis o f the linkage data (Badner and 
Gershon 2002a). Specifically to:
a) replicate the association of BDNF with BP reported by Sklar et alfNeves- 
Pereira et al (Sklar et al. 2002)/(Neves-Pereira et al. 2002)
b) replicate the association of P2RX7 with BP reported by Barden et al 
(Barden et al. 2006)
c) replicate the association of the methionine allele o f the COMT functional 
exon 4 polymorphism, rs4680 with BP
d) replicate the association of DAOA with BP reported by Hattori et al 
(Hattori et al. 2003).
For BDNF, P2RX7, COMT and DAOA additional polymorphisms were tested for 
association to further investigate the role of these genes in the aetiology of BP.
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Chapter 7: Materials and Methods
LD between alleles at DNA markers and BP was tested for using a population based case- 
control design. I will first describe the case-control sample, genotyping/sequencing 
techniques and statistical analysis in a generic sense. I will then proceed to discuss the 
specific details for each locus studied.
7.1 Case-control samples
7.1.1 Power considerations
It is not possible to calculate a priori the size of sample needed to detect association with 
a given allele, since the relative risk conferred by that allele in the population from which 
our sample is drawn is not known. This is evidently true for novel loci but also applies to 
loci in which replication of association is being attempted. The estimates o f the relative 
risk conferred by a particular allele from previous studies will only apply to the 
populations which have been studied. Overall, association studies in BP suggest that 
considerable variability in risk alleles exists across populations so it would seem 
dangerous to rely on power calculations based on such assumptions.
It is clear that the larger the sample, the greater the power to detect allelic association. 
Thus the UCL laboratory has tried to maximise the size o f the sample. By necessity, the 
collection of the UCL sample has run parallel to the association testing. Therefore, there 
is considerable variability in the total number of individuals genotyped for different 
markers, reflecting the point in time at which the genotyping was performed. 
However, no selection of cases or controls occurred for the association testing. At the 
point at which a particular marker was genotyped, the full sample that was 
available was used. The only exception to this was where genotyping was outsourced to 
Kbiosciences, as the stock of DNA held by them was, for logistic reasons, updated in 
batches. At the time I began the work, the sample consisted o f approximately 300 cases
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and 300 controls. The recruitment o f cases preceeded that o f controls. Therefore in all but 
the most recent tests of association the number of cases is greater than controls. The 
DAOA locus is an exception to this pattern, as approximately 300 cases and 300 controls 
were initially tested. At a later date further controls were genotyped in relation to an 
association study in schizophrenia and the control genotypes added into the bipolar 
analysis. The maximum number of cases and controls available for testing was 613 and 
600 respectively.
Power calculation shows that a sample of 600 cases and 600 controls has 89% (2-sided) 
power to detect LD at the p<0.05 significance level when there is an allele frequency 
difference of 5% in the context o f less common alleles - alleles present in 5% of controls 
and 10% of cases. To detect a 5% difference in a common marker allele which has a 
frequency of 45% in controls and 50% in cases, the power is only 38% (2-sided).
7.1.2 UCL Sample
U.K. National Health Service (NHS) multicentre and Local Research Ethics Committee 
approval was obtained. Each volunteer was given an information sheet and description o f 
the study. All volunteers signed an approved consent form.
The cases were recruited from London NHS psychiatric services and from volunteers 
who were members o f the Manic Depression Fellowship, a support organisation for 
sufferers o f BP. The control subjects were recruited from London branches o f the 
National Blood Service, from local NHS family doctor clinics and from university 
student/staff volunteers.
As discussed in chapter 4, it is crucially important for association studies that the case 
and control sample are derived from the same population. Ancestry criteria for 
participation in the study had been set out at the very start o f the study. Volunteers had to 
be of predominately British or Irish ancestry. This was defined as having at least three of 
four grandparents of such ancestry. Volunteers with a grandparent o f non-western
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European ancestry were excluded. All volunteers were screened with an ancestry 
questionnaire. The validity of using this questionnaire had previously been assessed. 
Twenty-six microsatellite markers were genotyped at loci not thought to be associated 
with affective disorders in the first 300 BP cases and 300 controls to test for population 
stratification, as suggested by Pritchard and Rosenberg (Pritchard and Rosenberg 1999). 
No difference in allele frequencies between the groups was observed (McQuillin et al. 
2006).
All volunteers were interviewed using the SADS-L (Endicott and Spitzer 1978). This 
information was supplemented by material from case-notes where appropriate. Diagnoses 
were always assigned prior to genotyping and were made at the “probable” level o f the 
RDC. A second psychiatrist reviewed the diagnoses. Most o f the cases had BPI (88%). 
All the BP cases were rated with the 90 item OPCRIT checklist (McGuffin et a l  1991). 
Information regarding family history o f mental disorder and drug treatment response was 
also collected. Phenotypic information was collated in a Microsoft Access database.
Only ‘supernormal’ controls were recruited. Control volunteers with a personal history o f 
any RDC defined mental disorder or a family history of BP, schizophrenia or alcoholism 
were excluded. It has been argued that it is more efficient to use such controls (Morton 
and Collins 1998).
7.2 Genotyping
7.2.1 DNA extraction
DNA was extracted from whole frozen venous blood using a cell lysis, proteinase K, 
phenol/chloroform method (Sambrook et al. 1989). The DNA was quantified by 
fluorimetry with Picogreen according to manufacturer’s instructions (Invitrogen).
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7.2.2 PCR reactions
Genotyping was performed using DNA amplified by the polymerase chain reaction 
(PCR). All PCR reactions were made up to a volume of 12 ul. 50 ng o f genomic DNA (2 
ul of 25 ng/ul) was used in each reaction. The concentration o f 0.2 mM dNTPs (0.096 ul 
o f 25 mM dNTPs. Oligonucleotide primer concentrations varied depending on the marker.
PCR conditions were optimised by varying the magnesium concentration (2.0-2.5 mM), 
the addition of 1 mM betaine and the PCR programme. The PCR reactions for each 
marker were carried out separately in 96-well PCR plates. Reaction mixes were plated 
out with a MWG Biotech RoboAmp 4200. PCR was performed in MWG Biotech Primus 
Thermocyclers (MWG Biotech, DE). Details of the PCR programmes after given in 
appendix 1.
7.2.3 Microsatellites
An infrared fluorescence-based method of genotyping most o f the microsatellite markers 
was used (Oetting et a l  1995).
Generally, established microsatellite markers were genotyped. Where necessary, 
sequence databases were interrogated for repeat structures. Primers were designed for 
repeats thus identified using the program Primer 3 (Rozen and Skaletsky 2000).
A 19 bp M l 3 tail (CACGACGTTGTAAAACGA) was added to the 5’ end o f the primers 
in silico. The four primers thus created were analysed using NetPrimer, 
(www.premierbiosoft.com/netprimer), for self-complimentary and likely formation o f 
secondary structures. The primer pair with the highest combined score, i.e. lowest 
likelihood of developing these structures, was chosen. The oligonucleotides were 
synthesised by MWG (MWG Biotech, DE). 2-4 pmoles (0.167 uM - 0.333 uM) of each 
digonuclectide was used in the 12 ul reaction.
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In order to increase throughput, a strategy o f running pooled PCR products on the 
polyacrilamide gels was employed. Consequently, primers were selected or re-designed 
so that, for a given group of markers, there was no overlap o f product sizes.
A third universal M l3 sequence primer labeled with IRD 700 or 800 was included in the 
PCR reaction so as to directly label the product. Post-PCR Fuschin (50mgs o f Basic 
Fuchsin in 50mls formamide 0.05%) loading buffer was added to each reaction. Pooling 
of aliquots from each marker was then carried out.
Labelled PCR products were denatured (three minutes at 96°C) and manually loaded on 
6% polyacrylamide gels. Separation and visualisation was achieved by electrophoresis on 
LiCor DNA 4200L sequencers (Li-Cor, NE, US). Molecular weight markers, 
microSTEP-20a IRD700/800 (Microzone Limited, UK), were run in multiple lanes in 
accordance with the genotyping software requirements.
Allele scoring was carried out with either GenelmagIR (Scanalytics, VA, USA) or 
SAGA-GT (LiCor) genotyping software.
A few o f the early markers were genotyped using PCR with a P-labelled 
oligonucleotide primer followed by polyacrylamide gel electrophoresis and
32autoradiography. One of the oligonucleotide primers was end-labelled with y P-ATP 
using T4 polynucleotide kinase (Promega, UK). Once amplification had been completed 
the products were denatured in formamide loading buffer and separated on 6% 
polyacrylamide gels under denaturing conditions. Products were detected by 
autoradiography.
7.2.4 SNPS
The SNPs were genotyped by one or more o f the following methods: KASPar 
(Kbiosciences, UK), Pyrosequencing (Pyrosequencing, Sweden), Taqman (Applied 
Biosystems, CA, US), Amplifluor (Serologicals, GA, US) or PCR/restriction digest/
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agarose gel electrophoresis. Some of the genotyping was outsourced to Kbiosciences 
(Hoddeson, UK) who employed the KASPar and Amplifluor methods. ‘In house’ assays 
were performed according to manufacturers’ instructions. For amplifluor PCR reactions 
Titanium Taq (Clontech) was used. The fluorescence o f Taqman and Ampliflour assay 
products was end-read on an ABI700 or Roche LightCycler 480.
RFLPs were typed by PCR, restriction enzyme digest and agarose gel electrophoresis. 
Digests were performed overnight at 37°C. Products were run on 1.5% agarose gels 
alongside molecular weight markers (Hyperladder, Bioline). DNA detection was 
achieved by incorporation of ethidium bromide and visualisation under UV light. Digital 
photographs o f the gel were taken and the genotypes scored manually.
7.2.5 Sequencing
Sequencing was carried out using the Li-Cor infrared fluorescent sequencing system. The 
method involved direct sequencing of PCR products amplified from genomic DNA using 
M l3 tagged PCR primers. Amplification products were purified with Microclean reagent 
according to the manufacturers’ instructions (Microzone, UK). PCR products were then 
sequenced simultaneously in both directions with the SequiTherm Excel II DNA 
sequencing kit (Epicentre, WI, US) using two M l3 primers fluorescently labelled with 
IRD700 and IRD800 (MWG Biotech, DE). Sequencing products were analysed on Li­
Cor 4200 automated sequencers (Li-Cor, NE, US). The samples were arranged such that 
the guanosine dideoxy nucleotide terminated tracks from each o f the samples were loaded 
together followed by the adenosine, thymidine and cytidine. This facilitated visual 
scoring of potential mutations and allowed recognition o f polymorphisms in their 
heterozygote state. The validity o f potential mutations was assessed by comparison with 
the gel image produced from simultaneous sequencing reactions primed from the 
opposite strand.
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7.3 Statistical analysis
7.3.1 Error detection
Genotypes were read by two independent assessors, each blind to both the diagnosis and 
the allele scoring o f the other. Genotypes that could not be agreed upon were repeated.
To assess the general comparability of results between in house and Kbiosciences 
genotyping 621 individuals were genotyped for the SNP rs6265 by Taqman in house and 
Amplifluor at Kbiosciences. 98.7% of genotypes correlated.
For markers genotyped by Kbiosciences, 17% of samples within each 96 well plate were 
duplicated in order to detect error and confirm the reproducibility o f genotypes.
The data for each SNP was analysed to confirm the presence o f HWE. The SNP data was 
also tested for significant differences in haplotype frequencies between 96 well plates 
using the SCANGROUP support program of the GENECOUNTING software (Zhao et al. 
2002). This allows plates with atypical haplotype frequencies to be identified and 
scrutinised. If genotyping errors occur on one particular plate, overall allele frequencies 
and thus allelic association may be minimally affected. However, such errors may 
produce rare or non-existent haplotypes and create strong haplotypic association.
7.3.2 Testing of allelic association
Allelic association between each SNP marker and BP was tested using the chi-squared 
test. Allelic association between BP and each microsatellite marker was tested using the 
CLUMP programme (Sham and Curtis 1995). This performs a Monte Carlo evaluation o f 
significance levels to produce an empirical p-value for the observed chi-squared statistics, 
since the asymptotic p-value may be inaccurate for markers having large numbers of
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alleles. Four different chi-squared statistics are calculated, labelled T1-T4: T1 is the 
standard Pearson chi-squared statistic; T2 is the statistic obtained by collapsing together 
rare alleles; the T3 statistic is the maximum obtained by considering each allele 
separately against all the rest; the T4 statistic is obtained by grouping together all the 
alleles positively and negatively associated with disease.
Association testing of subsets of the case group was performed only where there was 
prior evidence that the chromosome region might harbour a susceptibility allele to a 
specific subtype o f BP. The subanalysis performed is summarised in table 7.1 below. 
This evidence may have originated from linkage, chromosomal aberration or association 
studies. Subdivision of the case group was achieved using queries o f the Microsoft 
Access phenotypic database. Only markers associated in the primary analysis were tested 
in the subanalysis, except for the COMT locus where all markers were tested.
Table 7.1: Summary of allelic association subanalysis performed
Subtype analysis
Loci
12q
UCL
21 q
UCL DISCI BDNF P2RX7 COMT DAOA
Age of onset Y Y Y Y Y Y Y
Gender - - Y - - Y -
Psychotic
symptoms - - Y - -
Y Y
Persecutory
delusions - - - - - - Y
Rapid cycling - - - Y - Y -
Comorbid
alcoholism - - -
- - Y -
Lithium response - - - - - Y -
Linkage disequilibrium between pairs of markers was determined using LDP AIRS, 
another option within the GENECOUNTING package. Markers found to be in linkage 
disequilibrium with one another were used for subsequent haplotype analysis.
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7.3.3 Haplotype analysis
Haplotype analysis was carried out using the above quoted program, GENECOUNTING. 
This method computes maximum likelihood estimates o f haplotype frequencies from 
phase unknown case-control data. It uses an algorithm capable o f analysing both SNPs 
and microsatellites. It also has the advantage of being able to deal with missing data. The 
significance o f any overall haplotypic association with BP was computed using 
permutation testing o f the observed haplotype distributions. Where empirical significance 
was high, greater numbers o f permutations were employed to achieve better estimates o f 
significance. Analysis o f haplotype block structure was performed using HAPLOVIEW 
(Barrett et al. 2005).
The results of both the single marker and haplotype analysis are presented without 
correction for multiple testing and therefore these significance values should be 
interpreted with caution. Correction for multiple testing has not been applied because 
the appropriate method for correcting these analyses is unclear.
7.4 UCL 12q24 linked region
LD fine mapping o f the 12q24 linkage region was initially carried out using microsatellite 
markers.
Fifteen microsatellite marker loci were selected and oligonucleotide sequence 
information obtained from the Marshfield Centre for Medical Genetics database 
(http://research.marshfieldclinic.org/genetics) and from the Genome database 
(http://www.gdb.org). In addition, publicly available genomic sequence was examined for 
potential microsatellite repeat structures within the region. These sequences were 
amplified in 32 samples and the products were investigated for potential polymorphic 
markers. Seven novel microsatellites were identified using this approach and 
subsequently genotyped. The oligonucleotide sequences for these microsatellites are 
given in appendix 2. A total of 21 microsatellite markers were typed.
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Analyses of these microsatellite markers implicated a subregion, which was further 
investigated using SNP markers. The SNP genotyping was performed in stages. In the 
first stage, SNPs were either identified by re-sequencing o f predicted genes in the sub- 
region or from the databases. Re-sequencing o f exons and flanking intronic sequence was 
performed in 32 individuals. In the second stage, further SNPs were selected using 
Tagger (http://www.broad.mit.edu/mpg/tagger) to more systematically fine map the 
region. Oligonucleotide sequence information was obtained from the databases for known 
SNPs. The oligonucleotide sequences for SNPs identified by sequencing are shown in 
appendix 2.
In total 22 SNPs were tested. SNPs rs4765108, 47783-CT, rsl 194031 and 29818-insT 
were typed using Pyrosequencing. SNPs rs2292446, rs7133178 and rsl0773323 were 
typed using Taqman MGB probes. SNPs M ette_l, rsl212337, rs7308299, rs4765448, 
rsl0773322, rs7311054, rsl 194050, rsl0847208, rsl 1058793, rsl 194029, rsl616006, 
rs4765451, rs4765449 and rsl0773324 were typed by Kbiosciences using the Amplifluor 
SNP genotyping method. The rs3830490 polymorphism was genotyped as per the 
methods for microsatellite markers above. The positions o f all the markers tested are 
shown in figure 8.1 in the results section.
7.5 UCL 21q22.3 linked region
In a similar manner to that described in section 7.4, LD fine mapping of the 21q22.3 
linkage region was initially carried out using microsatellite markers and then extended by 
SNP genotyping.
10 microsatellites (D21S266, D21S1260, D21S212, White-PolyT, D21S1411, PKNOX1- 
CA, PFKL-CA, D21S171, D21S1903, and D21S1897) were selected and sequence 
information obtained from the Marshfield Genetics and Genome databases. These were 
supplemented by a further nine novel microsatellites (22A5.GT124a, 218C10.CA44a,
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C21orf2, AGAT10, ATTT11, 314n7CT18, 314n7CA28, 314n7CA23 and Col6al) 
identified from the sequence databases. The oligonucletide sequences for these 
microsatellites are given in appendix 3. C21orf2 was genotyped using 32P-labelled 
primers. The Col6al VNTR was genotyped by PCR and agarose gel electrophoresis.
Microsatellite analysis implicated the genes TSPEAR and TRPM2. Therefore these genes 
were screened for polymorphisms in BP subjects selected for having inherited 
polymorphisms associated with or linked to the chromosome 21q22.3 BP locus. In total, 
28 BP subjects were chosen for sequencing, including 16 affected members from seven 
English BP families and seven NIMH BP families that had produced LOD scores >1 on 
21q. A further 12 BP patients were selected from the association sample based on the fact 
that they carried alleles associated at the D21S171 and AGAT10 loci. Four control 
subjects were also screened. I f  nucleotide changes were detected, a further 32 controls 
were sequenced to verify whether the detected nucleotide changes were likely to be 
pathogenic or simply common polymorphisms. Controls were chosen without regard to 
their genotypes at the chromosome 21 loci. Primers were designed to sequence all the 
exons and 100 bases into each intron.
Again, SNPs for association testing were either identified through re-sequencing or from 
the databases. 11 SNPs were genotyped in total. Oligonucleotide sequence information 
was obtained from GDB and dbSNP for TMEM1_IN/DEL, ITGB2-^4c/I, S100B-//aeIII, 
rsl556314, rsl785437, rsl618355, rs933151, rsl785467, rs458178 and rs233283. 
Oligonucleotide sequence information for the PCNT2-^/wI SNP identified by sequencing 
is shown in appendix 3. SNPs r s l556314 and r s l785437 were typed using 
Pyrosequencing. SNPs rsl618355 and rs458178 were typed using Taqman. SNPs 
rs933151, r s l785467 and rs233283 were typed using Amplifluor. TMEM1, ITGB2-^c/I 
and S100B-//aeIII were genotyped using 32P-labelled primers. The positions o f all 
markers tested are shown in figure 8.2 in the results section.
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7.6 UCL lq42 linked region
Initial fine mapping of the lq42 linked region was performed with microsatellite markers 
as for the 12q24 and 21q22 regions. Four micro satellites in the region were selected from 
UCSC Genome Browser: D1S103, D1S3462, D1S235 and D1S251. Association was 
found with D1S3462, which maps to intron 8 of DISCI. Therefore, two further database 
microsatellites mapping in or near DISCI were typed: D IS C 5 ’ microsatellite and 
D1S2709. The positions of all markers tested are shown in figure 8.3 in chapter 8. The 
oligonucleotide sequences and PCR conditions are set out in appendix 4.
7.7 BDNF
In order to attempt to replicate the findings o f Neves-Pereira et al (Neves-Pereira et al.
2002), the BDNF -1040bp (GT)n repeat was genotyped. To further investigate LD at the 
locus an intragenic microsatellite, AFMA275YB9, was selected using the UCSC Genome 
Browser.
The four SNPs which were found to be individually associated with BP in the Sklar et al 
(Sklar et al. 2002) study were selected for genotyping by Kiobioscience: the Val66Met 
SNP rs6265 (a39); rsl 1030096 (al3); rsl6917204 (a20) and rsl 1030101 (a40). 
Unfortunately, the last two o f these - rsl6917204 (a20) and rsl 1030101 (a40) - failed 
assay design and were abandoned. The Val66Met SNP rs6265 was also genotyped in- 
house in 621 individuals by Taqman. The positions o f all markers tested are shown in 
figure 8.5 in chapter 8. The oligonucleotide sequences and PCR conditions are set out in 
appendix 5.
Two subanalyses were performed. The association of rapid cycling BP was tested after 
Muller et al (Muller et al. 2006) and Green et al (Green et al. 2006). The association o f 
early onset BP was tested after Geller et al (Geller et al. 2004) and Strauss et al (Strauss 
et al. 2004).
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7.8 P2RX7
An attempt was made to replicate the finding of association with the microsatellite 
marker NBG6 (Shink et al. 2005a). To further test association at the P2RX7 locus, the 
UCSC Genome Browser sequence for P2RX7 was interrogated for repeat structures. 
Three potential markers were identified and optimisation attempted. However, only the 
marker denoted P2RX73 gave products which could be adequately resolved. Therefore a 
total o f two microsatellites were genotyped. The oligonucleotide sequences and PCR 
conditions are set out in appendix 6.
Assays were designed for nine SNPs from the original sudy by Barden et al (Barden et al. 
2006): rs208293 (P2RX7-I04B), rs208294 (P2RX7-E05A), rs504677 (P2RX7-I07E), 
rs7958311 (P2RX7-E08A), rsl718119 (P2RX7-E11B), rs2230911 (P2XR7E11C), 
rs2230912 (P2RX7-E13A), rsl 1065501 (P2XR4-UTR3A) and rs3817190 (CAMKK2- 
E01B). O f note, rs2230911 is referred to as rs6489795 by Barden et al. These SNPs were 
chosen so that the replication o f the individual allelic association and 7-SNP sliding 
window haplotypic association reported in the study could be attempted. Unfortunately, 
two of these SNPs - rs7958311 (P2RX7-E08A) and rs2230911 (P2XR7E11C) - failed to 
give reliable genotypes and were abandoned.
Genotyping was carried out by Kbiosciences using the Kaspar method. Genotyping was 
initially carried out on the 604 BP samples and 450 controls available. Subsequently, 110 
additional control samples were recruited and these samples were typed for the two 
markers showing association in the preliminary analysis - rs208294 (P2RX7-E05A) and 
rs2230912 (P2RX7-E13A).
The entire sample was screened for the exon 13 deletion described by Barden et al 
(Barden et al. 2006). Primers were designed to flank the deletion (see appendix 6). 
Alleles were separated and visualised on 1 % agarose gel using standard techniques.
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The positions o f all markers tested are shown in figure 8.6 in chapter 8. Analysis of 
individual haplotype association was performed using HAPLOVIEW.
A combined association analysis for marker rs2230912 was performed using the data 
from this thesis, the Barden et al (Barden et al. 2006) and Lucae et al (Lucae et al. 2006) 
studies. Lucae et al tested for association with UP rather than BP. It was considered valid 
to combine the results on the basis that the conditions may be genetically related. With 
regard to the 12q24 region specifically, the linkage findings of Abkevich et al (Abkevich 
et a l  2003) could suggest the presence of a common susceptibility locus.
7.9 COMT
The Vall58M et polymorphism (rs4680) was genotyped in house using the Amplifluor 
system and genotypes were detected on a Roche LightCycler 480.
To extend the testing o f association o f COMT with BP a further SNP (rs2075507) and 
microsatellite (intron 1 tetranucleotide) were also genotyped.
The HindUl restriction site polymorphism rs2075507, identified by DeMille et al 
(DeMille et al. 2002), maps to the critical region for the oestrogen-dependent repression 
of the P2 promotor. DeMille et al also identified the tetranucleotide repeat that maps to 
intron 1 o f MB-COMT isoform (Alfred site identifier - SI000269R). The quoted primers 
were redesigned to give PCR products of a smaller size which would accord with our 
pooling strategy.
The UCSC Genome Browser sequence for COMT was interrogated for other repeat 
structures and three potential markers were selected for optimisation. The three potential 
markers were either found to be monomorphic or the alleles could not be accurately 
scored.
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Primer sequences and cycling conditions are show in appendix appendix 7. The positions 
of all markers tested are shown in figure 8.8 and 8.9 in chapter 8.
7.10 DAOA/G30
An attempt was made to replicate the individual marker and haplotypic association 
reported by Hattori et al (Hattori et a l  2003). Therefore, the eight relevant SNPs were 
selected for genotyping: rsl815686, rsl935058, rsl341402, rs2391191 (M15), rsl935062, 
rs947267 (M18), rs778294 (M19) and rs954581. Unfortunately, rsl815686 and 
rsl935058 failed assay design.
To extend the testing o f association of DAOA with BP, rs3918342 (M23) and rsl421292 
(M24) were also genotyped.
Genotyping was performed by Kbiosciences using the Amplifluor method. The positions 
of all markers tested are shown in figure 8.10 in chapter 8.
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Chapter 8: Results
8.1 UCL 12q24 region
All SNPs were in HWE. The association results are summarised in figure 8.1, table 8.1 
and table 8.2 below.
In total seven markers showed allelic association with BP. Four of the associated markers 
were microsatellites: 1634tet, 307GT4, D12S307 and D12SDK1. Three were SNPs: 
rs4765449, rs7133178 and 29818-insT.
The results for 1634tet, 307GT4, D12S307, 29818-insT and D12SDK1 are the same as 
reported by our group previously (Kalsi et al. 2006). Typing o f additional individuals 
resulted in rs7133178 becoming slightly less significant. The pufu in/del (rs3830490) was 
previously associated at the p=0.034 level but was no longer formally significant, 
/?=0.079, in the enlarged dataset. From the most recent set o f SNPs tested one further 
SNP, rs4765449, was found to be associated, />=0.039.
The region defined by the most proximal and distal associated markers - 1634tet at 
125,621,931 bp and D12SDK1 at 125,802,874 bp respectively - spans approximately 180 
kb.
Analysis o f BP cases with early onset illness against the control group generally 
increased the evidence for association. The most significant results were obtained with 
D12S307 (p=0.0001) and rs7133178 (p=0.0003). The minor allele (A) of rs7133178 was 
increased in cases compared to controls (15% versus 9%). The direction of the 
association was the same as observed in the whole dataset.
Haplotype analysis based on the associated markers was consistent with the allelic 
association results for the whole dataset and early onset subset. However, it’s usefulness 
for identifying haplotypes likely to harbour aetiological mutations has proved limited.
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Figure 8.1: LocusView output of 12q24 markers typed (May 2004 Assembly)
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Table 8.1: Single marker association results for the UCL 12q24 region
M arker
Location 
(M ay 04 
A ssem bly)
N um ber o f  
Sam ples*
M A F***
M inor
Allele
A llelic
A ssociation
Controls BP C ontrols BP p-value**
1 D 12S1614 124,400,331 295 271 0.736
2 D 12S342 124,408,720 298 267 0.129
3 A F M b332Z C l 124,650,140 288 241 0.38
4 D 12S340 124,666,617 297 263 0.053
5 D 12S1639 124,903,049 247 254 0.276
6 D 12S 324 125,149,966 294 262 0.53
7 D 12S 866 125,207,206 293 234 0.35
8 D 12S386 125,366,006 277 275 0.58
9 1634GT2 125,526,244 310 297 0.089
10 A FM b337Z D 5 125,596,235 283 265 0.33
11 1634tet 125,621,931 412 561 0.007
12 D 12S 1634 125,689,128 315 282 0.183
13 rs2292446 125,699,946 311 300 14% 14% A 0.8002
14 rs4765108 125,701,352 266 264 15% 13% C 0.4968
15 rs7308299 125,725,413 424 587 13% 13% G 0.603
16 307GT4 125,726,085 394 544 0.001
17 rs4765448 125,732,172 551 581 8% 9% A 0.157
18 rs4765449 125,735,688 531 586 18% 15% A 0.039
19 D12S307 125,741,191 431 590 0.0018
20 rs l 0773322 125,741,404 409 576 35% 35% A 0.954
21 rs7133178 125,741,788 595 589 9% 12% A 0.042
22 rs3 830490 125,743,175 576 600 9% 12% DEL 0.079
23 44783-ct 125,743,735 290 296 3% 2% T 0.241
24 rs7 3 1 1054 125,747,922 537 568 9% 11% C 0.052
25 rs l 194050 125,750,661 412 555 3% 2% G 0.388
26 M ette 1 125,751,572 435 588 6% 6% A 0.833
27 rs l2 1 2 3 3 7 125,751,852 435 587 2% 2% T 0.337
28 rs l 0773323 125,754,207 442 581 49% 50% T 0.923
29 rs l 0847208 125,754,386 426 565 46% 47% C 0.693
30 rs l 1058793 125,754,644 538 574 3% 5% T 0.057
31 rs l  194029 125,755,075 432 585 38% 38% G 0.707
32 rs l  194031 125,755,312 443 591 38% 37% A 0.584
33 rs l  616006 125,755,566 426 556 39% 37% C 0.515
34 rs l  0773324 125,756,776 436 586 27% 25% G 0.306
35 29818-insT 125,761,701 306 293 36% 30% INS 0.022
36 rs4 7 6 5 4 5 1 125,762,344 435 586 28% 25% T 0.179
37 307CA1 125,786,142 306 284 0.116
38 307C A 2 125,790,180 311 301 0.054
39 D 12S D K 2 125,790,929 308 272 0.354
40 D12SDK1 125,802,874 426 553 0.0002
41 D 12S1658 126,099,303 267 252 0.66
42 G A T A 41E 12 126,444,213 291 252 0.26
43 D 12S2075 126,485,922 241 274 0.397
* N um ber o f  indiv iduals successfully  genotyped
** M ost significant p-value quoted from  CLU M P results
*** M A F = m inor allele frequency
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Table 8.2: Distribution of alleles for associated microsatellite markers in the UCL 12q24 region
Marker
Location 
(May 2004 
Assembly)
Sample
(Number)*
Allelic association
Distribution of alleles Chi2 Empiricalp-value
1634tet 125,621,931
217 221 225 229 233 237 241 245 249 253 257 261 265 269 273
18.3314 0.007Controls (412)
0 8 41 175 219 169 56 14 28 34 46 26 6 1 1
0% 1% 5% 21% 27% 21% 7% 2% 3% 4% 6% 3% 1% 0% 0%
Bipolars (561) 4 16 90 263 242 190 85 14 49 38 69 41 16 4 10% 1% 8% 23% 22% 17% 8% 1% 4% 3% 6% 4% 1% 0% 0%
307GT4 125,726,085
352 354 355 356 358 360 362 363 364 366 368 370 372 374 376
25.7512 0.001Controls (394)
1 2 0 1 8 7 61 0 289 244 99 25 49 1 1
0% 0% 0% 0% 1% 1% 8% 0% 37% 31% 13% 3% 6% 0% 0%
Bipolars (544) 1 1 1 8 13 37 58 1 369 367 146 35 45 4 20% 0% 0% 1% 1% 3% 5% 0% 34% 34% 13% 3% 4% 0% 0%
D12S307 125,741,191
148 152 154 156 158 160 162 164 166 168 170
20.94T2 0.0018Controls (431)
64 1 5 700 47 24 1 0 3 15 2
7% 0% 1% 81% 5% 3% 0% 0% 0% 2% 0%
Bipolars (590) 133 4 4 891 80 36 5 3 6 10 811% 0% 0% 76% 7% 3% 0% 0% 1% 1% 1%
D12SDK1 125,802,874
158 160 164 166 168 170 172 174 176 178
27. 16t1 0.0002Controls (426)
0 6 515 9 0 137 118 54 12 1
0% 1% 60% 1% 0% 16% 14% 6% 1% 0%
Bipolars (553) 1 3 650 9 1 179 157 106 0 00% 0% 59% 1% 0% 16% 14% 10% 0% 0%
For each m arker the repeat num ber is shown in the top row. A llele frequencies and percentages are show n below. 
*N um ber o f  individuals successfully  genotyped.
T 1,T2,T4=T1,T2,T4 statistic from  CLUM P
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8.2 UCL 21q22 region
All SNPs were in HWE. The results of the association testing are summarised in figure
8.2 and tables 8.3 and 8.4 below.
Two microsatellites - D21S171 and D21S1260 - provided significant evidence for 
association with empirical p-values o f 0.016 and 0.031 respectively, both with the T3 test 
of CLUMP. The 90 kb region between AGAT10 and D21S171 was targeted for further 
analysis. Although AGAT10 was not associated using the empirical tests o f significance 
an uncorrected p-value o f 0.026 was obtained when each allele was compared with the 
sum of the remaining alleles in a 2x2 contingency table. At that time there were only two 
candidate genes - TRPM2 and C21orf29 - within the region.
Seven SNPs were typed across these genes. SNPs r s l556314 and r s l785467 showed 
allelic association with BP with p-values of 0.008 and 0.025 respectively. The minor 
allele (G) o f r s l556314 was increased in controls (23%) compared to BP cases (18%). 
SNP r s l556314 is in exon 11 o f TRPM2 and causes an amino-acid change from aspartic 
acid to glutamic acid at position 543. The minor allele (C) of r s l785467 was also 
increased in controls (17%) compared to cases (12%). SNP rsl785467 is in intron 23 of 
TRPM2. There is strong LD between these two markers, D  -0.876.
Five other SNPs in TRPM2 and C21orf29 were identified by sequencing (see table 8.5). 
The three TRPM2 SNPs are now referred to as rs36007753, rs34214578 and rs35288229. 
The minor allele (A) o f the exon 6 SNP rs36007753 was observed in one of 28 BP 
patients and not in any o f 36 controls. However, it was not predicted to alter an amino 
acid. From an evolutionary standpoint it should be noted that there is conservation of the 
major allele (G) across human, chimp and rat sequences, but the minor allele (A) is 
observed in the mouse. The minor allele of the intron 8 SNP rs34214578 was detected in 
one of four controls examined and not in any of 28 BP patients. This polymorphism 
occurs 78 nucleotides before exon 9. SNP rs35288229 is located in exon 15 and is 
predicted to alter the amino acid at position 755 from arginine to cysteine. This amino
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acid is located in part of one of the protein’s predicted transmembrane domains. However 
analysis of the amino acid change with transmembrane structure prediction programmes 
TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/) and TMpred (http://www.ch. 
embnet.org/software/TMPRED_form.html) did not predict significant alterations in 
TRPM2 transmembrane structures.
The two C21orf29 SNPs are now referred to as rs35449326 and rs35028190. The intron 7 
substitution, rs3 5449326, was detected 26 nucleotides before exon 8 in one of 28 BP 
cases but in none o f 48 controls. SNP rs35028190 is located in exon 8. It is predicted to 
alter amino acid 408 from histidine to glutamine. However, the minor allele was observed 
in 5 o f 28 BP cases and in 3 o f 48 controls that were sequenced.
These polymorphisms have not yet been typed in the full sample.
Analysis of BP cases with early onset illness against the control group increased the 
evidence for association with TRPM2. Both rsl556314 and rsl785467 became more 
significant with p-values o f 0.0023 and 0.0173 respectively. The direction of association 
remained the same.
Haplotype analysis using the two associated SNPs supported the single marker 
association results for the whole dataset and early onset subset, but again did not help 
identify haplotypes for sequencing.
163
Figure 82: LocusView output of 21q22 markers typed (May 2004 Assembly)
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Table 8.3: Single marker association results for UCL 21q22 region
Marker
Location 
(May 04 
freeze)
Number of 
Samples * MAF Minor
Allele
Allelic
Association
Controls BP Controls BP p-value**
1 D21S266 41,606,447 302 281 0.189
2 D21S1260 41,717,912 290 272 0.031
3 D21S212 42,026,060 278 256 0.293
4 White 42,589,753 289 269 0.351
5 D21S1411 43,033,739 307 279 0.116
6 PKNOX1 43,323,394 309 280 0.351
7 22A5.GT124 43,996,361 300 261 0.222
8 218C10.CA44 44,182,320 312 274 0.505
9 TMEM1 44,303,314 306 278 18% 21% 0.408
10 PFKL 44,543,467 275 259 0.063
11 C21orf2 44,580,622 271 250 0.761
12 AG AT 10 44,626,239 510 414 0.163
13 rsl556314 44,635,771 427 578 23% 18% G 0.008
14 rsl785437 44,646,222 316 306 25% 23% G 0.280
15 rsl618355 44,650,890 316 306 26% 24% C 0.427
16 rs933151 44,660,433 306 303 23% 25% C 0.331
17 rsl 785467 44,663,060 311 286 17% 12% C 0.025
18 ATTT11 44,712,642 275 267 0.388
19 rs458178 44,815,716 438 580 22% 21% C 0.818
20 rs233283 44,816,731 273 244 46% 44% G 0.494
21 D21S171 44,817,095 414 560 0.016
22 314n7CT18 44,843,434 273 243 0.118
23 314n7CA28 44,919,010 283 270 0.824
24 314n7CA23 44,952,292 305 270 0.149
25 D21S1903 44,965,481 302 298 0.053
26 ITGB2 45,130,368 267 269 26% 25% 0.791
27 D21S1897 45,369,052 292 253 0.130
28 Col6al 46,623,392 274 273 0.470
29 PCNT2 46,689,126 247 243 31% 31% 0.788
30 S100B 46,842,673 313 286 4% 3% 0.393
* N um ber o f  ind iv iduals successfu lly  genetyped 
** M ost sign ifican t p -value  quoted  for C L U M P results
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Table 8.4: Distribution of alleles for associated microsatellite markers in the UCL 21q22 region
Marker
Location 
(May 2004 
Assembly)
Sample
(Number)*
Allelic association
Distribution of alleles Chi2 Empiricalp-value
D21S1260 41,717,912
204 206 208 210 212 214 216 218 220 224 226 228
8.128T3 0.031Controls (290)
5 35 15 161 29 217 84 20 3 5 4 2
1% 6% 3% 28% 5% 37% 14% 3% 1% 1% 1% 0%
Bipolars (272) 4 27 7 156 51 179 80 25 2 3 7 31% 5% 1% 29% 9% 33% 15% 5% 0% 1% 1% 1%
D21S171 44,817,095
213 215 217 219 223 225 227 229 231 233 235 237 239
8.953t3 0.016Controls (414)
1 0 23 7 4 84 385 122 141 55 6 0 0
0% 0% 3% 1% 0% 10% 46% 15% 17% 7% 1% 0% 0%
Bipolars (560) 1 1 23 9 1 117 571 172 137 72 9 5 20% 0% 2% 1% 0% 10% 51% 15% 12% 6% 1% 0% 0%
For each m arker the repeat num ber is show n in the top row. A llele frequencies and percentages are show n below . 
*N um ber o f  individuals successfully  genotyped.
T3=T3 statistic from  CLU M P
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Table 8.5: Results of mutation screening of TRPM2 and C21orf29
SNP Gene Position Sequence around change [Major allele/Minor Allele]
Predicted Amino 
Acid Change
MAF
(number individuals tested)
Controls Bipolar
rs36007753 TRPM2 Exon 6 GGACCAGGCTGGAGAAGTTCATATC[G/A] GAGC AG ACC A AGG AAAGAGG AGGT A None 0.00 (36) 0.02 (28)
rs34214578 TRPM2 Intron 8 ACCCAAGGCTCTGGCTGTGTCCGGG[G/T]CCTCAATTCTATGTGTCCTGGAGGA None 0.13(4) 0.00 (28)
rs35288229 TRPM2 Exon 15 GCTCTCCGTGGACAATGGGCTGTGG[C/T]GTGTGACCCTGTGCATGCTGGCCTT R755C 0.13 (4) 0.02 (28)
rs9974831 TRPM2 Intron 15 GTGGAGGTCAGGACCCTGGCCCTGG[C/T]GGTCACTGTCTCCTCTCTGCTGTGA None 0.07 (36) 0.05 (28)
rs35449326 C21orf29 Intron 7 CTGGCACCGACCCAAGCAGAACCA[C/G]GTGGTCCCGGTTTACTCTCTTTCAG None 0.00 (48) 0.02 (28)
rs35028190 C21orf29 Exon 8 TCTCTGTCATTTACAAATGGAGCCA[C/G]AGAAAGCTGAAGTTTACCCCATATC H408Q 0.03 (48) 0.05 (28)
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8.3 DISCI
The positions o f the typed markers are shown in figures 8.3 and 8.4. The association 
results are summarised in table 8.6.
The marker D1S3462, mapping to intron 8 of DISCI, was found to be significantly 
associated (p=0.0160). Analysis o f D1S3462 by gender revealed that significant 
association was observed with BP males (p=0.0126) but not BP females (p=0.2005). 
Analysis o f BP cases with OPCRIT defined psychotic symptoms against controls resulted 
in the association becoming more significant, (p=0.0089). No association was found with 
non-psychotic BP cases. On this occasion the evidence for association was not increased 
by selecting out the early onset cases (p=0.0516).
The marker D ISC l_5’_Microsatellite, which was observed to be an imperfect repeat, was 
also found to be associated (p=0.0189). A gender effect was not observed for this marker. 
Evidence for association was neither increased by subanalysis according to the presence 
of psychotic symptoms nor by age o f onset.
Low intermarker LD, as measured by D \  was observed except between D1S251 and 
DISCl_5’_M icrosatellite (D -0.803). Thus haplotype analysis was only performed with 
these two markers. Association was not supported by this analysis.
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Figure 83: UCSC multiple BLAT output for lq42 markers genotyped
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Table 8.6: Single marker association results for lq42 region
Marker
Location 
(March 2006 
Assembly)
Sample
(Number)*
Allelic association
Distribution o f  alleles
Empiri 
cal p- 
value
D1S103 228,903,359
104 106 108 110 112 114 116 118 120 122 124 126 128
0.718T1
Controls
(435)
0 38 7 149 54 321 78 110 29 21 58 4 1
0% 4% 1% 17% 6% 37% 9% 13% 3% 2% 7% 0% 0%
Bipolars
(596)
1 41 9 200 73 457 125 148 43 29 65 1 0
0% 3% 1% 17% 6% 38% 10% 12% 4% 2% 5% 0% 0%
D1S251 229,780,888
263 265 269 271 273 275 277 279 281 283 285 287 289 291 295
0.23517
Controls
(435)
0 0 48 10 185 101 147 25 59 14 225 24 3 29 0
0% 0% 6% 1% 21% 12% 17% 3% 7% 2% 26% 3% 0% 3% 0%
Bipolars
(596)
1 1 73 14 298 108 188 24 86 15 315 20 5 41 3
0% 0% 6% 1% 25% 9% 16% 2% 7% 1% 26% 2% 0% 3% 0%
DISCI 5’ 
MICRO 229,828,914
276 278 280 282 283 284 285 286 287 288 290 292 300 302 304 306
0.01817
Controls
(438)
19 289 1 1 3 293 41 155 5 11 1 0 2 0 52 3
2% 33% 0% 0% 0% 33% 5% 18% 1% 1% 0% 0% 0% 0% 6% 0%
Bipolars
(588)
28 350 1 4 0 444 37 196 7 33 1 1 0 2 69 3
2% 30% 0% 0% 0% 38% 3% 17% 1% 3% 0% 0% 0% 0% 6% 0%
D1S3462 230,017,109
266 269 272 275 278 281 284 287 290
0.016T1
Controls
(436)
9 2 112 277 291 83 77 19 2
1% 0% 13% 32% 33% 10% 9% 2% 0%
Bipolars
(598)
8 0 119 354 406 150 120 39 0
1% 0% 10% 30% 34% 13% 10% 3% 0%
D1S2709 230,096,973
208 210 212 214 216 218 220
O JO l73
Controls
(423)
1 103 233 398 102 9 0
0% 12% 28% 47% 12% 1% 0%
Bipolars
(600)
3 147 336 553 153 7 1
0% 12% 28% 46% 13% 1% 0%
D1S235 233,960,378
182 184 188 192 194 196 200 202 204 206 208 210 212 214 216
0.16173
Controls
(437)
0 0 12 1 336 4 5 3 5 222 129 40 112 4 1
0% 0% 1% 0% 38% 0% 1% 0% 1% 25% 15% 5% 13% 0% 0%
Bipolars
(600)
2 1 9 4 498 3 5 4 9 265 164 43 176 15 2
0% 0% 1% 0% 42% 0% 0% 0% 1% 22% 14% 4% 15% 1% 0%
* For each marker 613 cases and 443 controls were genotyped. The numbers of individuals successfully genotyped are shown in brackets
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8.4 BDNF
Both SNPs were in HWE. A 98.7% correlation between in-house and Kbiosciences 
genotypes was obtained. The markers genotyped are shown in figure 8.5. The association 
results are summarised in tables 8.7 and 8.8.
Statistically significant association was found with the marker -1040bp (GT)n repeat, 
although the association was modest: />=0.048. As can be seen in table 8.4.2, a modest 
increase in the frequency o f the 235 bp allele in cases compared to controls is observed 
(3% versus 1%). The alignment and frequency o f the alleles reported by Neves-Periera et 
al (Neves-Pereira et a l  2002) and those observed here is shown in table 8.9. Analysis of 
BP cases with rapid cycling against controls led to an increase in the significance of the 
association /i=0.0028. The overrepresentation of the 235 bp allele in the case group was 
accentuated (7% versus 1%). No association was found when early onset BP cases were 
compared against controls.
Moderately strong LD, Z)’=0.841, was observed between -1040bp (GT)n repeat and the 
rs6265 (Val66Met) polymorphism. Haplotype analyisis incorporating these two markers 
provided additional evidence for association, empirical />=0.0021. The LRT contribution 
suggested an overrepresentation o f the Valine-235 and Valine-237 haplotypes in the case 
sample (3% versus 1% and 5 % versus 2% respectively). The Methionine-237 haplotype 
was by contrast underrepresented in the case group, 12% versus 16%.
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Figure 85: UCSC multiple BLAT output for markers genotyped at BDNF locus
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Table 8.7: Single marker association results for genotyped BDNF markers
Marker
Location 
(March 06 
Assembly)
Number of 
Samples Tested* MAF Minor
Allele
Allelic
Association
Controls
(443)
BP
(613) Controls BP p-value
1 rsl 1030096 27,622,119 436 578 49% 49% C 0.786
2 rs6265(V al66Met) 27,636,492 441 582 17% 15% A 0347
3 -1040bp (GT)n repeat 27,637,640 436 561 0.048 T4
4 AFMA275YB9 27,694,422 419 600 0.223 T3
* T o ta l n u m b er o f  ind iv iduals geno typed  show n in brackets
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Table 8.8: Distribution of alleles for BDNF -1040bp (GT)n repeat
Marker
Location 
(March 2006 
Assembly)
Sample
Number*
Allelic association
Distribution of alleles Chi2 Empiricalp-value
-1040bp (GT)n 
repeat 27,637,640
225 227 229 231 233 235 237 239 243
8.72 0.048 T4
Controls
(436/443)
0 3 8 56 632 13 160 0 0
0% 0% 1% 6% 72% 1% 18% 0% 0%
Bipolars
(561/613)
3 1 14 71 803 34 192 2 2
0% 0% 1% 6% 72% 3% 17% 0% 0%
"“(N um ber o f  individuals successfully  genotyped/total num ber o f  individuals genotyped)
Table 8.9: Comparison between -1040bp (GT)n repeat allele fragment sizes and frequencies observed in UCL sample and Neves Pereira et al (Neves-Pereira et 
al. 2002)
Sample Repeat number Frequencies
UCL - . _ 225 227 229 231 233 235 237 239 243- - - 0.00043 0.00602 0.00473 0.07134 0.71036 0.02063 0.18436 0.00129 0.00086
Neves-Pereira 
e t a l
156 158 160 162 164 166 168 170 172 174 - -
0.002 0.004 0.004 0.003 - 0.009 0.065 0.7 0.03 0.184 - -
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8.5 P2RX7
The 21 bp deletion in exon thirteenl3 of P2RX7 was not observed in any o f the BP 
individuals. The data for six of the seven SNPs were in HWE for the control samples. 
SNP rsl 1065501 showed a modest departure from HWE (p=0.027).
The positions o f the genotyped markers in relation to P2RX7 are shown in figure 8.6. The 
LD between SNP markers is shown in figure 8.7. The association results are summarised 
in and tables 8.10 and 8.11.
Statistically significant evidence for allelic association with BP was obtained from the 
microsatellite NBG6 (/f=0.01) and the SNP rs2230912 (/>=0.043). Strong LD was 
observed between markers NBG6 and rs2230912 (D -0.976). The frequency of the 
minor allele (G) o f rs2230912 was increased in cases compared to controls (18% versus 
15%).
Relatively low LD was observed between the seven SNP markers. Specifying a spine o f 
LD with a D ’ o f >0.8, two small haplotype blocks were generated using HAPLOVIEW. 
Block one consisted o f two SNPs: rs208293 (P2RX7-I04B) and rs208294 (P2RX7-E05A). 
Block two consisted o f three SNPs: rs504677 (P2RX7-I07E), rsl718119 (P2RX7-E11B) 
and rs2230912 (P2RX7-E13A). This block covers the region that includes the 
microsatellite marker NBG6.
It is not possible to directly compare these results with LD patterns observed in the study 
of Barden et al (Barden et al. 2006) where a greater number of markers spanning a 
broader region were typed. However, block 2 sits within Barden et al’s wider block 2. 
Analysis o f this seemingly important block two revealed significant association using 
data from rs504677 (P2RX7-I07E) and rs2230912 (P2RX7-E13A), global empirical 
p=0.0079. Testing o f individual haplotypes from this analysis using HAPLOVIEW 
revealed two significantly associated haplotypes. The frequency o f haplotype TG was 
estimated to be 14% in controls and 18% in cases (empirical / j=0.03), while haplotype
174
TA was estimated to be found in 29% of controls and 24% of cases (empirical />=0.027). 
It was not possible to reconstruct the 7-SNP haplotype which Barden et al reported to be 
associated. However, the haplotype analysis provided further evidence for the association 
o f P2RX7 with BP, see table 8.12.
The present study found association of the mutated G (arginine) allele of rs2230912 with 
BP. This is in line with the findings o f both Barden et al and Lucae et al. A total o f 3,586 
individuals were included in the combined analysis o f this marker. This revealed 
significant allelic association (/>=0.0025) and genotypic association (p=0.0005). The 
allelic and genotypic associations are explained by an increase of heterozygotes rather 
than homozygotes which suggests a dominant mode of transmission, odds ratio of 1.302 
(Cl 1.129-1.503).
Analysis o f UCL BP cases with early onset illness against the control group increased the 
evidence for association o f the G allele,/ j=0.0062. The G allele occurred in 21% of cases 
compared with 15% of controls. However the evidence for association of NBG6 
decreased slightly, />=0.0181, with this analysis.
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Figure 8.6: UCSC multiple BLAT output for markers genotyped in the P2RX7 region
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Figure 8.7: M arker to marker LD between genotyped SNPs at the P2RX7 locus.
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Table 8.10: Marker positions, allele frequencies and tests of allelic association in or adjacent to the 
P2RX7 locus
Marker
Location 
(March 06 
Assembly)
Number of 
Samples* MAF Minor
Allele
Allelic
Association
Controls BP Controls BP p-value
1 P2RX73 120,070,375 439(443)
608
(613) 0.190 T1
2 rs208293(P2RX7-I04B) 120,084,563
427
(443)
562
(613) 29% 25% A 0.067
3 rs208294(P2RX7-E05A) 120,084,636
542
(600)
569
(613) 43% 44% A 0.590
4 rs504677(P2RX7-I07E) 120,089,572
429
(443)
578
(613) 43% 42% T 0.591
5 NBG6 120,098,415 438(443)
604
(613) 0.010 T4
6 rsl718119 (P2RX7-E1 IB) 120,099,486
427
(443)
571
(613) 41% 40% T 0.562
7 rs2230912(P2RX7-E13A) 120,106,579
546
(600)
587
(613) 15% 18% G 0.043
8 rsl 1065501 (P2XR4-UTR3A) 120,156,353
424
(443)
583
(613) 34% 33% G 0.644
9 rs3817190 (CAMKK2-E01B) 120,196,460
424
(443)
567
(613) 43% 43% A 0.893
T1,T4 T1 and  T 4  p -v a lu e s  f ro m  C L U M P
* N u m b e r o f  in d iv id u a ls  su c c e ss fu lly  g e n o ty p e d . T o ta l n u m b e r o f  in d iv id u a ls  g e n o ty p e d  sh o w n  in b rack e ts  b e lo w
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Table 8.11: Distribution of alleles for the microsatellite NBG6
Marker
Marker 
location 
(May 2004 
Assembly)
Sample
(Number)*
Allelic association
Distribution of alleles** Chi2 Empiricalp-value
NBG6 120,098,415
211 215 217 219 221 223 225 227 229 231 233 235 237 239
15.2 0.010T4
Controls
(438/443)
1 14 7 364 98 148 17 72 48 30 17 27 12 21
0% 2% 1% 42% 11% 17% 2% 8% 5% 3% 2% 3% 1% 2%
Bipolars
(604/613)
0 9 8 528 138 231 36 88 46 55 12 26 7 24
0% 1% 1% 44% 11% 19% 3% 7% 4% 5% 1% 2% 1% 2%
*(Number o f  individuals successfully genotyped/total number o f individuals genotyped) ** For each marker the repeat number is shown in the top row. Allele frequencies and percentages are shown below.
Table 8.12: Haplotypic association analysis results for 2-SNP haplotypes from block 2 of the P2RX7 locus
Marker Alleles
Estimated
frequency
(cases)
Estimated
frequency
(controls)
LRT LRT d.f. p-value
Empirical
p-value
1 2 3 4 5 6
3 rs504677 
5 rs2230912
C A 58% 56% 0.26
11.88 3 0.0078 0.0079C G 0% 1% 2.93T A 24% 29% 4.15
T G 18% 14% 4.11
4 rsl718119
5 rs2230912
C A 60% 58% 0.19
9.52 3 0.023 0.019T A 21% 26% 4.14
T G 18% 15% 2.36
LRT: Likelihood ratio test, cells with estimated frequencies o f zero in both cases and controls omitted
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Table 8.13: Combined analysis of SNP rs2230912 data from Barden et al> Lucae et al and UCL study
Study Sample
Genotype
AA GA GG
Barden et al 2006
Controls 150 54 8
BP 134 73 6
Totals 284 127 14
Lucae et al 2006
Controls 760 235 34
Unipolar depression 684 293 22
Totals 1444 528 56
UCL study
Controls 389 147 10
BP 390 177 20
Totals 779 324 30
Combined analysis
Controls 1299 436 52
BP and unipolar depression 1208 543 48
Totals 2507 979 100
Allelic association Chi2=9.171,/i=0.002
Allelic odds ratio=T.213 confidence interval=1.070-1.375
Genotypic association Chi2=15.118,/>=0.0005
Genotypic odds ratio (GG+GA vs AA)=1.302 confidence interval=1.129-1.503
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8.6 COMT
Both SNPs were in HWE. The positions of the markers typed are shown in figures 8.8 
and 8.9. None of the markers showed allelic or genotypic association with BP, (table 
8.14). Highest LD was found between the intron 1 tetranucleotide repeat and rs4680, 
D  -0.77. No haplotypic association was found using these two markers.
Analysis o f BP cases with comorbid panic disorder revealed modest association with the 
valine allele o f rs4680 uncorrected for multiple testing, Jp=0.0485. No association of 
rs2075507 or the intron 1 tetranucleotide was found with this subgroup.
Further analysis o f rs4680 was performed. BP cases with psychotic symptoms, comorbid 
alcoholism, early onset disease, lithium response and rapid cycling were tested against 
controls. Analysis by gender was also performed. No significant associations were found.
It has been recognised that the intron 1 tetranucleotide is an imperfect repeat (Palmatier et 
a l 2004). In addition to the TAAA ladder there is a secondary ladder with a final TAA 
repeat sequence. The imperfect 285 bp allele has generally been found to be the most 
common across different populations (http://alfred.med.yale.edu/alfred/). Table 8.15 
shows how the alleles observed correspond with those quoted in the Alfred database. The 
allele frequencies observed in the UCL sample were consistent with those previously 
found in European populations.
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Figure 8.8: UCSC multiple BLAT output of COMT markers genotyped
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Table 8.14: Single marker association results for COMT markers
Marker
Location 
(March 06 
Assembly)
Number of 
Samples* MAF Minor
Allele
Allelic
Association
Controls
(443)
BP
(613) Controls BP p-value
1 rs2075507 18308092 439 599 45% 45% G 0.76
2 Tetra repeat 18320477 423 600 0.77 T2T3
3 rs4680(Vall58Met) 18331271 431 585 47% 48% G 0.56
* N u m b er o f  in d iv id u a ls  su c c e ss fu lly  g e n o ty p e d . T o ta l n u m b e r  o f  in d iv id u a ls  g e n o ty p e d  in d ic a te d  in  b rack e ts .
Table 8.15: Comparison of alleles observed in UCL sample and alleles reported on Alfred database
UCL alleles (bp) Frequency* Alfred alleles (bp) Frequency**
114 0.000 282 -
117 0.458 285 0.447
121 - 289 0.013
122 0.320 290 0.292
126 0.112 294 0.124
130 0.103 298 0.115
134 0.007 302 0.009
* co m b in ed  c a se /c o n tro l U C L  a lle le  fre q u e n c ie s
** A lle le  f re q u e n c ie s  fo r  I r ish  sa m p le  A lfre d  ID  S A 0 0 0 0 5 7 M
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8.7 DAOA/G30
All SNPs were found to be in HWE. The positions of the genotyped markers in relation to 
DAOA are shown in figure 8.10.The LD between SNP markers is shown in figure 8.11. 
The association results are summarised in table 8.16.
Allelic association was detected with rs3918342 (M23), p=0.038. The T allele was 
increased in cases compared with controls (54% versus 48%). A trend towards 
association was observed with rs954581,/?=0.073.
Markers rs 1341402 to rs778294 (M l9) form an LD block defined with a solid spine of 
LD with a D ’ >0.8. Strong LD was also observed between rs3918342 (M23) and 
rs 1421292 (M24). Haplotype analysis within the LD blocks did not show evidence for 
association.
Analysis o f the data for rs3918342 (M23) using phenotypic subdivisions that were 
previously found to be important in DAOA/G30 studies did not provide additional 
evidence for association. BP cases with psychotic symptoms showed association at the 
p=0.04 level. No significant association was observed when BP cases with persecutory 
delusions were compared against controls. However there were only 45 such cases. There 
was an insufficient number o f BP cases with panic disorder to perform a meaningful 
analysis. Selection o f cases by early onset again increased the evidence for association, 
p=0.0247, with overrepresentation o f the T allele.
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Figure 8.10: UCSC multiple BLAT output of DAOA markers genotyped
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Table 8.16: Single marker association results for DAOA locus
Marker
Location 
(March 06 
Assembly)
Number of 
Samples* MAF Minor
Allele
Allelic
Association
Controls BP Controls BP p-value
1 rs 1341402 104,913,510 313 299 22% 21% C 0.679
2 rs2391191 (M15) 104,917,447 435 303 37% 41% A 0.226
3 rs 1935062 104,926,137 313 303 34% 34% C 0.917
4 rs947267 (Ml 8) 104,937,663 435 302 42% 41% C 0.548
5 rs778294 (Ml 9) 104,940,236 438 302 27% 27% T 0.856
6 rs954581 104,950,267 310 301 16% 20% C 0.073
7 rs3918342(M23) 104,983,750 428 303 48%
54% T 0.038
8 rs 1421292 (M24) 104,996,236 430 303 46% 50% T 0.126
* N u m b er o f  in d iv id u a ls  su c c e s s fu lly  g e n o ty p e d
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Chapter 9: Conclusions
In this chapter I will consider each locus individually and then make some overall 
comments. I intend to be limited and specific in the inferences I make from the results. I 
will indicate the future direction of enquiry for each locus. I will defer discussion of the 
broader issues raised by these association studies until chapter 10.
12q24 UCL region
The results presented here provide evidence for the presence o f a novel BP susceptibility 
locus on 12q24.
As was discussed in section 5.2, there is evidence for multiple BP susceptibility loci in 
the 12q23-q24 region. P2RX7 is the nearest of the previously implicated genes to the 
associated markers in this study. However the distance between P2RX7 and these 
markers is still not compatible with a single locus producing the evidence for association 
that was detected. LD over such a large distance would be unprecedented.
Three of the four markers originally found to be associated in the Danish cohort (Kalsi et 
al. 2006) lie within the 180 kb region defined by the most proximal and distal markers 
associated in the UCL sample. However, these particular markers were not found to be 
significantly associated in the UCL sample. Therefore only partial replication for this 
region can be claimed.
There are five ACE VIEW (http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly) gene 
predictions within the 180 kb region. These are: LOC338825, Skoynar, LOC387895, 
Slynar and Zorgawby (see figure 9.1). The region is not well characterized, but o f these 
the most promising candidate is Slynar. Slynar is expressed in the human brain and so far 
five splice variants have been demonstrated. No known function has been attributed to 
this gene, although predicted translation products o f some splice variants contain 
PSORT-predicted membrane localization motifs (Nakai and Horton 1999).
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Another candidate gene termed LOC387895 is antisense to Slynar and so may have a role 
in the control of Slynar expression (Yelin et a l  2003). LOC387895 is also brain 
expressed, although to a lesser extent than Slynar (http://www.ncbi.nlm.nih.gov/ 
UniGene/ESTProfileViewer). 13 alternative splice variants have been isolated from 
various tissues.
The analysis by age o f onset suggests that the region harbours a susceptibility locus for an 
early onset form o f BP. The most significant allelic associations with early onset BP were 
found with D12S307 and rs7133178. Both o f these markers map to within the 
LOC387895/Slynar predicted genes, see figure 9.2. D12S307 is intronic. Relative to 
Slynar rs7133178 is intronic but is located in the predicted exon4 of LOC387895 
(www.ncbi.nlm.nih.gov/SNP). SNP rs7133178 is synonymous and hence unlikely to 
confer susceptibility in itself. LD between these markers and the aetiological mutations is 
thus presumed.
On the basis o f these results, mutation screening of LOC3 87895 and Slynar has now 
begun. Given the significance o f the association of rs7133178, sequencing of exon 4 of 
LOC387895 must be considered a priority. Since sequencing of all individuals is 
unfeasible, careful consideration must be given to the selection o f cases for analysis. 
Sequencing o f early onset cases with the minor, A, allele o f rs7133178 (n=85), in the first 
instance, would seem to represent the most parsimonious approach.
Replication o f the genetic association findings presented here in multiple samples is now 
needed to confirm that a novel susceptibility locus has been identified. Testing o f the 
hypothesis that the risk is specific to early onset BP may help alleviate the problem of 
non-replication in the context o f genetic heterogeneity.
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Figure 9.1: UCSC multiple BLAT output of associated markers in the UCL 12q24 region, annotated 
with gene prediction tracks
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Figure 9.2: Position o f D12S307 and rs7133178 in relation to LOC387895 and Slynar
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UCL 2lq22 region
The results presented here provide evidence for the presence of two novel susceptibility BP 
loci on 21q22.3.
In the region o f the associated micro satellite marker D21S171 the candidate genes TRPM2 
and C21orf29 were analysed by mutation screening and association testing. While the 
sequencing o f these genes has not, to date, produced any obvious pathogenic mutations the 
association results are compatible with the involvement o f either gene (see figure 9.3). The 
age o f onset analysis provides further support for the involvement o f TRPM2, and suggests 
it confers risk to early onset BP.
TRPM2 also represents the most promising functional candidate as it is a member of a 
family o f calcium channel genes involved in calcium homeostasis which is highly 
expressed in the brain. TRPM2 is implicated in the mechanism of lithium action by virtue 
of the coregulation o f calcium release from internal stores and the production of inositol 
1,4,5 triphosphate (Nagamine et a l  1998). It has also been found that TRPM2 mRNA 
transcripts in B cell lymphoblastoid cell lines derived from peripheral blood lymphocytes 
were down-regulated in a subgroup o f BP subjects with higher basal calcium levels. The 
authors suggest that expression o f TRPM2 may be involved in altered calcium homeostasis 
in some BP patients (Yoon et al. 2001).
A number o f differentially spliced isoforms of TRPM2 have been identified and some of 
these truncated peptides may have a role in regulating the function of the full-length 
isoform (Zhang et al. 2003). The expression of some or possibly all o f these isoforms 
appears to be tissue specific and o f note is the discovery o f an N-terminal truncated TRPM2 
that has only been detected in the striatum (Uemura et al. 2005). Another TRPM2 isoform 
has been isolated where part o f exon 11 and all o f exon 27 is deleted. In contrast to full- 
length TRPM2 and exon 27 deleted TRPM2, the exon 11 TRPM2 deletion did not respond 
to H 202 stimulation (Wehage et al. 2002). SNP rsl556314, which showed the most 
significant association with BP, causes a conservative amino acid change in the exon 11
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deleted region. However there is no evidence that this change has any role in either the 
dysregulation of cellular calcium homeostasis in response to oxidative stress or in BP 
susceptibility.
There is no database support for C21orf29 brain expression. While this has not been 
empirically tested in the UCL laboratory, C21orf29 cannot be considered a strong candidate 
gene.
Figure 93: Associated markers in relation to TRPM2 and C21orf29
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The UCSC RefSeq annotation o f the interval between D21S171 and the associated SNPs 
now includes the gene leucine-rich repeat-containing 3 precursor (LRRC3) and a cluster o f 
Keratin-associated protein (KRTAP) genes. Although LRRC3 is predominately expressed 
in the cervix, brain expression has also been demonstrated and thus it must also be 
considered a candidate. The KRTAP genes encode keratin imtermediate filaments which 
are a major component o f hair fibers. Multiple intronless KRTAPs map to the introns of 
C21orf29. Expression is restricted to the hair root and hence the involvement o f this family 
o f genes in BP susceptibility would seem unlikely.
Allelic association was also detected with the more proximal marker D21S1260. SNP 
analysis o f this region has not yet been performed. This marker is over 3 Mb from 
D21S171 so association cannot be explained by a single mutation. However, the evidence 
for association at D2IS 1260 is very modest even without correction for multiple tests. The 
issue of multiple testing will be revisited at the end o f this chapter.
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While the results argue for the further analysis of TRPM2 the optimal strategy for this is 
not immediately apparent. An increased frequency o f the major alleles at both the TRPM2 
associated SNPs in BP cases was observed. Hence the majority o f the BP cases would have 
to be sequenced to be confident that an aetiological change is not missed. So far mutation 
screening has only been carried out in a small proportion o f the BP cases.
In contrast to the 12q24 region, it seems that further association testing is indicated. It 
should be possible to reduce the sequencing burden by employing the systematic approach 
of genotyping haplotype tagging SNPs across TRPM2. Study o f the polymorphisms already 
identified by sequencing (table 8.5) should also be included in future association testing.
Allelic association with TRPM2 has now been independently replicated in a Canadian case- 
control sample (Xu et a l  2006). Seven SNPs were tested in 178 BP cases and 268 controls. 
Four o f these SNPs were significantly associated even after stringent correction for multiple 
testing: rsl785437 (p=0.042), rsl618355 (^=0.00007), rsl612472 (p=0.00022) and 
rs933151 (p=0.011). For all o f these SNPs the minor allele was increased in the cases 
compared to controls. Highly significant haplotypic association was found with haplotypes 
incorporating all o f the SNPs tested. One particular haplotype, TTTCTTA, was estimated to 
be present in 12% o f  cases but only 0.9% o f controls (p=2.3><10'12).
The two SNPs associated in the UCL sample were not tested. SNPs r s l785437, rsl618355 
and rs933151 were tested in the UCL sample but not found to be associated, suggesting that 
the aetiological mutation(s) occurred on a different haplotypic background in the two 
samples. This is somewhat surprising as approximately 25% of the Canadian sample has 
British ancestry (both case and control groups). It is o f note that the MAF of r s l785437, 
rsl618355 and rs933151 in the control was similar in the Canadian and UCL samples.
More recently, Roche et al failed to replicate TRPM2 association in a sample o f 125 BPI 
trios from Ireland (Roche et al. 2007). 14 SNPs were tested across the TRPM2 gene. No 
evidence o f individual marker or haplotypic association was found. O f the six previously
193
associated markers two were tested by Roche et al, r s l556314 and rs933151. By contrast 
they implicated the neutrophic factor S100B. Two SNPs were found to be associated: 
rs2839350 and rs3788266. The evidence for association was increased in the subset o f trios 
with psychosis. In the UCL sample one SNP was tested in S100B but no association found. 
Since the loci are over 2 Mb apart it does not seem feasible that the same signal is being 
detected.
Kostyrko et al (Kostyrko et a l  2006) performed mutation screening of TRPM2 in 60 
unselected BP cases by SSCP and sequencing. Seven polymorphisms were thus identified 
which were then genotyped in a control group. No significant difference in allele 
frequencies was observed. This study would not seem to add greatly to the data on TRPM2. 
The sample size was very small and little information is given about the control group other 
than that it consisted o f 66 “healthy persons”. Furthermore, only about 30% of the coding 
sequence o f TRPM2 was screened. Interestingly, a synonymous exon 19 change, at 
rs35698354, was found in the BP group but not in the controls.
DISCI
The results add to the evidence that DISCI influences susceptibility to BP. For the first 
time individual markers rather than haplotypes have been found to be associated. 
Furthermore, the results suggest that DISCI specifically confers risk to BP patients with 
psychotic symptoms. Given that association has also been reported with schizophrenia and 
schizoaffective disorder, it does raise the possibility that DISCI association defines a 
psychotic illness that crosses traditional diagnostic boundaries. I will return to the subject 
of common susceptibility loci in chapter 10.
It is difficult to relate the UCL microsatellite results to previous findings (section 5.4.2) 
where SNPs were typed. The associated microsatellite D1S3462, mapping to intron 8, is 
located within the associated region 3 of Thompson et al (Thomson et a l  2005) and the 
broader associated region o f Maeda et al (Maeda et a l  2006). The 
D ISC l_5’_Microsatellite is within the associated region 1 o f Thompson et a l  Thus some
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consistency o f results is discernible. However, the relationship o f the microsatellite alleles 
to the individually associated haplotypes in these regions is not known.
Despite the equivalence of BP and schizophrenia rates in males and females there is 
accumulating evidence of a gender effect at the DISCI locus. However, the male specific 
association described here is generally at odds with previous findings, although Thompson 
et al did observe male specific association in the more centromeric region 1. Epigenetic 
mechanisms or hormonal influences have to be invoked to explain sex effects for autosomal 
markers.
It certainly cannot be claimed that systematicic LD fine mapping o f the UCL lq42 linked 
region was performed or that DISCI is unequivocally responsible for the linkage peak. 
However, given that allelelic association was observed with a previously implicated locus 
in the first set o f markers tested a priori probability suggests efforts should focus on DISCI. 
Since the SNP and microsatellite results cannot be directly compared and the distribution of 
microsatellite allele frequencies are not helpful in selecting individuals for sequencing, 
systematic LD mapping with SNPs is again indicated. This is now underway as part o f a 
multicenter European consortium. However, this does not preclude more extensive fine 
mapping o f lq42.
BDNF
Recent work on the -1040bp (GT)n microsatellite has called into question the validity of 
using this marker in association studies. Sequencing has demonstrated that it is a highly 
polymorphic marker with a complex structure rather than a simple dinucleotide repeat 
(Okada et al. 2006). A total of 23 allelic variants were identified, arising from a 
combination o f three separate dinucleotide repeats, an insertion/deletion and a substitution. 
Since some of the variants are o f the same size, the variants cannot be unequivocally 
identified by fragment size based genotyping methodologies. This is not only relevant to 
the association findings presented here but also to the original finding o f association at the
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marker (Neves-Pereira et al. 2002) and the subsequent finding o f haplotypic association 
(Kremeyer et al. 2006).
The fragment sizes obtained in the UCL sample were at variance from those reported by 
Neves-Pereira et al. Kreyemer et al also noticed variance with the Neves-Pereira et al 
allele and concluded that the fragments were 57 bp larger than previously described. 
However, the allele frequencies o f Kreyemer et al did not correspond well with those 
reported by Neves-Pereira et al. Allele frequencies in the UCL sample corresponded 
closely with Neves-Pereira et al frequencies if it is assumed that the fragments are 53 bp 
larger. It is not clear that these discrepancies can be accounted for by the underlying 
complexity o f the polymorphism.
In the UCL sample, association was only found with the -1040bp (GT)n microsatellite or 
with haplotypes incorporating this marker. Association was not replicated with either of the 
SNPs. It is intriguing that the association became more significant when cases with rapid 
cycling were compared against controls, in line with the findings o f Green et al (Green et al. 
2006), and that the frequency o f haplotypes containing the valine allele o f rs6265 was 
estimated to be increased in the case group. However I do not think it would be right to 
interpret these results in light o f the new information regarding the marker. Thus, it has to 
be simply concluded that neither the valine allele of rs6265 nor alleles at rsl 1030096 
influence susceptibility to BP in the UCL sample. This by no means excludes the 
involvement o f BDNF in BP.
Okada et al (Okada et al. 2006) suggests that the -1040bp (GT)n microsatellite is a 
functional polymorphism affecting transcriptional activity. While it would be o f interest to 
perform a more detailed analysis o f this marker in the UCL sample, sequencing of this 
region in each individual would represent a considerable undertaking.
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P2RX7
The results presented here independently replicate the association o f P2RX7 with BP. Two 
markers intragenic to P2RX7, the intron 9 microsatellite NBG6 and the non-synonmous 
exon 13 SNP rs2230912, had previously shown association. Both of these associations 
were replicated in the UCL dataset. It was not possible to test the 7-SNP haplotypic 
association reported by Barden et al (Barden et a l  2006) due to SNP assay failures. 
However, 2-SNP haplotype analysis o f the haplotype block covering the region to which 
the associated markers mapped supported the individual marker associations.
Association o f P2RX4 and CAMKK2 was not supported, although only one marker relating 
to each gene was tested. Very recently association of P2RX4 and CAMKK2 with anxiety 
disorders has been reported (Erhardt et a l  2007). The case group consisted of inviduals 
with anxiety disorders and syndromal panic attacks. Association with illness thus defined 
was found for one SNP in the 5’UTR of P2RX4. Severity o f panic and agrophobic 
symptoms was associated with rs3817190 mapping to CAMKK2. Further analysis 
according co-morbid anxiety disorder would therefore seem to be justified.
The initial association o f rs2230912 was found in a family based sample, derived from 
SLSJ pedigrees in which the linkage to 12q24 had originally been found. Hence, replication 
in a population based case-control sample suggests that initial association results were not 
confounded by linkage. The consistent association o f the G allele o f rs2230912 is 
particularly interesting because this allele alters a highly conserved glutamine residue in an 
SH-3 domain to arginine. The arginine substitution has been found to lead to a functional 
decrease in Ca2+ influx in transfected recombinant human embryonic kidney cells and in 
lymphocytes from patients with chronic lymphocytic leukaemia (Cabrini et a l  2005). The 
residue is located in an intracellular domain o f P2RX7 and may have effects on P2RX7- 
mediated signalling (Denlinger et a l 2001). However, the G allele occurs in controls in
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both the heterozygous and homozygous state. Thus more complex aetiological mechanisms 
would have to be invoked.
COMT
The results do not generally support the involvement of COMT in the aetiology of BP. The 
previous association o f the low activity methionine allele o f the Vall58M et functional 
polymorphism with the disorder was not replicated in the primary analysis. The modest 
association o f BP cases with comorbid panic disorder implies that there may be a subtype 
o f BP disorder in which COMT variation is relevant. This analysis should only be 
considered exploratory, yet provides a cogent hypothesis that could be tested in other 
samples.
Risk o f BP was not affected by variation at a SNP within the region of the promoter critical 
for oestrogen-mediated repression o f COMT expression. No gender affect was seen with 
this marker. Furthermore, no association was found between the intron 1 tetranucleotide 
repeat and BP.
COMT cannot be excluded as an aetiological gene in BP, even in the UCL sample, as much 
more extensive genotyping o f markers spanning the COMT gene and associated promoter 
regions would be required to capture all the haplotypic diversity.
DAOA/G30
Only very modest evidence to support a role for DAOA was found in the UCL sample. 
None o f the individual marker associations reported by Hattori et al (Hattori et a l  2003) 
were replicated. However the results do not constitute a formal non-replication, as two of 
the individually associated markers were not tested due to assay failures. Consequently, the 
haplotypic association could not be tested either. O f note, these failed SNPs included the 
most strongly associated marker in the Hattori et al study, r s l935058.
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Evidence for the involvement o f DAOA came from the SNP rs3918342, (M23), which was 
associated originally with schizophrenia by Chumakov et al (Chumakov et al. 2002). The 
association o f this marker with BP replicates the finding o f Schumacher et al (Schumacher 
et a l  2004). However, the results did not support the hypothesis that DAOA specifically 
confers risk to a psychotic subtype of BP. The ramifications o f association in both BP and 
schizophrenia will be explored further in the next chapter.
It should be borne in mind that rs3918342 does not actually map to DAOA but is located 
approximately 40 kb 3 ’ to the gene. According to UCSC annotation the SNP is intergenic. 
The closest gene is the anti-sense G30 to which rs3918342 lies approximately 30 kb 5’. 
Although translation o f G30 has not been demonstrated, the genetic evidence argues that it 
should not be overlooked.
Summary
Two novel BP susceptibility loci have been implicated by LD fine mapping of linked 
regions o f chromosomes 12q and 21q. The identification o f novel risk loci represents a 
significant step in attempts to understand the aetiology o f BP. The fact that this was derived 
from a case-control sample implies that the loci are relevant at a population level.
No clear aetiological base pair changes have been identified, although neither locus has yet 
been comprehensively analysed. Hence, the possibility that the observed associations are 
false positive results must at least be considered. The most likely source o f type I error is 
multiple testing. Empirical testing of significance negates the need for correction for 
multiple alleles or multiple haplotypes. However, it is difficult to know how to correct for 
testing o f multiple markers. A simple Bonferroni correction would be overly conservative, 
as results from different markers are likely to be correlated to some extent because of LD 
and therefore represent non-independent tests o f association.
I would argue for the robustness o f the results presented in this thesis on a number of 
counts. Firstly there was a priori probability of susceptibility loci in these regions on the
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basis of confirmed linkage. Furthermore, multiple associated markers were found at each 
locus. Association was not confined to one type o f marker, with SNPs and microsatellite 
markers both yielding association. This assertion is supported by the replication o f TRPM2 
in an entirely independent sample.
Independent replication is important as it addresses the problem of false positive findings. 
Generally this has been hard to achieve for genes implicated in BP, but is necessary if 
research efforts are to be well directed. In this study association o f the gene P2RX7 with 
BP was independently replicated. Hence further investigation o f this gene is advocated.
With regard to the DAOA/G30 I would be more cautious in my claims. Since only one 
marker was modestly associated with BP and no haplotypic association was found, I would 
suggest that the UCL sample provides some supporting evidence for the involvement of 
this locus. The inability to reconstruct the originally associated haplotypes is clearly a 
weakness.
It is here, in the interpretation o f negative or equivocal replication results, that the 
limitations o f the current study are demonstrated. Only very circumscribed inferences can 
be made. For example, COMT could not be excluded as a susceptibly locus for BP. All that 
can be concluded is that the previously associated SNP, rs4680, showed no association in 
an outbred population derived from the UK and Ireland. Despite the UCL sample being 
relatively large, the power to detect association at this marker would not have been high 
and therefore may represent a type II error. Thus the result should, strictly speaking, be 
considered preliminary and be added to as more volunteers become available. When this 
study began it was only realistic to replicate a limited number o f markers. However, recent 
technological advances have revolutionised the field and much more systematic allelic 
association studies can now be undertaken.
Phenotypic subanalysis yielded some intriguing findings. Most notably, the results suggest 
that selection o f cases by early onset enriches the genetic liability. This not only generates a 
specific hypothesis to test in relation to future association studies o f Slynar/ LOC387895,
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TRPM2 and P2RX7 but also has more general repercussions for the design of genetic 
association studies of BP.
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Chapter 10: Discussion
In this final chapter I will briefly comment on some of the broader issues which have been 
raised in the course o f this thesis.
What exactly are we mapping?
The historical paradigm o f genetic disease mapping - identification o f a gene followed by 
isolation o f aetiological coding changes - has not, to date, revealed unequivocal BP risk 
alleles. The nature o f the variation that we are attempting to map is a fundamental question 
at both the population and molecular level, with implications for association studies, 
subsequent mutation screening and functional studies.
From a population genetics perspective, the common-disease/common variant (CDCV) and 
multiple rare variant (MRV) models have been hypothesised to account for common 
disorders exhibiting complex inheritance (Pritchard 2001). In relation to association studies, 
the disease allele frequency is one o f the determinants of the observable marker effect size 
and thus has major implications for the power o f a study to map novel loci or replicate 
previous association (Zondervan and Cardon 2004). For instance, if  there are multiple rare 
variants with only individually small effect sizes, extremely large case-control samples will 
be required.
Under the CDCV hypothesis invocation of an interactional model would seem to be 
required given the heterogeneity o f linkage results. Gene-environment interaction, gene- 
gene interaction and allelic interaction at a particular locus have been postulated in other 
complex conditions. An interaction between childhood maltreatment and MAOA genotype 
was reported (Caspi et al. 2002). Exposure to severe childhood maltreatment and a 
genotype conferring low MAOA activity greatly elevated the risk o f developing both 
conduct disorder and antisocial personality disorder.
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Bardet-Biedl syndrome provides an example o f a condition in which gene-gene interaction 
can be necessary for expression o f the clinical phenotype. On the assumption o f autosomal 
recessive inheritance, two genes were identified: BBS2 and BBS6. Subsequently, affected 
individuals were shown to possess three mutant alleles in a number o f pedigrees. In 
addition, unaffected individuals with two mutant copies o f the BBS2 gene were found. 
Hence a triallelic disease model was proposed (Katsanis et al. 2001). It is feasible that more 
than three alleles are involved and that the number o f relevant alleles varies between sets of 
susceptibility loci. However, the interaction of risk alleles may not necessarily operate 
across different genes but occur at one particular locus. Potentially, mutation synergy could 
involve one copy o f a homologous gene pair, both copies or operate in a combined manner.
Mutation screening has, to date, focused on exonic changes which would affect amino acid 
residues and, in turn, protein characteristics. A MRV interpretation would be that this has 
not yielded convincing aetiological variants. However, from a CDCV perspective one could 
argue that, for example, the mutant G allele of the P2RX7 exon 13 SNP rs2230912 could 
be causative. With regard to the novel UCL loci, exon screening has not been fruitful for 
TRPM2, although only a subset of individuals carrying the associated alleles has been 
sequenced. It is also now usual to perform sequencing o f the promoter region. Again, 
interpretation o f associations with promoter variants, e.g. the 5HTTLPR polymorphism at 
the 5-HTT gene, is dependent on one’s theoretical stance.
An increasingly complex anatomy o f genes and their regulatory mechanisms is emerging. 
Thus, comprehensive mutation screening needs to extend beyond the exons and promoters. 
Intronic and 3 ’ regulatory sequences are now well-established sites for disease mutations, 
e.g.(Yokoi et al. 1991; Qian et a l  2004). Intronic changes may alter splice sites and thus 
affect mRNA species. The 3 ’UTR’s of some genes contain microRNA recogniton sites.
The issue is, perhaps, even more fudamental than conceptualizing the boundaries of a 
‘gene’. A radical shift in mindset away from a blinkered search for exon containing 
genomic sequence is now being indicated. Preliminary results from the ENCODE project 
indicate that, contrary to previous assumptions, there is in fact very little ‘junk DNA’ in the
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genome. In the 1% of the genome studied, the majority o f sequence was found to be 
transcribed (2007b). Since non-translated RNA species such as microRNAs are known to 
perform important cellular functions the inference is that a disease mutation could occur at 
virtually any base.
Recently, large duplications, insertions and deletions have been shown to occur frequently 
in the genome (Sebat et al. 2004). Such copy number variation (CNV) is a plausible 
mechanism for genetic disease. There is now some evidence that the CNV is relevant to BP 
and schizophrenia. In a small post-mortem study, CNV at three loci containing genes 
involved in glutamate signalling was only found in the case group (Wilson et a l  2006). 
CNV may not have previously been detected using standard association and screening 
techniques.
Association findings can only be considered the starting point to the convincing implication 
of variant in BP risk. In general, expression and functional studies will be necessary to 
achieve this goal. There is a very real dilemma as to when research efforts should make the 
transition from the genome to the transcriptome and proteome. It seems likely that this will 
be made earlier in an era when the non-synonymous base change is no longer thought of as 
the ‘holy grail’ o f the gene-hunter.
The future o f LD mapping in bipolar disorder
The enthusiasm for LD mapping in BP seems to be ever increasing. As discussed in section 
4.5, two GWA studies have recently been published and others are in progress. Indeed the 
UCL sample forms part o f one o f these studies in progress. However, there remain serious 
methodological considerations for both the design and interpretation of association studies 
in BP.
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Study design
The cross-sectional nature o f association studies limits the ability to test for gene- 
environment interactions. However, the prevalence of BP means that truly prospective 
studies would be unfeasible. Information regarding psychosocial stressors could be more 
extensively gathered in cross-sectional studies but would be affected by retrospective bias. 
The recording o f accurate phenotypic data is important if  multivariate analysis is to be 
performed. This has not generally been done in loci specific association studies to date. 
However, on the assumption that at least some genetic subtypes correlate with phenotypic 
subtypes it would seem a missed opportunity if  the GWA results were not subjected to this 
form o f analysis
Without wishing to recapitulate the family based versus population based LD mapping 
debate, I think a few points need to be stressed, especially as the current large GWA studies 
have employed a case-control design. In my opinion the problem o f population 
stratification remains a concern. Allele frequency differences between control groups have 
been observed at markers associated with BP (Bellivier et al. 1998b). This highlights the 
need to ensure that the case and control groups are derived from the same population. The 
trend towards multicentre studies and the use of shared control groups would seem to 
increase the risk o f cryptic differences. However, this can be addressed by ‘genomic 
control’ using ancestrally informative markers. Testing of association using both designs is 
clearly desirable and this has been carried out at some loci, e.g. P2RX7 (Barden et a l  2006). 
However, obtaining a suitably sized trio sample for GWA represents a financial and 
logistical challenge.
The overarching aim o f testing multiple markers in an implicated region is to identify 
specific haplotypes which harbour the aetiological mutation(s) and thus refine cases for 
further study. This is rendered more difficult by unphased case-control data. In the case- 
control data the significance in the overall distribution o f estimated haplotype frequencies 
was, generally, tested rather than the difference in individual haplotype frequencies.
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Association studies in BP have now reached an industrial scale. Although consumable costs, 
such as SNP genotyping, are concomitantly reducing, large studies require significant 
research funding. Given finite research resources it is beholden on the research community 
to strive to achieve mapping in the most efficient way without compromising scientific 
rigour. For example, pooling strategies have been attempted (Baum et a l  2007). While 
such pooling techniques have not been without their detractors, strategic and practical 
collaboration in association studies would seem to be dictated.
Power
As alluded to above, the marker effect size will be a function of a number o f factors: the 
effect size o f  the aetiological variant, the allele frequencies o f marker and aetiological 
variant and the LD relationship between them (Zondervan and Cardon 2004). Since some 
o f these parameters are unknown it cannot be established a priori what power is required. 
In the course o f reviewing the association results the lack o f adequately powered replication 
studies became apparent. According to Zondervan et aVs simulations the full UCL sample 
o f 600 cases and controls - which represents one of the larger international single centre 
samples - would still be insufficient under a variety o f scenarios. This should caution 
against over-interpretation o f negative replications presented here and elsewhere and argues 
for continued meta-analysis.
These concerns regarding power have clearly come to the fore in the design o f the GWA 
studies. Large sample sizes have been achieved by pooling samples from multiple centres. 
Potential sources o f heterogeneity between centres, e.g. due to method o f recruitment, must 
be considered with such study designs. However, a coordinated multicentre study should be 
less affected by heterogeneity than a meta-analysis o f individual studies. Certain aspects o f 
the experiment can be standardized, for example genotyping may be performed on a single 
platform in one designated centre. Nevertheless, even with GWA studies o f in excess of
1,000 subjects, meta-analysis o f GWA results will be required.
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The UCL sample now consists o f approximately equal numbers o f cases and controls. 
Unfortunately at the time some markers were genotyped there was an excess o f cases. In 
fact, there is an argument that controls should be in excess. The population o f mentally 
healthy controls is larger than the population of BP cases. Consequently a larger sample is 
required to accurately represent the control population.
Subjects
Genetic heterogeneity o f BP has implications for the optimal population to use for LD fine 
mapping based on linkage results. Sampling from the same population in which linkage 
was obtained should maximise the probability o f finding association. This issue is not 
directly relevant to GWA, although variation in results between studies conducted in 
different populations is to be expected under a heterogeneity model. The likelihood o f 
inconsistent results is further increased by the possible lack of sensitivity of case-control 
studies to allelic heterogeneity.
Case definition remains a critical issue and is intimately related to study power. The 
identification o f endophenotypes, representing more genetically homogenous subtypes of 
BP, continues to be pursued by investigators. This subject has recently been reviewed 
(MacQueen et al. 2005). Subsequently, the familiality o f phenotypic features in 172 
multiplex BP pedigrees has been studied using mixed-regression analysis (Schulze et al. 
2006). DSM criteria continue to prevail in ascertaining BP ‘caseness’ for association 
studies. However, post hoc analysis using putative endophenotypes is becoming common 
practice. Such analysis in the UCL dataset yielded increased significance of association at 
four loci, most notably with respect to early onset disorder. These results could be 
interpreted as evidence for an early onset subtype or that the genetic liability is increased if 
the case group is defined by early onset. The latter interpretation would be consistent with 
the age o f onset effect seen in both segregation and linkage analyses. While it may be 
parsimonious to continue to ascertain cases by DSM criteria, I believe there is a compelling 
rationale to test specific hypotheses based on putative endophenotypes in the primary 
analysis o f future studies.
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Recently the argument that BP and schizophrenia share some genetic liability has gained 
momentum. Proponents o f ‘common susceptibility loci’ have cited family, twin, linkage 
and association findings as evidence (Craddock and Owen 2005). In my view the 
association findings provide the most persuasive evidence that there are at least some loci 
where variation confers susceptibility to both disorders or genetically define a clinical 
entity which crosses traditional diagnostic boundaries. In medical genetics there is certainly 
a precedent for different mutations at a given gene to give rise to differing clinical 
phenotypes, e.g. the dystrophin gene (Muntoni et al. 2003).Yet it is also plausible that the 
same mutations have pleitropic effects.
O f the loci tested in the UCL sample, DISCI, COMT and DAOA have been implicated in 
the aetiology o f  schizophrenia by association studies. In addition, the genes neuregulin 1 
and dysbidin which were originally implicated in schizophrenia have subsequently be 
associated with BP (Breen et al. 2006; Blackwood et al. 2007). Ideally these loci should 
therefore be tested in both BP and schizophrenia samples. However, this has obvious 
resource implications. The alternative approach of recruiting both individuals with 
schizophrenia and BP to a combined case group does not follow from these findings.
Markers
A study’s power to detect association is dependent on marker selection. Two properties of 
the marker influence power - LD with the aetiological mutation and the marker allele 
frequency. Unfortunately it is not possible to optimise these properties a priori.
SNP markers are now used in the vast majority of association studies. This in itself confers 
some benefit, as it facilitates comparison and meta-analysis o f studies. Generally SNPs with 
a MAF>10% are selected. However, the optimal SNP MAF for detecting association is 
unknown. This will depend on the allele frequency o f the aetiological variant with which it 
is in LD. The allele frequencies o f aetiological variants are likely to vary between loci and 
possibly at a given locus. In some scenarios a very large case-control sample - of more than
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1,000 cases and 1,000 controls - would be required to detect association (Zondervan and 
Cardon 2004).
The HapMap project is progressively elucidating the LD relationships between SNPs in 
different human populations. However, the process is not complete and variants 
aetiological to BP may not be database SNPs. Increasingly haplotype ‘tagging’ SNPs have 
been selected for systematic LD fine mapping. Implicit in this approach is the assumption 
that non-database aetiological variants will conform with the LD relationships of SNPs 
within a given LD block. While this may not be an entirely safe assumption, haplotype 
tagging represents the best available method for optimising marker/unknown aetiological 
variant LD in a systematic way.
The HapMap project also has a bearing on replication studies. Traditionally, replication has 
referred to the testing o f an associated marker or markers. This has been the general 
approach taken in the thesis, so as to test simple hypotheses and minimise multiple testing. 
However, some investigators have started to consider the gene as the unit o f replication, 
and test a tagging SNP set designed to screen the gene. Such an approach may mitigate the 
effect o f locus heterogeneity but does normally increase the number o f tests carried out. 
Furthermore, it may create problems comparing results between centres as LD patterns and 
therefore the tagging SNP set may vary between samples. Care in the interpretation of 
results is needed with both approaches.
No such database o f LD relationships between microsatellite markers exists. Consequently, 
they must be derived empirically in each sample. However, LD mapping using 
microsatellite markers did prove successful in the UCL sample with reference to the 
chromosome 12q and 21q loci. In neither case could it be claimed that the linkage regions 
were systematically mapped according to measures o f LD. It has been suggested that 
microsatellite markers are more informative than SNP markers (Varilo et a l  2003). It may 
be that multiallelic microsatellite markers are less likely than biallelic markers to give false 
negative results when aetiological variants occur on different haplotypic backgrounds. With 
a bialleic marker an aetiological variant may be in LD with a particular allele in some
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individuals and with the opposite allele in others. This would diminish any observable 
differences between the case and control groups. With multiallelic markers the probability 
o f this cancelling out o f association is reduced. It was interesting that the strongest evidence 
for association was generally obtained with microsatellite markers.
This thesis did, however, highlight some of the disadvantages o f using microsatellite 
markers. Established highly polymorphic microsatellite markers may have cryptic 
complexity which renders interpretation o f allele frequencies between case-control groups 
difficult. Using the microsatellite genotyping methodology employed in this thesis, PCR 
fragment size differences o f 1 bp cannot be reliably resolved. I would suggest that this may 
account for some o f the allele frequency variation between populations reported for the 
COMT micro satellite (http://alfred.med.yale.edu/). Consequently it is recommended that 
only perfect repeats are tested.
It is clear that the gene chip technology currently being employed for GWA studies is 
elevating the examination o f the genome for variation aetiological to BP to a new level. 
However, the combination o f uncertainties over the amount o f haplotypic diversity being 
captured, power o f the studies to detect association and nature o f variation being sought 
argues against such studies being perceived as definitive.
Analysis
There is a dilemma as to the extent to which association data should be analyzed. Statistical 
rigour argues for the minimisation o f multiple testing. However, there appears to be a 
danger o f overlooking covert associations which have been masked by overinclusiveness of 
the diagnostic criteria for BP or complex mechanisms o f inheritance.
In this study I chose to test a limited set o f putative endophenotypes for which there was a 
priori evidence in the literature. No claim is made that this was exhaustive as some 
legitimate endophenotype, e.g. lithium responsiveness, were not readily available from the 
database for all individuals. Alternatively, association found in the primary analysis could
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have been explored by multivariate analysis. Certainly application o f these statistics to the 
GWA data may help to define genetic subtypes.
No analysis o f genetic interaction was attempted in this thesis. Interaction between genes, 
for example belonging to a neurotransmitter system, or even interaction between alleles at a 
given gene is highly plausible. Recent evidence from GWA data suggests an interaction 
between the established late onset Alzheimer’s susceptibility allele APOE4 and novel loci 
GAB2 (Reiman et a l  2007). It could be argued that interaction analysis should be deferred 
until definite aetiological variants have been identified, but this is certainly o f great interest.
A case-control monopoly?
One could question the relative cost-effectiveness o f large scale GWA studies as compared 
to sequence-based approaches targeted at genomic regions implicated by linkage and/or 
association studies. Given the uncertainties alluded to above direct sequencing is attractive 
in its simplicity.
It may be that genetic susceptibility to BP will be difficult to interpret without investigation 
of gene environment interactions. While technically possible within a LD mapping 
framework, employing prospective cohort designs would represent massive practical 
challenges. However, there are alternatives to this.
One classical approach to studying environmental effects has employed MZ twins 
discordant for the trait o f interest. Recently a molecular perspective has been brought to 
bare on this paradigm (Kato et al. 2005). Using micoarrays, gene expression was assayed in 
the discordant twins. While differences in expression cannot be definitively attributed to the 
specific environment - as, for example, lyonisation in female twins could cause differential 
expression - they could give a strong indication o f the molecular sequelae o f environmental 
effects. The integration o f human data with expression studies in animals, where the 
environment can be manipulated in a more controlled manner, is another possible avenue 
for investigation.
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Final remarks
It is disappointing that despite the great investment in genetic association studies no clinical 
benefit for patients suffering from BP has yet been realised. The identification o f BP 
susceptibility genes continues to challenge our understanding o f the mechanisms of 
inheritance operating in complex disorders and the nature o f sequence variation that can 
result in disease. More positively, a number o f novel therapeutic targets have been 
identified and drug development has begun. Furthermore, the coalescence of advances in 
SNP genotyping technology, expanding case-control samples and multicentre collaboration 
is yielding unprecedented power to examine BP susceptibility with genetic association 
studies.
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Appendix 1: PCR cycling conditions
PCR Programme 
Standard 60 °C Touch Down
Lid Heated to 105 °C 
Products are denatured at 94 °C 
for 5 minutes
35 cycles of:- 
94 °C -  30 seconds 
60 °C -  30 seconds*
72 °C -  30 seconds
Hold at 72 °C -  10 minutes 
Store at 4 °C
Lid Heated to 105 °C 
Products are denatured at 94 °C 
for 5 minutes
3 cycles of:- 
94 °C -  30 seconds 
63 °C -  30 seconds 
72 °C -  30 seconds
3 cycles o f 
94 °C -  30 seconds 
60 °C -  30 seconds 
72 °C -  30 seconds
3 cycles o f 
94 °C -  30 seconds 
57 °C -  30 seconds 
72 °C -  30 seconds
3 cycles o f 
94 °C -  30 seconds 
54 °C -  30 seconds 
72 °C -  30 seconds
3 cycles o f 
94 °C -  30 seconds 
51 °C -  30 seconds 
72 °C -  30 seconds
20 cycles o f 
94 °C -  30 seconds 
48 °C -  30 seconds 
72 °C -  30 seconds
Hold at 72 °C -  10 minutes 
Store at 4 °C
* standard 55 °C and standard  57 °C  cycles are the  sam e standard  60 °C cycle b u t w ith  d ifferen t annealing  tem perature. 
V ariation in cycle num ber is in d ica ted  in b rackets in subsequent appendices.
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Appendix 2: Novel microsatellite and SNP markers at the 12q24.3 locus generated for fine mapping
Marker Type of marker
Size range of alleles (bp) 
or sequence around SNP
Oligonucleotide
name Oligonucleotide Sequence
307CA2 Dinucleotide 122-166 307CA2F TTGCCATCATATTCCAACACA307CA2R CAGGTTCCGTTTTCAAATGC
1634GT2 Dinucleotide 140-150
1634GT2F GGC AT AC AAT GTGGTGTTTCG
1634GT2R GGAGGGCTTCAATGTTTTCA
1634TET Tetranucleotide 212-268
1634TETF GCTGGACTTTAGAATCCCACA
1634TETR GCATGAGGTACAGGCATCAA
307GT4 Dinucleotide 350-376
307GT4F TTCCAGATGTCCATTGCAGA
307GT4R CACCACTATCTTCCCCCAAT
307CA1 Dinucleotide 296-308 307CA1F AGCT GT GCT AAGG AGC AAAAA307CA1R TT GT CTACC AACC AG AT AAT GG A
D12SDK1 Dinucleotide 134-152 D12SDK1F TTGGGATCACACCACTGCD12SDK1R CCTCCTTCAGCCAACAATTC
D12SDK2 Dinucleotide 115-164 D12SDK2F AAATGGGCAAAGCTTGGCD12SDK2R GCCCAGATATTGCTCAGTACAG
47783-CT SNP aagtctatagatcG/Actggcacaagcttcca 47783-CT-F GCAAAGAGAACAGGCTCACAGA47783-CT-R TGCTGAACACTTGCTTCCTT
pufu in/del SNP
gaagaagaaaagtG ATG AAC AC AT / - 
ttggattttataa
pufu-indel-F CATGGGGCATATGGAAAAAC
pufu-indel-R TCCAGAAAGATGGATGTCTTCA
29818-insT SNP agcatatttttttT/-acagaagaatctgcagt 29818-insT-F
TTGCAAAATGAAACCAAGTCC
29818-insT-R ACCCTTTGCACCTGTGTTG
rsl0773323 SNP agaaaaggaagaaA/ T caacactttcagagat
Forward: CAAACAAACGATATTGATTCCTGTTT
Reverse: GGCTCAACAGGCTCCATCTC
Mette_l SNP gctggcccattggaaG/Agagacctgagcttgg
Forward: CATGGACCCAAGAGGGTATG
Reverse: AGGATTCATGGCATTTCCAC
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Appendix 3: Novel microsatellite and SNP markers at 21q22.3 generated for fine mapping
Marker Type Oligo name Oligo sequence
22A5.GT124a Dinucl.
22A5.GT 124-1 GC AGGGTCC AG ATT CTGCT A
22 A5.GT 124-2 AGAAACTGTCTCCACCGCAC
218C10.CA44a Dinucl.
218C10.CA44-1 AGAGGGAGGAGGAAGCAGCT
218C10.CA44-2 ATCCTGTTAGCAGCCCAAGA
C21orf2c In/del
C21orf2-l GT AAT GAAT GCTCTGTCTCC ACTG
C21orf2-2 AGCGAGGTACCTGAGCGTG
AG AT 10 Tetranucl.
AGAT10-1 AAT G AATT GAT AT GAT AGAT AG ATGGA
AGAT10-2 ACACACACCCACCTACCAAC
ATTT11 Tetranucl.
ATTT11-1 GTGCCGTAGCTTCAGCATTT
ATTT11-2 CT GGGC AAC AG AGT GAG AC A
314n7CT18 Dinucl.
314n7CT18-l GTCCCATATGGAAGCAGAGG
314n7CT18-2 CGGTGGGATGAATTGTCTTT
314n7CA28 Dinucl.
314n7CA28-l CATGACCACACCACGACT G
314n7CA28-2 CCAGTTTTTAGAGCATAGTCTCTG G
314n7CA23 Dinucl.
314n7CA23-l ATCCCTCCTGGCTGCCTA
314n7CA23-2 TCTCTCGCTCGCTCTCTCTC
Col6alb VNTR
Col6al-l CACCGTCTCCTCCTGTGTGTTCCAGGGAAGAC
Col6al-2 CT GGG AAG ACCGGGGG AGT C AC AC ACGCT G
PCNT2-AluI RFLP (Alul)
PCNT-1 GAAGTGATCCAGCAAAGATTGG
PCNT-2 CAAAACAACAGGAAGCCATTCT
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Appendix 4: Oligonucleotide sequences and PCR conditions for lq42 markers
Marker Oligonucletide sequence* [MgCl2]mM Betaine
Cycling
Conditions
D1S235
Forward- C ACG ACGTTGT AAAACG ACC AGC AAG AGTT C ATGGG A 2.0 Y Touch DownReverse- AACAGTCAATTACAAAATATGTGTG
D1S3462
Forward- CACGACGTTGTAAAACGACTTTCTCACCTTTAAATGTCATCA
2.5 N Touch DownReverse- CCAGTACGCAGATGGTCCTA
D1S251
Forward- GTCTCCAGCCTGCCAC
2.5 Y Standard 60 (30)Reverse- CACGACGTTGTAAAACGACGACCAAGCAACTTCACTCC
D1S103
Forward- ACG AAC ATT CT AC AAGTT AC
2.5 N Standard 57 (27)Reverse- CACGACGTTGTAAAACGACTTTCAGAGAAACTGACCTGT
DISC_5’_
microsatellite
Forward- CACGACGTTGTAAAACGACTTAAATCATGCGTCTGGAAGG
2.0 Y Standard 55Reverse- TTCTTCTCCTCAGCGAGTCC
D1S2709
Forward-C ACG ACGTTGT AAAACG ACTC AT ACC AC AT ATC AG AAT GT C 2.5 N Touch DownReverse- ATCAATCAGTATCTAATAGCATCA
* M l 3 tail indicated in bold
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Appendix 5: Oligonucleotide sequences and PCR conditions for BDNF microsatellite markers
Marker Oligonucletide sequence* [MgClJmM Betaine
Cycling
Conditions
-1040bp (GT)n 
repeat
Forward- C ACG ACGTT GT AAAACG AC AGCACTAGCT GCCT ATT
2.0 Y Touch DownReverse- GCCACTTTATCTCCTCCAGT
AFMA275YB9
Forward- C ACG ACGTT GT AAA ACG ACTGGC AT GT AAATTT AAG
2.0 Y Standard 55Reverse- CTGCTACCTCAGAAGTATCTCAA
*M 13 tail indicated  in bold
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Appendix 6: Oligonucleotide sequences and PCR conditions for P2RX7 microsatellite markers
Marker Oligonucletide sequence [MgCldmM Betaine
Cycling
Conditions
NBG6
Forward- C ACG ACGTT GT A AAACG ACCG AACC AGCCCT AACCT 2.0 N Touch DownReverse- GTTTCTTGGACAGGATGTCGTGGG
P2RX73
Forward- TGCAGCCACGT1TGTAACAT 2.5 Y Standard 60Reverse- C ACG ACGTTGT AA AACGACCT ACTTGGG AGGCT GAG
Exon 13 
deletion
Forward- TTCCTGGACAACCAGAGGAG
2.5 Y Touch DownReverse- GAACAGCTCTGAGGTGGTGA
P2RX71*
Forward- AGGGGCAAGATAGAGGGAAG
Reverse- C ACG ACGTT GT A AAACG ACCTCC AGCCT GGGT GAT A
P2RX72*
Forward- C ACG ACGTTGT AAAACG ACTT GT AAGGT AAGCCCC A
Reverse- GCCCTATTGGACAGCACAGA
*M arkers that failed optim ization
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Appendix 7: Oligonucleotide sequences and PCR conditions for COMT markers
Marker Oligonucleotide sequence [MgCl2]mM Betaine
Cycling
Conditions
rs4680
Forward red-
GAAGGTCGGAGTCAACGGATTCATGCACACCTTGTCCTTCAC
Standard 57Forward green-
GAAGGTGACCAAGTTCATGCTCATGCACACCTTGTCCTTCAT
Reverse— ACCCAGCGGATGGTGGATTT
rs2075507
Forward- CTCTGGCGGAAAGGAAT
2.5 N Touch DownReverse- TCGGC ATC AAAAGG AGG AAAA
Intron 1 
tetranucleotide
Forward- CACGACGTTGTAAAACGACCAGAGTGACAGCCCGTCTC
2.0 Y Touch DownReverse -GGCCTT G AAC AAAC ACT AAC A
COMT2* Forward- CC AAT AT GC AT GT AACT C AAGG AReverse-.CACGACGTTGTAAAACGACAGATCGTGCCACTGCACTC
COMT3*
Forward- CAGATCACACCATGGCACTC
Reverse- CACGACGTTGTAAAACGACTGAGGTCAAAGCTGGCTAGAA
COMT4* Forward- C ACGACGTT GT A A AACG ACCTT CCTG AGC AGG AGG ATGTReverse- GCTG AGGC AGG AG AAT C ACT
*M arkers that failed optim ization
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Appendix 8: Publications related to this thesis
1. Kalsi, G., McQuillin A., et al. (2006). "Identification o f the Slynar gene (AY070435) 
and related brain expressed sequences as a candidate gene for susceptibility to affective 
disorders through allelic and haplotypic association with bipolar disorder on 
chromosome 12q24." Am J Psychiatry 163(10): 1767-76.
2. McQuillin, A., Bass N.J., et al. (2006). "Fine mapping o f a susceptibility locus for 
bipolar and genetically related unipolar affective disorders, to a region containing the 
C210RF29 and TRPM2 genes on chromosome 21q22.3." Mol Psychiatry 11(2): 134-42.
3. McQuillin A, Bass N.J., (2008). “Case-control studies show that a non-conservative 
amino-acid change from a glutamine to arginine in the P2RX7 purinergic receptor 
protein is associated with both bipolar- and unipolar-affective disorders.” Mol 
Psychiatry. Feb 12 [Epub ahead o f print]
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